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Since the discovery of cyclosporine in 1971, calcineurin inhibitors have play d  
critical role in the therapeutic suppression of the immune response.  Patients receiving 
solid organ transplants rely heavily on these medications to prevent the acute and chronic 
rejection of allografted tissue.  Introduction of tacrolimus, the most frequently prescribed 
calcineurin inhibitor, has lead to improved clinical outcomes for organ tr nsplant 
recipients; however, little improvement has been noted in lung transplantation.  
Difficulties with current oral dosing regimens for lung transplant patients stem primarily 
from drug systemic toxicity, heightened risk of invasive infection, ad erratic oral 
bioavailability.  We have proposed that pulmonary delivery of a tacrolimus formulation 
with improved solubility can provide high lung concentrations, while limiting 
corresponding systemic levels associated with toxicity. 
Chapter 2 investigates the pulmonary administration of tacrolimus dispersion for 
nebulization to lung transplanted rats.  Resulting lung and blood levels were determined 
 viii  
by appropriate bioanalytical methods.  Limited systemic absorption was seen after 
pulmonary delivery, resulting in a 50 to 1 lung to blood concentration ratio.     
A 28 day safety and stability evaluation of tacrolimus dispersion for nebulization 
was conducted in Chapter 3.  Results showed no signs of toxicity in Sprague Dawley rats 
and proved the stability of tacrolimus powder for dispersion for 3 months.    
For cases of severe asthma, immunosuppression is also necessary to restore 
normal lungs function and is typically treated with corticosteroids.  Corticosteroids, 
however, are well know for their untoward side effects and can prove ineff ctive in 
severe asthmatics that have developed corticosteroid resistance.  Chapter 4 investigates 
the use of tacrolimus dispersion for nebulization for prophylactic treatment of asthma.  
Efficacy was determined in an asthma-induced animal model by quantific tion of 
inflammatory cells and signaling chemicals.       
In Chapter 5, tacrolimus powder for inhalation is investigated in a novel dry 
powder inhalation platform.  Respirable particles are produced when bulk particles (500 
µm) comprising a matrix of drug/excipient are sheared apart by a marketed inhalation 
device to produce particles of the appropriate geometric diameter (50 µm).  
Biocompatible material with brittle properties were found to produce fine particle 
fractions (FPF) up to 70.3% and total emitted doses (TED) higher than 95%. 
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Chapter 1: Recent Developments in Drug Delivery to Prolong Allograft 
Survival in Lung Transplant Patients 
 
1.1 INTRODUCTION  
Of the major forms of solid organ transplantation (kidney, liver, heart, and lung), 
lung transplantation has proven to be the most difficult in providing effective 
immunosuppression, while maintaining the body’s ability to protect against invasive 
infection.  Further risks of infection are added in lung transplanted patients by the 
disruption of the mucociliary escalator and cough reflex (1).  While consistently 
improving, survival of lung transplant patients lags behind other forms of transplantation 
with an approximate 50% survival rate after 5 years.  Chronic allogr ft rejection caused 
by bronchiolitis obliterans syndrome (BOS) effects 50 to 60% of 5-year post-operative 
patients and is a major hurdle in improving quality of life and patient survival (2).  To 
prevent chronic rejection, maintenance immunosuppressive therapies consisting of a three 
drug regimen (calcineurin inhibitor, antimetabolite, and corticosteroid) are typically 
administered (3).  Calcineurin inhibitors hinder T-cell proliferation, and the subsequent 
immune response, by complexing with immunophillins and binding to calcineurin, 
resulting in the inhibition of cytokine transcription.  Antimetabolites, such as azathioprine 
and mycophenolic acid, reduce expansion of T and B cells by blocking purine synthesis 
(4).  Corticosteroids have a broad mechanism of action which is not completely 
understood (5); however, they are effective inhibitors of T-cell and macrophage cytokine 
production.  Withdrawal from prolonged corticosteroid therapy can be particul ly 
troublesome in lung transplant patients due to dangerous side-effects including 
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hypertension, increased cholesterol, and osteoporosis. (6, 7).  A new method of erapy 
has been developed in poly- and monoclonal antibodies.  Monoclonal antibodies such as 
basiliximab and daclizumab bind specifically to IL-2R surface protein, inhibiting 
signaling for further T cell expansion.  A schematic depicting he cycle of CD4 T cell 
activation with sites of immunosuppressive action is shown in Figure 1.1.  Development 
of new immunosuppressive drugs (i.e. daclizumab, basiliximab, everolimus, FK788) has 
further raised expectations of successful immunosuppressive therapy.  The purpose of 
this review paper is to summarize how advances in drug delivery may lead to improved 
clinical outcomes specifically relating to lung transplants.  The majority of research done 
in this area investigates improved delivery of calcineurin inhibitors cyclosporine and 
tacrolimus. 
In this review, innovative drug delivery with the potential to improve survival rate 
in lung transplanted patients is discussed.  Many of these delivery methods are currently 
used extensively in transplantation therapy and also may be applied to lung transplant 
recipients, while other novel methods are specifically intended for rejection prevention 
specifically in transplanted lung patients.          
 
1.2 DELIVERY SYSTEMS INTENDED FOR THE ORAL ROUTE OF ADMINISTRATION  
Consistent oral immunosuppressive regimens are common in the clinical setting 
as well as during long term maintenance therapies.  Self administration and patient 
compliance make the oral delivery route attractive; however, toxic side-effects, variations 
in clearance (8) and bioavailability of some poorly soluble immunosppressive drugs 
present obstacles in maintaining therapeutic drug levels.  Many novel f rmulation 
approaches have been developed for lung (9, 10), as well as other solid organ transplant 




In all solid organ transplantation, including lung transplantation, oral cyclosporine 
has been frequently used to block T cell proliferation; although, due to its improved 
potency, oral tacrolimus (Progaf®, Astellas Pharma Inc.) has replac d cyclosporine in 
many transplant centers (6) (Figure 1.2).  Cyclosporine, like many other lipophilic drugs, 
suffers from low bioavailability and has been extensively studied for formulation 
methods to improve drug delivery.  The Biopharmaceutics Classification System (BCS) 
Guidance classifies cyclosporine as a class IV drug, meaning that it is both poorly water 
soluble and poorly permeable.  Despite a high affinity for hydrophobic molecules (log P 
= 2.92), cyclosporine remains poorly preamble due to its high molecular weight and rigid 
cyclical structure (11).  Oral delivery of this drug is further indered by P-glycoprotein-
mediated efflux and extensive degradation by cytochrome P450 during fist pass 
metabolism.  Variability in bioavailability of orally administered cyclosporine in 
immunosuppressed patients has been shown to be more influenced by p-glycoprotien 
levels rather than intestinal enzymes (12).  It has been suggested by some that li iting the 
role of p-glycoprotein action is an effective way to reduce variability in oral 
immunosuppressant absorption, consequently reducing incidence of acute graft r jection 
(13, 14).  While metabolic rates may be effected by other medications (i.e. triazole 
antifungals, macrolide antibiotics, calcium channel blockers), the majority of research has 
focused on improvement of oral bioavailability through solubility enhancement, rather 
than chemically limiting the body’s ability to metabolize these drugs. 
The originally marketed oral cyclosporine product, Sandimmun® (Novartis), is 
available in soft gelatin capsules or as an oral solution dissolved in an ethanol/maize oil 
formulation.  Bioavailability and resulting systemic concentrations f cyclosporine after 
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oral dosing of this oil based formulation was low due to its dependence o  bile salt 
concentration in the upper small intestine (15).  Bile salts are needed to elicit micellular 
solubilization of these oils, and because these salts may vary in concentration on inter and 
intra subject basis, the overall bioavailability of this product proved to be variable.  An 
improved oral formulation was reported where in situ micoremulsification of 
cyclosporine occurs as soon as the formulation comes in contact with an external aqueous 
phase.  By utilization of an emulsion stabilizing surfactant (DL-α-tocopherol) (16), 
Neoral® (Norvartis) is able to achieve therapeutic immunosuppressant levels with less 
variability.  In a multicenter, double blind clinical study, efficacy in prevention of 
episodes of heart transplant rejection was shown to be superior in micore ulsified 
cyclosporine when compared to the older formulation.  As would be expect d, reduced 
variability in blood pharmacokinetic profiles using Neoral® was seen in the 1st year of 
treatment (17).  Additionally, therapeutic blood targets were met with lower dosing of the 
microemuslion formulation, proving improved bioavailability.  These results agreed with 
earlier findings reported by Tan et al in a single dose study in patients awaiting lung 
transplant suffering from cystic fibrosis.  Overall bioavailability of microemulsified 
cyclosporine was shown to be 1.84 to 2.09 times higher (at 200 mg and 800 mg dose, 
respectively) than that of the conventional formulation in these patients (18).  
Other novel oral cyclosporine drug delivery systems have been reported; many of 
which have not undergone substantial animal and human testing for efficacy and safety in 
lung transplantation.  Engineered particles designed for delivery to lymphatic tissue have 
been reported by several groups in order to produce an enhanced effect on T 
lymphocytes.  This strategy demonstrated moderate success in in vivo testing of 
engineered nanoparticles (19-21).  Specifically, El-Shoabouri has sown increased 
absorption through the intestinal mucosa by incorporation of charge carrying polymers 
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which resulted in an increase in overall bioavailability of 73% when compared to 
microemulsified cyclosporine composition.  Improvements in solubility and Caco-2 cell 
permeability have also been reported by incorporation of synthetic amphiphilic polymers, 
resulting in micellization of cyclosporine (22).  Nanoparticle drug release was effectively 
targeted to the upper small intestine by incorporation of poly(methacrylic acid and 
methacrylate) copolymer and this showed an approximate 15% increase in bioavailability 
relative to Neoral®(23).  Other attempts to control release nd enhance cyclosporine 
solubility have incorporated the use of sodium lauryl sulfate-dextrin (24) and poly(lactic 
acid)-poly(ethylene glycol) (25) microspheres.  Enhanced solubilites and rapid 
dissolution have been shown in poorly soluble drugs when amorphous particles are 
produced.   Processes for making stabilized amorphous cyclosporine have been 
developed, including evaporative precipitation into aqueous solution (EPAS) (26, 27).  
Compositions containing polyoxyethylene (40) stearate dispersions (28) have also been 
reported to achieve comparable bioavailability to Neoral® using a solvent-melt technique 
to produce a stable amorphous powder.   While generally unproven in complex biological 
models, these formulations should be considered when addressing the future o  drug 
delivery systems developed for improving solid organ transplant rejection rates.  
 
1.2.2 Tacrolimus 
Orally administered tacrolimus is the cornerstone of immunosuppressive therapies 
for all forms of solid organ transplant.  In the past 10 years, trends have shown oral 
tacrolimus use increasing as a maintenance therapy.  In 2006, approximately 78% of lung 
transplant patients one year post-operative and approximately 73% of patients five years 
post-operative were using tacrolimus along with steroids and antimetabolites to prevent 
lung graft rejection (29).  The replacement of cyclosporine as a calcineurin inhibition 
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agent with tacrolimus is based on data collected in both the laboratory nd clinical 
setting.  Specifically, patients receiving lung transplants over the course of a 3 year study 
were given immunosuppressive therapy with either orally administered cyclosporine or 
tacrolimus.  In the first two years, survival rates were similar; however, early signs of 
rejection and cases of obliterative bronchiolitis were seen much more frequently in 
cyclosporine dosed patients (38% vs. 21.7%) (30).  In a trial in the UK involv g patients 
having received liver transplants, clinical outcomes were compared between patients 
dosed with tacrolimus (Prograf®) and microemulsified cyclosporine (Neoral®).  
Tacrolimus therapy was initiated at 0.1 mg/kg/day orally and adjusted appropriately to 
maintain blood trough levels of 5 -15 ng/mL, while cyclosporine was given orally at 10 
mg/kg/day for maintenance of therapeutic trough levels between 150 ng/mL and 250 
ng/mL.  The reduced mortality rate  and decreased need for retransplantation shown in 
this study after one year demonstrated the clinical advantage provided by tacrolimus as 
compared to cyclosporine. (31).   Additionally, replacing oral cyclosporine with oral 
tacrolimus has been shown to improve pulmonary function in lung transplanted patients 
as determined by improvements in forced vital capacity and reduced exhaled nitric oxide 
levels (32).    From a pharmacodynamic view point, these two drugs show almost exactly 
the same method of T cell inhibition; although  improvements in therapeutic outcomes 
using tacrolimus may also be due to a potency that is 10-100 times greater than that of 
cyclosporine (30, 33).  In addition to showing clinical improvements in daily 
maintenance therapy, oral tacrolimus has been shown effective as a rescue therapy in 
patients experiencing acute rejection while receiving oral cyclosporine.(34). 
The innovator product, Prograf®, consist of a fine dispersion of amorphous 
tacrolimus in a hydroxypropylmethylcellulose (HPMC) carrier at 1:1 ratio and is intended 
for a twice daily dosing regimen.  Superior drug solubility was reported for the Prograf® 
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formulation when compared to bulk, crystalline tacrolimus in dissolution testing due to 
improved tacrolimus solubility (35).  Stabilized amorphous powders are often used in 
oral formulations as a strategy to enhance drug solubility (36).  Overhoff et al 
successfully stabilized amorphous tacrolimus with a polymeric carrier by a rapid freezing 
technique and showed the ability to supersaturate dissolution media in in vitro testing.  
Further testing of oral dosing in a rat model showed greater systemic absorption when 
poloxamer 407 stabilized tacrolimus was dosed in comparison to Prograf® (37).  In the 
granulated formulation of Prograf® intended for oral administration, lactose, 
croscarmellose sodium, and magnesium state are also included in capsules with the 
HPMC:tacrolimus combination.  In the interest of enhancing patient compliance and 
reducing medication confusion for transplant recipients, a once daily tcrolimus 
formulation, Prograf® XL (formerly MR tacrolimus), has been developd.  This once-
daily (qd) formulation substantially reduced the maximum concentration (Cmax) of the 
tacrolimus in comparison to Prograf® by providing a more gradual drug release, while 
showing a similar extent of absorption (ratio of Prograf® XL to Prograf® for AUC0-inf 
= 97.3%) (38).  Milligram-for-milligram conversion form twice daily tacrolimus to qd 
tacrolimus in clinical studies has been shown to produce equivalent systemic levels in 
kidney (39) (40) and liver (41) transplant patients in combination with oter 
immunosuppressive therapies. Prograf® XL is associated with improved  patient 
compliance due to reduced dosing frequency; however, variable gastrointesinal 
absorption with this formulation (also seen with the proprietary product, Prograf® and 
oral cyclosporin) necessitates close monitoring of trough blood levels.       
 Although much of the metabolic pathway is still not fully elucidate , tacrolimus 
is thought to undergo the same metabolic degradation as cyclosporine (12). When 
investigating tacrolimus absorption in the rat small intestine, it was found that the 
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presence of p-glycoprotein had an inhibitory effect on drug uptake, while the area of the 
intestine with a lower p-glycoprotein concentration, the jejunum, showed the highest 
absorption rates (42).  Somewhat conflicting results were recently r ported by Saitoh and 
coworkers.  They found that tacrolimus is neither a substrate nor an inhibitor of p-
glycoprotein and that cytochrome P450 was responsible for the drug’s extensive 
metabolism (43).   Unlike cyclosporine, tacrolimus is classified as a BCS class II drug, 
being poorly water soluble (4-12 µg/mL) (42), but highly permeable (log P = 3.3).  
Currently, some researchers are investigating other methods for enhancement of 
tacrolimus bioavailability, and many of the drug delivery technologies d scribed for 
cyclosporine could also be applied for tacrolimus.  Arima and coworkers have used 
various hydrophilic ß-cyclodextrins to enhance solubility in vitro as well as in a rat 
model, concluding that cyclodextrin solubilized tacrolimus showed a 1.2 fold increase in 
AUC compared to that of Prograf® (44).  In a subsequent study, it has also been 
hypothesized that increased bioavailability of ß-cyclodextrin incorporated tacrolimus in a 
rat model is due to inhibition of p-glycoprotein efflux as well as increased solubilization. 
Drug loaded poly(lactide-co-glyolide) (PLGA) biodegradable nanoparticles and pH 
sensitive nanoparticles have also been investigated for colonic delivery in the treatment 
of inflammatory bowel disease (45, 46).  These formulations also show potential for 
enhancement of systemic bioavailability in transplanted patients by targeting areas of the 
gastrointestinal tract where the drug is metabolized to a lesser extent.         
 
1.2.3 Other agents 
Many other oral immunosuppressive therapies such as corticosteroids and 
antimetabolites are used in the prevention of lung graft rejection (i.e. azathioprine, 
prednisolone) and are not confronted with the bioavailability obstacles se n in the 
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calcineurin inhibitors discussed above.  These drugs, however, are limit d in there 
clinical use and are often used in conjunction with other immunosuppressive agents 
because of their adverse side effects and narrow therapeutic windows (5).  Some of these 
drugs do require special considerations when dosing, including mycophenolic acid and 
sirolimus.  Mycophenolate mofetil, a prodrug commonly used as an antiproliferative 
agent, has been shown to cause irritation in the upper gastrointestinal tract when 
delivered orally due to the mofetil ester entity.  Enteric coated mycophenolate sodium 
(Myfrotic®) is offered as an alternative that allows for drug targeting of the upper small 
intestine, avoiding gastric and upper intestinal irritation.  Mycophenoat  sodium has been 
shown to be effective in conjunction with other immunosuppressive regimens in 
prevention of solid organ graft rejection (47).  Sirolimus, another immunosuppressive 
agent that blocks IL-2 proliferation, has been shown to be effective in transplant patients 
while avoiding nephrotoxicity normally seen with calcineurin inhibitors.  Oral sirolimus 
(also known as rapamycin) has been shown to have a synergistic effect when dosed with 
cyclosporine or tacrolimus. Since both sirolimus and calcineurin inhibitors are 
metabolized by cytorchrome P450, increases in sirolimus bioavailability may be seen 
when co-administered due to reduced metabolism (12).  This interaction should be noted 
by the clinician with doses adjusted accordingly.  .  Systemic toxi i y (i.e. bone marrow 
suppression) and interstitial pneumonitis associated with oral dosing of sirolimus, has 
limited the widespread use of this agent in lung transplant patients.(48-50).  Additional 
pulmonary complications associated with oral dosing of sirolimus such as lymphocytic 
alveolitis and alveolar hemorrhage have been reported to improve upon discontinuation 
or reduction of dose.        
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1.3 DELIVERY SYSTEMS INTENDED FOR THE PARENTERAL ROUTE OF 
ADMINISTRATION  
Many immunosuppressive therapies are administered intravenously during pat ent 
hospitalization, especially in the case of induction therapy.  Induction therapy is not 
advocated by all lung transplant centers, in fact it was preformed in less that 50% of lung 
transplant cases in recent years (29) (Figure 1.3).  Induction therapy occurs post-
operatively and involves dosing of powerful anti-lymphocyte antibody parenterals to 
achieve an initial level of immunosuppression.  Critics of induction therapy site that 
“over suppression” might increase risk of infection, while advocates of this therapy 
believe it helps prevent acute rejection in the critical firstew weeks (51).    Intravenous 
immunosuppressants such as IL-2R antagonist (basilizimab, daclizumab) and polyclonal 
antibodies (anithymocyte globulin) are typically used in this therapy. As of yet, no 
clinical studies have reported data making a strong case for induction therapy in lung 
transplantation (52).  
In cases of maintenance therapy, many marketed intravenous formulations are 
adaptations of the active used in oral compositions (as is the case for Prograf® and 
Neoral®).  In Prograf®, polyoxyl 60 castor oil and dehydrated alcohol are used to 
solubilize tacrolimus.  Sandimmune® for injection consists of cyclosporine in 
Cremophor® EL (castor oil) and alcohol solution.  Due to toxicity and high risk of 
anaphylaxis associated with intravenous castor oil, these formulations are typically 
avoided in favor oral immunosuppression   (53).  Other formulations have been studied 
for prolonged drug release and reduced systemic toxicity through drug targeting.  Injected 
liposomal cyclosporine (54) and tacrolimus (55) have been investigated in mice for their 
effect on therapeutic index and tissue targeting.  Evidence of tissue targeting as well as 
prolonged systemic half lives was observed in both studies due to manipulation of fatty 
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acid chain length, surface charge, and particle size.  Novel polymeric icelles of 
cyclosporine have also been studied and exhibited superior solubility, prolonged drug 
release, and lowered toxicity when compared with Cremophor® EL (Sandimmune®)  
solubilized injections (56, 57).  Specifically, poly(ethylene oxide)-b-poly(ε-caprolactone) 
(PEO-b-PCL) micelles increased solubility and prolonged releas  of cyclosporine due to 
high encapsulation efficiencies and reduced molecular mobility within the micelle.  Other 
methods of solubilizers such as ethanol and Cremophor® EL allow for higher mol cular 
mobility and thus faster drug diffusion.  In previous studies it was shown that 
cyclosporine for injection solubilized with Cremophor® EL causes hypersensitivity and 
toxicity in many patients.  Additional studies have shown that Cremophor® EL also 
causes leaching from polyvinylchloride (PVC) tubing, delivering diethylhex lphthalate (a 
potential carcinogen) to the patient during intravenous administration.  Due to these 
concerns with currently marketed intravenous cyclosporine, it is suggeted that oral 
cyclosporine be considered as an alternative treatment (58, 59).  Lactide and ε-
caprolactone biodegradable microspheres loaded with cyclosporine were shown by Li 
and coworkers to potentially deliver steady levels of cyclosporine for several weeks while 
bypassing metabolic variations seen in convention oral dosing (60).  After intramuscular 
injection in mice, similar results were seen as tacrolimus biodegradable microspheres 
maintained steady immunosuppressive blood levels for 2 weeks (61). By eliminating 
toxic solubility enhancers and slowing drug release rate, these types of extended release 
formulations become increasingly interesting for systemic immunosuppressive therapy.  
 
1.4 DELIVERY SYSTEMS INTENDED FOR IMPLANTATION   
Using similar prolonged release strategies, implantable polymeric devices have 
been designed for extended immunosuppressive release in corneal transplant patients.  
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Reservoir corneal implants of cyclosporine have been tested in equine and rabbit models, 
showing potential to provide sustained release for three to five years (62).  Specifically, 
when glycolide-co-clatide-co-caprolactone was used as a polymeric car ier for sustained 
release of tacrolimus in a rabbit corneal transplant model, therapeutic drug levels were 
maintained for over 180 days (63).  Similar results were seen for shorter release times 
with rapamycin loaded chitosan/polylactic acid nanoparticles in coreal transplanted 
rabbits (64).  This methodology is interesting for solid organ transplat recipients as well; 
potentially allowing for long term localized therapy.  Concern over invasive implantation 
procedures becomes a mute point in immunosuppression for transplant patients, since 
these implants could be inserted during transplantation surgery.  Further concerns over 
implant safety and clearance/metabolic variability convey the need for additional studies 
in this method of immunosuppressive delivery.  
 
1.5 DELIVERY SYSTEMS INTENDED FOR THE PULMONARY ROUTE OF 
ADMINISTRATION  
In an effort to localize immunosuppressive effects of calcineurin inhibitors, many 
groups have developed and investigated these drugs for inhalation.  This strategy for 
targeting the deep lung tissue should provide high local drug concentratio s, while 
limiting drug concentrations systemically; in turn reducing of toxic effects imparted by 
these medications.  Cyclosporine, having been used for prevention of transplant allograft 
rejection for 25 years, was an obvious candidate for development into a formulation for 




Early research in pulmonary targeted immunosuppression via cyclosporine 
aerosol delivery studied the drug’s efficacy and tolerability by this delivery method.  A 
basic formulation where pure drug was dissolved in ethanol was produced so that drug 
aerosolization could occur.  While ethanol is used in many pMDI and nebulization 
formulations and is GRAS (generally recognized as safe) for inhalation at low levels, at 
high levels it has been shown to be irritating to the lungs and may cause changes in lung 
function (65).  Regardless, cyclosporine in ethanol has been dosed in both animals and 
humans and shown promising results in comparison to traditional immunosuppressive 
therapy.  In patients experiencing acute cellular rejection, aerosolized cyclosporine (300 
mg) was administered as a rescue therapy daily for 10 days, followed by maintenance 
dosing at 3 doses per week.  While standard rescue therapy of pulse methylprednisolone 
or equine lymphocyte immune globulin proved unsuccessful in all 18 patients, 
aerosolized cyclosporine was effective in 14 of the 18 (66).  Additionally, patients 
displayed improvements in lung function and no significant change in renal fu ction.  In 
lung transplanted and non-transplanted experimental animal models, aerosolized 
cyclosporine showed superiority over intramuscular and subcutaneous injections (67, 68).  
At the same dosing level, the area under the concentration vs. time curve (AUC) of lungs 
in aerosol dosed rats was three times that of rats receiving intramuscular injection.  In an 
allogeneic rat lung transplant model an 80% greater dose was required in injected rodents 
as compared to aerosolized rodents to prevent graft rejection.  Furthermore, generally 
lower blood levels were seen in the aerosolized group at equivalent doses.   
More recently, cyclosporine has been reformulated in propylene glycol, which is 
less irritating to the lung mucosa.  In a 28 day safety study in rats and dogs, animals 
received as much as 2.7 times the equivalent maximum human dose (69).  At these high 
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dosing levels, no unexpected systemic toxicity or respiratory toxici y was seen in either 
aerosolized cyclosporine in propylene glycol or propylene glycol alone.  Additionally, 
cyclosporine lung concentration in rats was found to be 18 times than in the blood at 
given time intervals.   Added viscosity of this solubilizing agent presents another caveat 
to dosing to the lungs in that a specific air-jet nebulizer and air compressor must be used.  
Increased viscosity in pulmonary formulations can lead to high variability in mass 
median aerodynamic diameter (MMAD), total output, and respirable fraction (RF%) 
between different nebulizer systems.  Characterization of aerosolized cyclosporine in 
propylene glycol has been performed with the Aerotech II in combination with a high-
flow compressor, showing a MMAD of 1.6 µm were 90% of the aerosol produced is 
below 5.0 µm (70).  This method of aerosolization has been used in clinical trials of this 
formulation, ensuring consistent aerosol characteristics in the doselivered to the 
patient.  While clinical study samples size are small due to the infrequency of pulmonary 
transplant, several studies have been preformed for evaluation of this formulation in lung 
transplant recipients.  In evaluation of the deposition and absorption rate of erosolized 
cyclosporine, Burckart and colleagues concluded that the aerosolized drug displayed 
biphasic absorption shown by the rapid initial absorption into the blood (t1/2 = 0.73hr) 
until 6 hrs after dosing when slower absorption after was noted (t1/2 = 6.2hr) (71).  It 
was hypothesized that the prolonged retention of cyclosporine in the lung might be due to 
macrophage uptake or lipophilic interactions between cyclosporine and phospholipids 
found in pulmonary surfactant and the alveolar membrane (72).   Using radiolabelling 
and forced expiratory volume in one second (FEV1) , a linear relationship was developed 
showing a dose dependent relationship between post-transplant lung function and drug 
deposited in the lower airways.  Improvement in lung function was seen ov r a 2 year 
span in patents where dosing resulted in 5 mg of drug deposition in the lung periphery 
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(73).  In a study of patient survival after lung transplantation, conventional 
immunosuppressive therapy was given to 51 control patients, while 39 cases received 
cyclosporine aerosol in addition to conventional therapy.  Estimates provided by Kaplan-
Meier survival analysis showed a 4.5 year mean survival in patients r ceiving additional 
aerosol dosing, while the control group mean survival was only 2.3 years (74).  In a large 
efficacy study involving lung transplant patients, a randomized single-center trial was 
performed involving 30 aerosol placebo dosed patients and 28 aerosol cyclsporine 
patients; all of which received oral tacrolimus, azathioprine, and prednisone for 
immunosuppressive management in addition to aerosol therapy.  Results of thi trial 
showed that, while having no significant effect on the incidence of acute allograft 
rejection, both patient survival (47% placebo vs 11% cyclosporine) and chronic rejection 
rates were significantly  improved in the patients receiving aerosolized cyclosporine (75) 
(Figure 1.4).  Interestingly, and contrary to previous studies, there seems to be no 
relationship in this study between acute rejection and chronic rejetion in the aerosol 
dosed group.  The authors theorize that since aerosolized cyclosporine contributes 
minimally to blood concentrations, there is less immunosuppressive effect on vascular 
lung tissue.  Acute rejection, which is histologically characterized by lymphocytic 
infiltrates in and around vessels, might see little therapeutic ffe t with the addition of 
aerosol treatment.            
The underlying issue in the FDA approval of what seems to be much improved 
targeted delivery method is the lack of and homogeneity and small size of patient 
populations in trials.  With only 22 percent of lung transplant centers p rforming more 
than 20 transplants a year (29), the need for a unified multicenter effort becomes 
apparent.  This, however; only compounds the problems of different immunosuppressive 
treatment protocols (i.e, induction, maintenance, adjuvant, and steroid therapies) nd 
 16 
imbalances between treatment and placebo groups (76).  These issues, combined with a 
relatively small market outlook has led Novartis AG, the developer f this orphan drug, 
to sell rights to APT Pharmaceuticals (Burlingame, CA) who is expected begin Phase III 
trials this year.          
In an effort to enhance the solubility of cyclosporine without the use of a lung 
irritating solvent or highly viscous agent, liposomal cyclosporine for inhalation was 
developed by Gilbert and coworkers (77). Preparation of cyclosporine in 
dilauroylphosphatidylcholine (DLPC) consisted of dissolving both excipients in t-
butanol, followed by solvent removal and redispersion in water.  In addition to solubility 
enhancement, liposomal delivery may offer the added benefit of drug retention in the 
lungs.  Liposomal aerosol deposition in a dog model showed lung retention of 
approximately 120 min after a 25 mg dose (78).       
 
1.5.2 Tacrolimus 
As documented in laboratory and clinical studies, both oral and intravenous 
tacrolimus formulations have shown increased potency and efficacy over cyclosporine.  
Subsequently, many immunosuppressive protocols now have replaced the calcinurin 
inhibitor cyclosporine with tacrolimus.  In keeping with this trend, researchers are now 
investigating the efficacy and safety of aerosolized tacrolimus in transplanted and non-
transplanted animal models.  The goal, as with inhaled cyclosporine, is to enhance 
immunosuppressive effects in the lung, while limiting toxicity systemically.  In 
anticipation of the interest in using tacrolimus for targeted pulmonary delivery in 
transplantation as well as asthma therapy, Fujisawa (now Astellas Pharma Inc.) 
developed and patented a pMDI formulation containing tacrolimus, miglyol 812 (a 
lipophilic solubilizer), and HFA-227 (propellant)(79).  In the first study incorporating 
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inhaled tacrolimus, Ingu and coworkers investigated the efficacy of aerosolized 
tacrolimus in lung allograft immunosuppression and compared with immunosuppression 
afforded by tacrolimus intramuscular injection (80).  In both groups histopathological 
evaluation and suppression of cytokine expression denoted local immunosuppression in 
the transplanted lungs.  As is the case with inhaled cyclosporine, inhaled tacrolimus was 
found to provide the same efficacy in the lung as intramuscular injection, while showing 
reduction in systemic blood levels (<0.5 ng/mL inhaled, 5.2 ng/mL intramuscular).  
Subsequent investigations have quantified tacrolimus deposition levels in the lungs by a 
micropartilce enzyme immunoassay method in transplanted rats with dose administered 
through intramuscular injection and inhalation.  Significant immunosuppression was 
observed histologically in animals having a tacrolimus lung concentration of 270.4 
ng/mL one hour after sacrifice (81).  In addition to potential for lung transplant therapy, 
inhaled tacrolimus delivered by pMDI has also been investigated for in lammation 
reduction in egg-albumin challenged guinea pigs (82).   Another formulation for 
aerosolization of tacrolimus has been studied by Schrepfer et al.  Also in solubilized 
form, tacrolimus is aerosolized with 70% ethanol solution and studied for its inhibition of 
obliterative airway disease in tracheal transplanted rats (83-85).  Much like previous 
formulations, findings demonstrated that aerosolized tacrolimus can achieve potentially 
immunosuppressive concentrations in the lungs, while avoiding excessive systemic 
levels.  Upon histopathological examination, tracheal grafts did show 
immunosuppression in both oral and aerosol groups.  Interestingly, upon cessation of 
aerosol and oral treatments, tracheal influx of inflammatory cells is much more rapid in 
the aerosol treated group due to lower systemic immunosuppression.  Another vel 
formulation involving dispersed tacrolimus nanoparticles has been reported for 
prevention of lung allograft rejection via pulmonary delivery.  This formulation offers the 
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benefit of supersaturating pulmonary fluid without the use of lung irritating solvents.  In 
vitro efficacy was shown by lymphocyte suppression in mixed leukocyte culture (MLC) 
and mitogen stimulation assays (MSA) (86). A dispersion of tacrolimus and lactose (1:1) 
nanoparticles has been evaluated in vitro (as seen in Figure 1.5) and dose  to mice 
evaluated for blood and lung levels (87).  Preliminary studies involving pulmonary 
dosing of this dispersion in a rat lung transplant model showed that high lun  levels are 
achieved, while whole blood concentration remains low.  Additionally, it was noted that 
drug concentration in transplanted allografts showed prolonged therapeutic levels in 
comparison to non-transplanted lungs.      
Although no successful lung transplanted animal studies are shown in the 
literature, liposomal tacrolimus has been synthesized using 
dipalmitoylphosphatidylcholine (DPPC) for potentially targeting lung 
immunosuppression (88).  As in pulmonary liposomal formulations of cyclosporine, 
tacrolimus liposomal formulations may allow for longer drug resid nce times after single 
dosing.              
 
1.5.3 Corticosteroids 
Oral or intravenous administration of corticosteroids in conjunction with a 
calcineurin inhibitor and antimetabolite has long been standard practice for maintenance 
immunosuppressive therapy.  Inhaled corticosteroids used in the treatment of asthma and 
chronic obstructive pulmonary disease induce an anti-inflammatory response, suggesting 
possible application for immunosuppression in lung transplant patients.  In spite of these 
observations, conflicting results have been seen in inhalation of corticosteroids for 
prevention of lung allograft rejection.  Early success was seenin treating bronchiolitis 
obliterans syndrome (BOS) with inhaled budesonide and fluticasone (89, 90).  More 
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recently, in a clinical trial investigating reduction of lymphocyti  bronchiolitis in 
transplanted lungs, inhaled budesonide was shown to improve lung function (91); 
however, the absence of histological evaluation and long term patient success rates leave 
cause for further analysis.  A more recent placebo-controlled clinical trial found that 
inhaled fluticasone propionate dosing twice daily for three months did not significantly 
prevent BOS in 30 lung transplant patients tested (92).  Potential reasons for the 
inefficacy of this targeted therapy might have been the early onset of BOS (approx 6 
months after transplant), known difficulties with pMDI use, or inadequate drug 
deposition in small airways.  In a specific case cited by Naef and coworkers, co-
medication of inhaled fluticasone propionate and prophylaxis itraconazole resulted in 
Cushing’s syndrome in some lung transplanted patients.  It was deduce that inhibition of 
cytochrome P450 by itraconazole reduced clearance of fluticasone, causing accumulation 
in lung tissue and increased blood concentrations (93).  Based on these few tudies, it 
becomes apparent that further work investigating early intervention with various 
corticosteroid formulations for prevention of BOS is necessary.  
 
1.5.4 Antifungal prophylaxis 
In addition to immunosuppression, lung transplant patients often require 
prophylactic antifungal therapy to assist a weakened immune syst m in defending against 
invasive fungal infections.  Many of these treatments are delivered orally or 
intravenously for transplant recipients; however, novel inhaled antifungal formulations 
have been used to target infection in lung allografts.  Abelcet®, a lipid complex of 
amphotericin-B, has been dosed to single and double lung transplant recipients to 
determine drug deposition.  As expected, lower deposition was seen in the native lung of 
single transplant patients because of lower ventilation.  Clinical data has shown that  
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Aspergillus infections may originate from the native lung in patients with single lung 
transplants. (94); consequently, therapeutic drug levels in this region are important.  It is 
suggested that techniques for targeting lower ventilated areas should be evaluated to 
overcome this issue (95, 96).  In another study, efficacy of pentamide prophylaxis was 
demonstrated in lung transplant patients for the prevention of Pneumocystis jeroveci 
(formerly carinii) pneumonia (97).  This treatment was used instead of sulfamethoxazole-
trimethoprim to prevent sulfa-related allergy.  Future studies exploiting pulmonary 
delivery of antifungals in lung transplant cases are needed before this mode of therapy 
can be commonly used in clinical settings.     
 
1.6 DELIVERY SYSTEMS INTENDED FOR THE SUBLINGUAL /BUCCAL ROUTE OF 
ADMINISTRATION  
Cystic fibrosis, being one of the main indications for pediatric lung 
transplantation, is a disease that affects many organs, including the lungs and 
gastrointestinal tract.  It is characterized by production of thick mucus in the lungs, 
recurrent pulmonary infections, and diminished pancreatic enzyme production.  
Consequently, orally administered lipophilic substances tend to be poorly absorbed 
through the intestinal mucosa.  In the case of orally administered immunosuppressants 
after transplantation (i.e. tacrolimus, cyclosporine), a further reduc d bioavailability 
might be expected (98).  An alternative has been proposed to obtain therapeutic blood 
levels in transplanted patients by sublingual drug delivery (99).  Due to variations in drug 
absorption after sublingual administration, only 67% of the blood samples tak n in 6 lung 
transplanted patients with cystic fibrosis showed therapeutic levels.  In a recent case 
report involving a kidney transplant patient, a contraindication arose that eliminated oral 
tacrolimus as a treatment option.  For approximately one month, therapeutic levels 
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(between 7 and 15 ng/mL) of tacrolimus were targeted relatively successfully by taking 
the contents of oral tacrolimus and administering sublingually (100).  The contents of oral 
tacrolimus (Prograf®), HPMC:tacrolimus matrix, could be expected to swell in the oral 
cavity and release amorphous tacrolimus into the saliva.   Additionally, in pediatric liver 
transplants, buccal administration of tacrolimus suspension was used to prom te patient 
compliance and prevent interference with gastrointestinal function. When compared to 
trough levels achieved by nasogastric tube (NGT) administration, buccal administration 
showed comparable therarpeutic levels in the target range (31% buccal, 24% NGT) (101).  
More investigation into this method of calcineurin inhibitor delivery is needed including 
design of a mucoadhesive controlled release formulation and comprehensive 
pharmacokinetic evaluation in animal models.        
 
1.7 CONCLUSION  
As new immunosuppressive chemicals are developed, delivery methods to 
maximize and target their therapeutic effect must be developed.  In the case of lung 
transplantation, unique challenges confront clinicians as they try to avoid allograft 
rejection through suppression of the immune system, while not completely disabling the 
body’s ability to protect itself from invasive infection.  Likewise, unique opportunities for 
targeted drug delivery by pulmonary delivery may allow for local therapeutic effects, 
while limiting systemic toxicity.  As further discoveries are made in new 
immunosuppressive chemical entities and subsequent investigations are conducted in safe 
and efficacious ways to delivery them, lung transplant patient quality of life and survival 
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Chapter 2: Characterization and Pharmacokinetic Analysis of 
Tacrolimus Dispersion for Nebulization in a Lung Transplanted Rodent 
Model  
 
2.1 INTRODUCTION  
 
Cases of end-stage lung disease such as severe chronic obstructive p lmonary 
disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis (CF) often show 
limited response to treatment and pharmacotherapy, leaving very few treatment options 
for clinicians.  Lung transplantation has been accepted as an effective therapeutic option 
in the treatment of patients with end-stage pulmonary diseases. Annually, approximately 
2,000 patients undergo lung transplantation when conventional treatments are 
unsuccessful.  While surgical procedures and maintenance therapy can prove quite 
difficult,  recent years have shown the frequency of lung transplant procedures to increase 
dramatically, nearly doubling in the last ten years (1).  Much of this increase has been a 
result of improved patients outcomes resulting from more effective donor matching, 
advances in surgical techniques, and development of more effective rejection-preventing 
pharmaceuticals.   
The introduction of a more potent immunosuppressive agent, tacrolimus, has been 
associated with increased success in the prevention of allograft rejec ion and bronchiolitis 
obliterans syndrome (BOS) compared to its predecessors (2, 3).  Prograf, an oral 
tacrolimus formulation made by Astellas Pharmaceuticals, is used in mainten nce therapy 
for approximately 70% of lung transplant patients one year after transplantation (4).  
While its use is off label (having FDA approval for only kidney, liver, and heart 
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transplant only), oral tacrolimus has been proven more effective as a maintenance (2) and 
rescue (5) therapy in lung transplant patients, while also showing improved patient 
pulmonary function in comparison to other treatments (6).  Much of these improvements 
may be a consequence of tacrolimus being up to 100 times more potent than the 
alternative pharmaceutical, cyclosporine (7).     
Advances in animal transplant procedures have improved scientific modeling of 
transplant-related complications in humans, and enabled testing of novel pharmaceutical 
products. Experimental lung transplantation programs are needed to improve key aspects 
of transplantation surgery, such as preservation, duration of ischemia, and ischemia–
reperfusion injury.  Many different experimental lung transplantation models have been 
used to date. Initially, the canine lung transplantation model was preferred (8), although 
since 1971, rats have become the model of choice (9, 10).  Advantages of using the rat 
model include lower cost to the researcher as well as the availability of inbred strains 
which allow for discrimination between immunologic and non-immunologic events 
occurring after transplantation.  In 1989, the use of cuffs in rat lung transplantation by 
Mizuta et al. showed improvements in the microsurgical technique compared to micro-
suture anastamosis (11). In 1995, Reis et al. presented other significant improvements of 
the surgical technique (12), using Teflon cuffs instead of polyvinyl chloride or 
polyethylene cuffs which often leads to foreign-body reaction and fibrous tissue 
formation. Recently, Zhai et al. further improved the model by removing the holding tabs 
on the cuffs before insertion, decreasing the chance of kinking of the pulmonary artery, 
vein, and bronchus (13). The left orthotpic lung transplant on the rat is now performed by 
at least 10 research centers around the world.  
In spite of these improvements in surgical technique and therapy, lung transplant 
rejection rates exceed those of all other forms of solid organ transplant, stemming form 
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the complexity of the pulmonary immune system and the frequency of exposure to 
foreign antigens.  Further complexity is added to dosing regimens of immunosuppressive 
agents by the prevalence of nephrotoxicity, hypertension, and neurotoxicity (among 
others) at sustained and/or elevated systemic concentrations.  Tacrolimus blood 
concentration has also demonstrated high intra-patient variation due to rratic 
gastrointestinal absorption and the low solubility.  The delicate balance between 
therapeutic concentrations and toxic systemic concentrations combined with variable oral 
bioavailability requires frequent analysis of blood trough levels and often results in 
untoward complications.  Clearly, a reduction in systemic drug levels accompanied by a 
pharmaceutical product with increased and consistent local bioavailability would 
alleviate many of the problems encountered in maintenance therapy.       
The goal of targeting immunosuppressive therapy to the lungs and reduction of 
systemic side effects may be realized through the pulmonary delivery of tacrolimus.  In 
transplanted animal models, others have demonstrated that aerosolizd tacrolimus is 
effective in prolonging allograft survival, while maintaining systemic drug concentrations 
well below the toxic range (14-16).  The objective of this study was to characterize a 
novel tacrolimus formulation for inhalation and determine its pharmacokinetics in a non-
rejection lung transplanted rat model.  Additionally, pharmacokinetic differences of non-
transplanted and transplanted animals were studied.  In comparing the drug levels of 
transplanted and non-transplanted animals, we hypothesized that no significant difference 
in tissue levels will be observed and that blood levels would remain below the therapeutic 
range.   
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2.2 MATERIALS AND METHODS 
2.2.1 Materials  
Tacrolimus anhydrous (batch #070405) was purchased form Haorui Pharma-
Chem, Inc. (Edison, NJ).  Sirolimus (rapamycin) was bought from Spectrum Chemical 
(Gardena, CA).  High Performance Liquid Chromatography (HPLC) grade acetonitrile, 
lactose monohydrate, zinc sulfate heptahydrate, barium hydroxide (0.3 N), and 
phosphoric acid (85%) were all purchased from Fisher Scientific (Fair Lawn, NJ).  
Heparin Sodium (10,000 IU/mL) was purchased from Baxter Healthcare (Deerfield, IL).     
 
2.2.2 Formulation preparation 
Ultra-rapid Freezing (URF) technology was used to produce tacrolimus powder 
for reconstitution in deionized water.  This process is described in detail by Sinswat et al 
(17).  Briefly, a 1 to 1 solution of tacrolimus to lactose monohydrate containing 0.75% 
w/v total solids was made by dissolving powders in a cosolvent mixture of acetonitrile 
and water.  The transparent solution was applied to a rotating drum that had been 
cryogenically cooled to -50°C, where it was rapidly frozen (18).  The frozen product was 
removed from the cryogenic surface and subjected to lyophilization using a VirTis 
Advantage Tray Lyophilizer (VirTis Company Inc., Gardiner, NY) to sublimate aqueous 
and organic solvents.  After 40 hours of lyophilization, the product was packaged in a 
nitrogen rich environment at less than 20% relative humidity.  Before ae osolization, 
tacrolimus powder for reconstitution was dispersed in deionized water by probe 
sonication.      
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2.2.3. Formulation characterization 
2.2.3.1 Particle size analysis (Zeta, SEM) 
Analysis of the particle size of tacrolimus colloidal dispersion was measured by 
laser scatter using a BI-ZetaPlus (Brookhaven Instruments, Holtsville, NY) and analyzed 
by a digital autocorrelator (Brookhaven Instruments, Holtsville, NY).  Samples were run 
immediately after dispersion.  Qualitative particle size analysis was conducted using a 
Hitachi S-4500 field emission scanning electron microscopy (SEM).  Before imaging, dry 
samples were prepared by flash freezing tacrolimus colloidal d spersion in liquid nitrogen 
and adhered to a cooled SEM tray with carbon tape.  The aqueous phase was then 
removed by lyophilization, leaving dried powder for analysis.  Samples were gold-
palladium sputter coated for 20 seconds under vacuum and read at 10 kV accelerating 
voltage.     
 
2.2.3.2 Aerosol characterization 
Pharmaceutical aerosols produced by an Aeroneb® Pro (Aerogen, Galway, 
Ireland) vibrating mesh nebulizer were characterized by cascade impaction and laser 
diffraction techniques.  Aerosol impaction testing conducted with a Next G neration 
Pharmaceutical Impactor (NGI) (MSP Corporation, Shoreview, MN) was used to 
determine aerodynamic droplet size, dose emitted, and fine particle f a tion.  The NGI 
was operated at a flow rate of 30 L/min.  Impacted formulation was collected wi h mobile 
phase and injected for HPLC analysis.  The method used for HPLC analysis was adapted 
from Akashi and coworkers (19).  A Waters 515 liquid chromatograph with a 996 PDA 
(Waters Corp. Milford, MA) combined with a Lichosphere RP C18 5 µm column (Varian 
Corp., Lake Forest, CA) was used for analysis.  Mobile phase was composed of 
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acetonitrile, water, and phosphoric acid in proportions of 600, 400, and 1, respectively.  
Data collected was plotted in Sigma Plot (Systat Sofware Inc., San Jose, CA) and fit with 
a 3 parameter logistic curve for data interpellation.  Mass median aerodynamic diameter 
(MMAD) was calculated based on drug collected on states 1 through 7 and micro-orifice 
collector (MOC) in accordance with USP 31 <601> guidelines.  Fine particle fraction 
(FPF) was calculated as the percentage of the total emitted dose with an aerodyn mic size 
less than 5 µm.   A Malvern Spraytec (Malvern Instuments, Worcestershire, UK) was 
used to determine geometric droplet size distribution of colloidal dispersion and 
deionized water produced by the vibrating mesh nebulizer.   An air current of 1 L/min 
was used to create the plume exiting the device.  
  
2.2.4 Transplant study design 
Adult male Lewis rats weighing 250 to 300 grams were used as both recipient and 
donor in the non-rejection model.  All animals received proper care in compliance with 
an Institutional Animal Care and Use Committee (IACUC) approved protocol.  
Transplantation procedures were carried out using a cuff technique described by Mizuta 
et al (11).  Prophylactic enrofloxacin (Baytril) was administered after transplantation to 
prevent possible infection.  To confirm successful transplant and survival of allograft 
lung tissue, pathological review of the transplanted lung in preliminary animals was 
conducted.  This evaluation verified whether or not a successful transplant had been 
accomplished in the non-rejection model, and that the dosing portion of the study could 
commence.     Histology examples of tissues meeting evaluation criteria are given in 
Figure 2.1.  During this study, a total of 24 rats received aerosolized tacrolimus, 12 
having undergone unilateral left lung transplantation and 12 non-transplanted control rats.  
Each animal was given a nebulized dose of 6.4 mg of formulation dispersed in 3 mL 
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deionized water.  The dispersion was nebulized by an Aeroneb® Pro and delivere  via a 
four port nose-only dosing chamber (17).  The animals were sacrificed 1, 6, 12, or 24 
hours after the completion of single dose administration.  Whole blood, obtained by 
cardiac puncture, was collected in heparinized conical vials, while te lungs, liver, 
spleen, and kidneys were excised and frozen in 20 mL scintillation vials.      
 
2.2.4.1 Surgical Procedure 
The donor rat was placed in the supine position and a tracheotomy was 
performed.  A 14-20 gauge x 1 inch catheter (endotracheal tube) was placed via the 
tracheotomy site to facilitate continuous ventilation (Harvard rodent v ilator) using 
room air. Ventilation conditions consisted of a tidal volume of 2.5 to 3.0 ml and 
respiratory rate of 70 to 100 breaths/ min.  A full sternotomy/celiotomy was performed 
via midline incision.  Heparin (1000 units/kg) was then injected into the liver capsule.  
The inferior and superior vena cava was divided, the right and left atrial appendages were 
dissected, and a perfusion catheter was placed through a right ventriculotomy into the 
pulmonary artery.  Cold Perfadex™ solution was perfused into the lungs as circulation 
ceased.  The heart/lungs were harvested en-bloc after 20cc’s of old Perfadex had been 
perfused into the donor lungs under 10cm H20 pressure.  The left lung was then procured 
by carefully dissecting out the pulmonary artery (PA), pulmonary vein (PV) and left main 
bronchus (Br).  The  PA, PV, and Br were cannulated with a Teflon cuff constructed from 
a 16G catheter for the PA and a 14G catheter for the PV and Br.  Preparation of the cuffs 
began with cutting a 2.4 mm length and modifying to include a 1.5 mm extension (i.e., 
“handle”) for manipulation.  The cuff body was roughened with sandpaper to permit 
affixation.  The PV was passed through the cuff, the proximal end was everted over the 
cuff and firmly fixed with a circumferential ligature of 6-0 silk suture. Preparation of the 
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Br and PA occurred in the same manner.  The lung was then be wrapped in sterile gauze 
placed in a petri dish with Perfadex™ solution and placed on ice.  
To prepare for recipient surgery, the orotracheal intubation was perform d (14-
20ga x 1.5” catheter) and the lungs were ventilated at room air underconditions of a tidal 
volume 2.5 to 3.0 ml and respiratory rate of 70 to 100 breaths/ min.  Anesthesia for the 
recipient was maintained by inhalation of isoflurane to maintain comfort and immobility.  
The recipient then underwent a thoracotomy incision in the left third intercostal space and 
the native lung were weighted and pulled out of the chest, causing mild tension on the 
PA, Br, and PV and contributing to a smooth anastomotic procedure.  The nativ  PA, PV, 
and Br was then dissected and encircled with 6-0 silk suture using a microsurgical 
technique.  A removable microclip was placed on each.  Incisions were mad with micro 
scissors into each of the three structures (PA, Br, and PV).  The donor PA, followed by 
the donor Br and donor PV with attached cuff were inserted into the incisio s made into 
the recipient PA, recipient Br, and recipient PV respectively.  These anastomoses were 
then secured with the previously encircled 6-0 silk ligature suture in a circumferential 
fashion.  The clips were released allowing full aeration and circulation of the lung donor 
graft.  After pulmonary circulation was restored and the transplanted lung was functional, 
the recipient’s native lung as well as the cuff extensions (“handles”) were excised.  The 
thorax was closed in layers.  When the rat resumed spontaneous respiration, the 
orotracheal tube was removed.  
       
2.2.4.2 Analysis of tacrolimus levels in whole blood 
To determine systemic drug concentrations at each time point, a PRO-Trac™ II 
FK 506 Enzyme-linked Immunosorbent Assay (ELISA) kit (Diasorin Inc, Stillwater, 
MN) was used.  In accordance with the supplied protocol, 50 mL of whole bl od, 
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standards, and controls were each combined with 300 µL of digestion reagent in separate 
conical vials.  After incubation, cellular components were centrifuged down and 
supernatant serum was removed.  The samples were pipetted into a goat anti-mouse IgG 
coated 96-well plate along with anti-tacrolimus monoclonal antibody.  After further 
incubation and addition of tacrolimus-horesradish peroxidase conjugate, the wells were 
rinsed with mild wash solution.  Empty wells were filled with chromagen followed by 
acid stop solution to elucidate a colorimetric response.  Spectrophotometric readings at 
450 and 630 nm were recorded using a Bio-Tek® Instruments UV/Vis µQuant plate 
reader (Winooski, VT).  A 4-parapmeter logistic fit was applied to the supplied standards 
and used to determine experimental concentrations. 
 
2.2.4.3 Analysis of tacrolimus levels in lung tissue 
Drug levels in lung tissue were quantified using liquid chromatogr phy / mass 
spectrometry (LC/MS) after a liquid extraction procedure.  Tissue was homogenized in 2 
mL normal saline with 1.25 µg of internal standard (sirolimus).  Extraction was facilitated 
by the addition of 0.3N barium hydroxide, 0.4N zinc sulfate heptahydrous, and 
acetonitrile.  Centrifugation was used to separate tissue and precipitated proteins from 
dissolved tacrolimus.  Supernatant was filtered, and lyophilized for 12 hours t  remove 
all solvents.  The remaining drug was reconstituted with mobile phase, filtered again 
through a 0.2µm PTFE filter, and prepared for spectrometric analysis.  LC/MS equipment 
consisted of a Thermo Fisher Surveyor Plus HPLC system with PDA(Waltham, MA) 
and a Thermo Fisher LTQ FT Ultra Hybrid Mass Spectrometer (Waltham, MA).  Other 
equipment specifications included, a C18 3µ Thermal Hypersil Gold 50 X 2.1 column 
and a gradient flow of acetonitrile and water (5:95 to 80:20 to 5:95).  
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2.2.4.4 Statistical analysis 
 Drug concentration in the lungs and blood of transplanted rats was 
compared to that of control rats at each time point.  Analysis was conducted using 
Minitab® Release 14 statistical software (Minitab Inc., State College, PA).  One way 
ANOVA followed by a post hoc Tukey test was used at p=0.05 to determin  significant 
differences between transplanted and non-transplanted groups.   
 
2.3 RESULTS AND DISCUSSION  
2.3.1 Formulation 
Tacrolimus, a lipophilic drug molecule (log P = 3.3) with poor water solubility (4 
µg/mL), faces formulation hurdles in order to achieve high and reproducible 
bioavailability.  Efforts to improve the oral bioavailability of tacrolimus have been made 
through the inclusion of dimethyl-β-cyclodextrin to in enhance solubility and reduce p-
glycoprotein efflux (20) as well as microencapsulation to allow fr sustained colonic 
delivery (21).  To increase solubility, stabilization of the amorphous drug within a 
hydroxypropylmethylcellulose (HPMC) matrix was used and is market in the FDA 
approved oral formulation, Prograf (22, 23).   
A similar strategy is applied in our novel pulmonary formulation in that the 
amorphous drug is stabilized; however, use of stabilizing excipients are limited to those 
that are generally recognized as safe (GRAS) for use in the lungs.  In a formulation study 
involving URF particle engineering technology, it was found that a nanostructured solid 
dispersion of amorphous tacrolimus could be created using equal parts of l ctose (17).  In 
vitro testing of this drug product showed a 10 fold improvement in peak saturation of 
tacrolimus in simulated lung fluid.  Pulmonary delivery the nanostructu ed powder 
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created by this process is facilitated by dispersion in an aqueous media, and nebulized by 
a vibrating mesh nebulizer.  Particle size analysis of the resulting colloidal dispersion 
measured 5 minutes after addition to the aqueous phase showed a monodisperse 
distribution with a mean particle diameter of 239.2 µm.  As seen in Figure 2.2, over the 
course of 30 minutes, the dispersion particle size and distribution changes, i creasing in 
diameter and becoming more heterogeneous.  The mean particle diamter grows from 
240 to 352 µm in addition to a bimodal size distribution appearing at 30 minutes afr 
dispersion.  This phenomenon is not completely unexpected since the formulation is in a 
state of thermodynamic instability and contains no stabilizing polymers or surfactants to 
provide steric or ionic hindrance of particle interactions.  Measured particle growth can 
be attributed to both particle aggregation and Ostwald ripening.  Aggregation results as 
drug particle size is reduced and overall surface area of that mass is increased, leading to 
an increase in free energy of the system.  Free energy is directly proportional to surface 
area as made evident by the following equation:   
 
                                            ∆G = γs/l  * ∆A                                                   (1) 
 
where γs/l  represents the interfacial tension of a substance and ∆A represents the 
change in surface area .  In order to reduce the free energy and become a stable system, 
particles within a nanodispersion will aggregate to form larger particles with reduced 
surface area.   
The second reason for measured particle size growth may be due to th  actual 
crystal growth, not aggregation, of small particles, referred to as Ostwald ripening.  In a 
thermodymaically supersaturated state, dissolved drug and excipient w ll begin to 
precipitate out of solution, nucleating to form small particles and dsorbing onto existing 
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ones.  The rate of Ostwald ripening is dependant on mass transport due to molecular 
diffusion, interfacial surface tension, and the solute molar volume (24).    This is the 
rationale for bimodal distribution that appears 30 minutes after powder dispersion.   
Despite the aggregation and growth of particles over time, SEM images (Figure 
2.3) and zeta potential measurements confirm that the primary particle size of the 
formulation immediately after dispersion is approximately 200 to 400 nm. To prevent 
particle size growth, nanodispersions for oral use will incorporate excipients such as 
povidones, pluronics, polysorbates, and cellulose derivatives; however, high levels of 
these stabilizers are generally not proven safe for pulmonary delivery, and can often 
result in alveolar epithelial damage (25).  For these reasons, the colloidal dispersion used 
in this study was dispersed without stabilizing excipients.  To limit changes in particle 
size distribution, all formulations were dosed within 15 minutes of preparation, before 
substantial particle growth and aggregation could occur.   
In characterizing the nebulized aerosol produced by the Aeroneb® Pro, both 
cascade impaction and laser diffraction techniques were used.  Since the nebulized drug 
product is a dispersion and not a solution, it was essential to study impaction results 
based on drug mass recovery to determine amount of drug actually delivered to the deep 
lung.  The mass median aerodynamic diameter (MMAD) of the formulation measured 
according to NGI was 4.06 µm with a geometric standard deviation (GSD) of 2.7 µm.  
The aerodynamic size distribution of the aerosol is given in Figure 2.4.  The FPF of the 
nebulized colloidal dispersion was 46.1%.  Interestingly, volume median diameter 
(VMD), as measured by laser diffraction, for the same formulation was 6.55 µm.  
Theoretically, given that the dispersion media is water (unit density), all droplets 
produced should have identical aerodynamic and geometric diameter; however, testing 
differences may explain why the MMAD and VMD vary slightly.   
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NGI measurements taken according the USP 31 do not account for the dropl t 
mass impacting in the induction port of the device, which can be assumed to r present 
droplets with aerodynamic diameters exceeding 11.7 µm (the cut off of the first stage).  
Laser diffraction analysis collects data on all droplets produced, including droplets larger 
than 11.7 µm in the calculation of VMD.  When adjusted for the drug mass present in the 
induction port of NGI, the MMAD measured by impaction increases to 5.68 µm, much 
closer to want was measured by laser diffraction.  Other impaction testing conditions may 
further influence the measured MMAD.  Berg et al have studied the effects of 
temperature and humidity on partial droplet evaporation during impaction testing and 
concluded that under most ambient conditions (25°C, 50% RH) evaporation will occur
(26).  In order to prevent the skewing toward a lower MMAD, it is suggested that NGI 
testing be conducted at 5°C and 100% RH.  Since characterization of tacrolimus colloidal 
dispersion occurred under ambient conditions, the possibility of underestimation of the 
MMAD due to evaporation is possible, and may account for the remaining difference 
between VMD and MMAD.  Pan coating is another technique that is used to enable more 
accurate characterization by limiting aerosol “bounce” during NGI testing; however, this 
effect is thought to have a minimal contribution to liquid aerosol testing (27).     
Laser diffraction measurements were used to compare the effect o  the 
nanodispersion on aerosol generation and particle size distribution.  As seen in Table 1, a 
slight increase in aerosol droplet diameter was seen after the inclusion of dispersed 
tacrolimus formulation.  While surface tension has been shown to have minimal effect on 
the size distribution of aerosols produced by vibratory mesh nebulizers (28), an increase 
in droplet diameter may be due to the disruption of aerosol productin aused by 
dispersed particulates in the aqueous phase.   
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2.3.2 Single dose transplant model 
  Therapeutic concentrations necessary to provide significant 
immunosuppression in the lungs have been shown in previous studies.  Ide and coworkers 
determined that a tacrolimus concentration of  270 ng/g in the allografted lung is 
necessary to prevent transplant rejection (14).  Similar concentratio s were achieved in 
the allografted lungs in this study (399.8 ng/g) and resulting lung and blood levels over 
24 hours were analyzed.  As shown in Figure 2.5, peak total lung concentrations shown at 
1 hr were 294.7 ± 10.5 ng/g and 301.5 ± 55.5 ng/g in transplanted and non-transplanted 
rats, respectively, showing no difference in overall lung deposition.  Tracheal deposition 
was low, accounting for approximately 10% of total drug assayed 1 hour after dosing 
(Figure 2.6).  It is uncertain whether mucociliary action would contribute to an increase 
or decrease of drug presence in the trachea since it would function to both relocate drug 
from the trachea into the laryngopharynx as well as add drug to lower regions of the 
trachea from the right and left bronchus.  At the 6, 12, and 24 hour time points; however, 
mucociliary transit should have removed all solubilized and particulae drug in the mucus 
layer, meaning that only drug absorbed into tracheal tissue remains. 
Assuming that lung levels 1 hour after dosing are an accurate reprsentation of 
deposition level, average mass deposition in the right lung, 255.8 ng, was slightly larger 
than that in the left lung, 176.5 ng.  Under normal breathing conditions a greater 
difference in deposition would be expected since the rodent right lung is on average twice 
as massive as the left, and is capable of higher tidal volumes.  When tissue concentrations 
are compared, it is evident that deposition in the left lung is higher w n adjusted for 
tissue weight (Figure 2.7).   This discrepancy in lung concentration could be attributed to 
erratic breathing behavior.  Disruptions in normal breathing in this study may have been 
due to animal excitement/anxiety during dosing, thoracic constrains of the dosing 
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chamber restraint tubes, residual pain from surgical procedures, or a combination of the 
three.  This would result in a shallow-rapid breathing rate as describ d by Valberg et al 
(29). It has been noted that shallow breathing in rodents can lead to increased deposition 
in the central airways and heterogeneity in aerosol distribution (30).  Since the right lung 
volume of the rat is much greater than the left, it is conceivable that shallow breathing 
may have a greater limitation on deposition in that right lung.  The combination of 
shallow breathing with a MMAD that is slightly greater than the normal respirable range 
(1-5µm) may have magnified this deposition difference.  
Blood concentration measured after dosing confirmed findings made my other 
authors that tacrolimus delivered directly to the lung produces minimal systemic drug 
levels.  Specifically, in a lung transplant study where aerosolized tacrolimus was 
delivered via pressurized metered dose inhaler (pMDI), the ratio of tacrolimus 
concentration in the lungs to that in the blood was 55 to 1 one hour after the final dose 
(14).  In a similar study conducted by Schrepher and coworkers,  delivery of tacrolimus 
by pMDI to tracheally transplanted rats resulted a lung to blood ratio of 63 to 1 (15).  
When delivered orally in the same animal model, lung concentrations of 580 ng/g with a 
corresponding blood level of 67.1 ng/g were reached after 1 hour, giving a lung to blood 
ratio of only 9 to 1.  As demonstrated in this rodent model, therapeutic l ng 
concentrations are possible through oral delivery, however; it has been demonstrated in 
multiple clinical evaluations that excessive systemic concentrations will lead to untoward 
side effects, resulting in the reduction or elimination of the maintenance use of oral 
tacrolimus (31).  Preferential accumulation of solubilized tacrolimus in the lungs may be 
due to its potential to associate with pulmonary tissue and phospholipids rather than 
partition into the aqueous media of the blood (32).  Evidence of this preference has been 
observed with aerosolized cyclosporine, a drug molecule sharing a simil r lipophilicity 
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(33).  Specifically, cyclosporine dosed to human lung transplant patients showed biphasic 
absorption where initial absorption into the blood was followed by slow sustained 
partitioning into systemic circulation.   
In this study, lung to blood ratios of 55 to 1 and 59 to 1 were shown in non-
transplanted and transplanted rats, respectively.  While results proved similar in all three 
studies, it has not been demonstrated in vivo if the drug deposited in the lungs is indeed 
bioavailable, or whether it is merely present in particulate form n lung epithelia.  
Characterization of tacrolimus colloidal dispersion in vitro provides substantial evidence 
that the drug is in fact bioavailable on the epithelial surface.  Enhanced solubility in 
simulated lung fluid stemming from the nano-amorphous nature of this drug product has 
been demonstrated in previous studies and may impart superior drug availability to the 
lung epithelial layer in comparison to crystalline and/or micronized drug products.  
Future animal studies are needed to confirm that the enhanced solubility in simulated 
lung fluid translates to improved solubility and drug absorption in vivo. 
It is well documented that transplanted lung allografts exhibit multiple 
postoperative complications after reperfusion (34).  While most clinica  complications 
arise from injury due to inflammatory cascades, physiological problems also exist in the 
basic functionally of the lung tissue.  Disruptions of ciliary action, lymphatic clearance, 
and surfactant composition have been noted in multiple cases of animal d human lung 
transplant.  In addition to affecting lung function and immunogenicity, these areas of 
dysfunction may cause changes in the pharmacokinetic profile due to impairment of drug 
solubility and particulate clearance.  For the transplanted rat model investigated in this 
study, it was evident that tacrolimus is retained in the transplated lung due to 
physiological disruptions caused by transplantation surgery.  Six hours afte  the dose was 
administered, a statically significant difference (p<0.05) wasob erved between the left 
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lung concentration of control and transplanted animals (Figure 2.7a).  While the exact 
mechanisms of drug retention in the transplanted lung are unclear, it is reasonable to 
assume that one or a combination of the physiological disruptions mentioned may explain 
the pharmacokinetic disparity.          
In the upper airway, disruption of the mucociliary escalator due to d nervation of 
the lung effects clearance of particulate matter, making the lungs more susceptible to 
nosocomial infection (35, 36).  This may also contribute to prolonged ret ntion of solid 
and semi-solid aerosols in bronchoalveolar tissue of transplanted lungs. Macrophage 
uptake and subsequent translocation of drug particulates to the lymphatics of he lung 
may also contribute to drug retention in transplanted tissue given that lymphatic 
circulation is also impaired (37).  Reduced functionality of the alveolar macrophage itself 
has also been recognized after lung transplantation (38).  Finally, heightened insolubility 
of the drug formulation in pulmonary fluids may also contribute to retention of drug 
within transplanted lungs.  Previously, it has been shown that amorphous tacrolimus can 
achieve concentrations in excess of 70 µg/mL in simulated lung fluid (17); however,  the 
epithelial fluid of the transplanted lung has been shown to contain decreas d fr ctions of 
pulmonary surfactant (i.e. dipalmitoyl-phosphatidylcholine (DPPC)) (39 .  Wetting and 
eventual dissolution of drug particles could be reduced in an environment wh re this 
surfactant is not present and the surface tension of the fluid layer is increased (15.8 mN/m 
v 3.4 nN/m).  If tacrolimus drug particles deposited in the transplanted lungs show a 
reduced solubility when compared to those deposited in normal lungs, retention of the 




2.4 CONCLUSION  
It is clear that tacrolimus colloidal dispersion can be effectiv ly nebulized to the 
lungs of lung transplanted rats to obtain therapeutic local concentratio s.  As 
hypothesized, resulting systemic concentrations remained low, not exceeding 6 ng/mL 
after a single dose and avoiding potentially toxic levels.  Althoug it has not been 
demonstrated in vivo whether or not tacrolimus colloidal dispersion remains s 
particulates in the airway or is fully bioavailable as a solutin in pulmonary fluid, 
previous studies have demonstrated in vitro that the formulation possesses the capability 
of supersaturating simulated lung fluid (17).  This suggests that tacrolimus colloidal 
dispersion may be more locally bioavailable than previously studied formulations.  This 
combined with the natural lipophilicity of the molecule may allow for high pulmonary 
bioavailability with low resulting system drug levels, as shown in this study. 
Surprisingly, absorption of drug from the transplanted lung showed a slight, but 
significant retention of deposited drug.  Denervaition and physiological ch nges in 
transplanted tissue are most likely the reason for this pharmacokinetic difference.   
Several studies have shown the benefits of localized therapy in pulmonary 
delivery for maintenance or rescue immunosuppression in lung transplant recipients.  
Tacrolimus, a more potent and clinically effective immunosuppressive agent, is the 
therapy of choice for lung transplantation; although it presents some f rmulation 
challenges.     Using solubility enhancing technology adapted with a method of localized 
therapy may prove to further enhance the therapeutic potential of tcrolimus for lung 
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Chapter 3: Preclinical Safety Evaluation of Tacrolimus Dispersion for 
Nebulization 
 
3.1 INTRODUCTION  
  
Immunosuppressive therapy has become increasingly important in the succes  of 
solid organ and bone marrow transplantation over the past 25 years.  With advances in 
donor matching, continued surgical innovation, and the introduction of calcineurin 
inhibiting immunosuppressive drugs, the likelihood of allograft rejection has been 
substantially reduced, increasing a patient’s probability of survival and quality of life.  
Currently, lung transplantation is the least successful of all common solid organ 
transplant procedures.  Despite the improvements in surgical techniques and development 
of more potent immunosuppressive drugs, the survival rate of lung transplant patients 5 
years post-op is only 50 percent (1).  Many of the complications associ ted with 
treatment and maintenance dosing of lung transplant recipients ca  be attributed to the 
delicate balance that exists between proper immunosuppression of the lungs and 
prevention of untoward side effects and opportunistic infection.  The immunologica  
function of the lung is poorly understood and unique from any other organ of the body 
(2), complicating diagnosis and treatment of many immune-related lung diseases.  
Generally, immunosuppression of the allografted lung is achieved through oral dosing of 
a three drug regimen consisting of a calcineurin inhibitor, purine sy thesis inhibitor, and 
corticosteroid(3).  Maintenance dosing is continued for the rest of the patient’s life and 
does not routinely involve corticosteroids due to side effects associated with prolonged 
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administration.  Tacrolimus (TAC) and mycophenolate mofetil are the most common 
calcineurin inhibitor and purine synthesis inhibitor used for maintenance therapy.     
 A more logical approach for pulmonary immunosuppression is to 
administer the therapeutic agent directly to the lung via an inhalable aerosol.   
Researchers have investigated the delivery of an aerosolized calcineurin inhibitor, 
cyclosporine A (CSA), in animal models for determination of its efficacy and safety in 
lung tissue.  In a safety study in rodents and canines, Wang and coworkers determined 
that inhaled cyclosporine presented no detrimental effects on pathology r lung function, 
even at 2.7 times the proposed human dose (4).  This strategy has been investigated by 
various clinicians as well in hopes to improve maintenance therapy and prevent lung 
transplant rejection (5-8).  Clinical trials involving lung transplant recipients have shown 
that while no statistical improvements in acute graft rejection were seen when compared 
to inhaled placebo, prevention of chronic rejection, and ultimately patient survival, were 
significantly improved with aerosolized CSA (7).  In these trials, nebulization of CSA 
was facilitated by dissolving it in a viscous, non-toxic solvent, propylene glycol.  While 
recognized as safe for use in pulmonary drug products, high levels of propylene glycol 
have been shown to cause  mild to moderate irritation and cough in a majority of patients, 
and may require the use of a local analgesic before administration (7).  Additionally, the 
high viscosity of propylene glycol may prevent proper aerosol production w th certain 
nebulizers, changing aerosol characteristics and possibly limiting deep lung deposition 
(9).  These factors, as well as a relatively less potent therapeutic effect, may reduce the 
inclination for clinical acceptance of this therapy.          
Tacrolimus, first commercialized by Fujisawa, Inc in 1990 as Prograf®, elicits a 
therapeutic response by inhibiting the functionality of calcineurin and has been shown to 
be 10 to 100 times more potent than CSA (10).  Clinical comparisons of oral CSA and 
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TAC in solid organ transplant patients have concluded that TAC improves both short 
term graft success (11, 12) and overall patient survival (13).  In a pharmacoeconomic 
comparison, TAC was shown to reduce the associated healthcare and ther py costs by at 
least 25% in kidney transplant patients when compared to CSA (14).  Other indications 
where TAC has been investigated for reduction of inflammation include atopic dermatitis 
(Protopic®), ulcerative colitis, graft-versus-host disease, and asthma (15).    
While TAC therapy has noted success clinically and is currently more widely 
administered for transplantation than CSA (16), a variety of adverse side effects are 
associated with elevated systemic concentrations over prolonged periods of therapy.  
Among the most severe and commonly occurring side effects associted with oral TAC 
are nephrotoxicity, neurotoxicity, hypertension, diabetes mellitus, and increased risk of 
opportunistic infection; all of which have shown some evidence of dose dependenc .  
Typically, neurotoxicity due to TAC maintenance therapy will result in mild effects such 
as headache or tremor.  Cases of TAC-induced severe neurotoxicity are rare; however, 
they can lead to symptoms such as seizure, delirium, or coma and are commonly enabled 
by a reduction in p-glycoprotein efflux function (17).  High sustained systemic 
concentrations of TAC can also lead to new onset diabetes mellitus (NODM).  In a recent 
study analyzing reports form the past decade of calcineurin inhibitor- nduced NODM, 
evidence showed that TAC was found to be more likely to cause this disease than CSA 
(18).  A higher concentration of FK506 binding protein (FKBP-12) in the pancre s may 
explain the greater incidence of NODM in patients receiving TAC.  In comparison to 
therapeutic maintenance therapy with CSA, cardiovascular events associated with TAC 
are significantly reduced (19).  Close monitoring of trough blood concentrations is 
critical among patients using oral TAC to avoid severe side effects normally associated 
with blood levels above 50 ng/ml and to monitor variability of intestinal absorption. 
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 In order to avoid systemic side effects that might lead to dosing protocol 
complications, additional medication, and elevated patient discomfort, a method of drug 
delivery in lung transplant patients providing a reduced systemic TAC concentration is 
needed.  Additionally, local concentrations exceeding those provided by current oral 
therapy could potentially increase pulmonary therapy, resulting in enhanced suppression 
of the local immune response.  This study investigates the safety and pharmacokinetics of 
once-daily TAC colloidal dispersion in a rodent model over 28 consecutive days.  Blood 
chemistry, complete blood cell count, and tissue histology were conducted to evaluate the 
physiological effect of the dosing regimen.   Evaluation of the stability of TAC powder 
for reconstitution is also reported.  By providing organ-targeted therapy, multiple doses 
of TAC should provide heightened lung concentration, while reducing toxicity-inducing 
systemic blood levels.      
 
3.2 MATERIALS AND METHODS  
3.2.1 Materials 
Tacrolimus anhydrous (batch # 070405) was purchased from Haroui Pharma-
Chem (Edison, NJ).  High Performance Liquid Chromatography (HPLC) grade 
acetonitrile, lactose monohydrate, zinc sulfate heptahydrate, barium hydroxide (0.3 N), 
magnesium chloride, sodium phosphate dibasic anhydrous, sodium sulfate anhydrous, 
calcium chloride dihydrate, sodium acetate trihydrate, and phosphoric acid (85%) were 
all purchased from Fisher Scientific (Fair Lawn, NJ).  Sodium chloride and normal 
buffered formalin solution (10%) were purchased from Sigma-Aldrich, Inc. (St. Louis, 
MO).  Potassium Chloride was purchased from EM Industires, Inc. (Gibbstown, NJ). 
Dipalmitoylphosphatidylcholine (DPPC) was purchased from Avanti Polar-Lipids, Inc. 
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(Alabaster, AL).  Sterile 0.9% Sodium Chloride for injection, USP was purchased from 
Hospira, Inc. (Lake Forrest, IL).  Heparin Sodium (10,000 IU/mL) was purchased from 
Baxter Healthcare (Deerfield, IL).     
 
3.2.2 Formulation composition and preparation 
TAC powder for reconstitution was prepared using the Ultra-rapid Freezing 
(URF) process described by Sinswat (20).  Equal amounts of TAC and lactose are 
dissolved in acetonitrile/water (60/40) so that the total solids content of the formulation is 
0.75% w/v.  The solution is applied to a stainless steel rotating drumthat has been 
cryogenically cooled to -50°C.  The frozen solution is collected in liquid cryogen and 
freeze dried using a VirTis Advantage Tray Lyophilizer (VirTis Company Inc., Gardiner, 
NY) to remove water and organic solvent.  A detailed explanation of this particle 
engineering technology is given by Overhoff et al (21).  Product was packaged under 
nitrogen at 25°C and less than 20% relative humidity.   
 
3.2.3 In vitro characterization 
3.2.3.1 Powder x-ray diffraction (PXRD) 
X-ray diffraction patterns were determined for the drug product stored for up to 3 
months using a Philips 1710 X-ray diffractometer with a copper target and nickel filter.  
Leveled powder was measured from 15 to 55 2θ degrees using a step size of 0.05 2θ 
degrees and a dwell time of 2 seconds.   
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3.2.3.2 Dissolution testing 
Evaluation of the ability of formulated powder to supersaturate simulated lung 
fluid (SLF) was performed using a modified United States Pharmacopiea (USP) 31 Type 
2 dissolution apparatus.  Five small volume vessels were filled with 97 mL of SLF with 
0.02% DPPC, maintained at 37°C, and stirred at 100 rpm.  Preparation of SLF was 
carried out as outlined by Davies et al (22).  Addition of 0.02% DPPC was performed by 
creating a thin lipid film via rotary evaporation with a Buchi Rotavapor R-210 (Flawil, 
Switzerland) and dispersing in SLF at 50°C (23).  Five aliquots of 20 mg TAC powder 
for reconstitution were weighed, placed in 20 mL scintillation vials, nd dispersed in 3 
mL de-ionized water.  Dispersion was facilitated by probe sonication with a Branson 
Sonifier 450 (Danbury, CT) (output 6, 10% interval) for 2 minutes under cooled 
conditions.  Immediately after dispersion, each vial was added to a respective dissolution 
vessel.  Aliquots of 2 mL were drawn at 5, 15, 30, 60, 120, and 240 minutes and filtere
through 0.2 µm PTFE teflon syringe filters (National Scientific, Rockwood, TN).  
Subsequently, 1 mL of the filtrate is added to 1 mL HPLC mobile phase, consisting of 
acetonitrile, water, and phosphoric acid in a ratio of 600:400:1.  Quantitation of each 
sample is performed by HPLC according to a method adapted from Akashi et al (24).  A 
Waters 515 liquid chromatograph with a Water 996 Photo Array (Water Corp. Milford, 
MA) outfitted with a Lichosphere RP C18, 4 mm X 250 mm, 5 µm column (Varian 
Corp., Lake Forest, CA) was used for analysis.  Analysis conditis such as flow rate, 
column temperature, and injection volume were 1.5 mL/min, 50°C, and 20 µL, 
respectively.  Tautomers of TAC eluted at 8.3 and 13.2 minutes, while the main drug 
peak eluted at 17 minutes.  All three peaks were measured at 215 nm and represent the 
active moiety, therefore all three were used in quantitation.  Standards, prepared in 
mobile phase by serial dilution, ranged in concentration from 100 to 3.125 µg TAC per 
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mL.  Standard curve linearity (r² = 0.999), system precision (RSD = 1.9%), and accuracy 
were validated for this method.    
        
3.2.3.3 HPLC Testing 
Five concentrations, 5, 2.5, 1.25, 0.625, and 0.3125 mg/mL, of bulk TAC in 
HPLC mobile phase were evaluated for purity using the HPLC method explained in 
section 3.3.3.2.  Noise contribution from the solvent front was determined by blank 
injection and was seen to affect the chromatograph baseline until approximately 3.5 
minutes after injection.  All detectable non-tacrolimus peaks occurring after the solvent 
front were considered impurities and compared to tacrolimus peaks for determination of 
percent impurity.  The effect of processing, excipients, and storage n TAC purity in the 
drug product was also evaluated.  Product purity was evaluated immed ately after 
production and after 1, 2, and 3 months storage in sealed packaging at room temperature.  
Samples containing between 4 and 5 mg of drug product were dissolved in 2 mL mobile 
phase and analyzed by HPLC.  Two samples were reconstituted and analyzed for each 
month storage.  For identification of potential degradants, a battery of forced degradation 
tests were performed on the bulk drug in accordance with the guidelines presented by the 
International Conference on Harmonization Q3B(R2).   Acidic, alkaline, oxidative, and 
thermal degradation were each induced to a 5 mL solution containing 1 mTAC in 
acetonitrile.  Acid degradation was accomplished by adding 10 mL 1N HCl and 
incubating for 1 hr at room temperature.  The reaction was quenched by the addition of 
10 mL 1N NaOH.  Similarly, base degradation incubated the samples for 1hr with 10 mL 
1N NaOH.  The reaction was quenched with 10 mL 1N HCl.  Oxidative degradation 
involved the addition of 1 mL 30% H2O2 to the solution and incubating for 1 hr.  
Thermal degradation was completed by incubation in a 60°C water bath for 6 hours.  At 
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the conclusion of quenching and/or incubation, all samples were diluted to 100 mL with 
water.  Two milliliters of the diluted sample was filtered through a 0.2 µm PTFE teflon 
syringe filter.  One milliliter was then added to 1 mL mobile phase and injected for 
HPLC analysis.  Degradation peaks were identified and quantitated by the HPLC method 
outlined in section 3.2.3.2. 
HPLC was used to analyze the drug product potency after 1, 2, and 3 months 
storage.  Samples of between 4 and 5 mg of drug product were dissolved in 2 mL mobile 
phase and analyzed by HPLC.  Two samples were reconstituted and analyzed for each 
month storage.  Based on manufacture and batch formula detailed in section 3.3.2, 
theoretical potency is presumed to be 50% of the total drug product weight.     
 
3.2.3.5 Residual solvent analysis 
Gas chromatography (GC) performed with a Hewlett Packard 5890 Series II GC 
(Hewlett Packard, Palo Alto, CA) was used to determine the drug product residual 
solvent levels according to a revised USP 467 method for class 2 solvent .  A Zebron™ 
ZB-624, 30m, 0.32 id, 1.8 µm column (USP phase G43) (Phenomenex, Torrance, CA) 
was used at a helium flow rate of 2.2 mL/min.  Injection temperature as set at 140°C and 
oven temp was set to 40°C for the first 10 minutes then increased to 240°C for another 10 
minutes.  Flame ionization detector (FID) temperature was set at 240°C.  Standards for 
injection contained a concentration of 4, 2, 1, 0.5, and 0.25 µL/mL acetonitrile (ACN) in 
dimethyl sulfoxide (DMSO).  ACN peak elution occurred 6.15 minutes after injection.   
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3.2.4 In vivo tolerability study in a rat model 
3.2.4.1 Pulmonary dosing method and regimen 
TAC colloidal dispersion was administered to healthy male and female Sprague 
Dawley (SD) (Harlan Inc., Indianapolis, IN) rats in clean, humane conditions and in 
accordance with an Institutional Animal Care and Use Committee (IACUC) approved 
protocol.  Aerosol was produced by vibrating mesh nebulization using an Aeroneb® Pro 
(Aerogen, Galway, Ireland) and delivered to the animals via a four port nose-only dosing 
chamber (20).   
Eight female and 8 male rats were given treatments containing TAC (active 
group) for 28 days, while 4 male and 4 female rats were given equivalent volumes of 
normal saline (control group) for the same period.  Six rats in the active group and 4 of 
the control group were maintained for one week after the last dose in order to evaluate 
resolution of any pulmonary inflammation that might occur after 28 days of active 
treatment.  All other animals were sacrificed 24 hours after th  last dose was 
administered.  Eight animals in the active group were designated for determination of 
pharmacokinetic parameters.  All other animals were designated for histopathological 
evaluation.     
    Before nebulization, 6.4 mg TAC powder for reconstitution was dispersed 
in 3 mL deionized water as described in section 3.3.3.2.  Rats were exposed to the 
aerosolized dispersion for approximately 10 minutes, or until completion.  O ce daily 
aerosol administration was performed at the same time each day for 28 days.  Animals 
were sacrificed by isoflurane (over 10%) inhalation and subsequently confirmed with 
cardiac puncture.  Approximately 3 mL of whole blood was drawn for pharmacokinetic 
analysis and hematological testing.  Blood for pharmacokinetic analysis was placed in 1.5 
mL conical tubes containing 20 µL of 10,000 IU/mL heparin sodium.  Lung tissue was 
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excised from designated rats and frozen at -20°C until determination of TAC levels by 
tissue extraction.  Liver, spleen, kidney and lung tissue was excied and fixed in 10% 
formalin solution for histological investigation.   
    
3.2.4.2 Analysis of tacrolimus levels in whole blood 
Heparinized whole blood samples were evaluated for TAC levels using Enzyme-
linked Immunosorbent Assay (ELISA).  A PRO-Trac™ II FK 506 ELISA kit was 
purchased from Diasorin Inc (Stillwater, MN) and used according to the manufacturer’s 
protocol.  Fifty microliters were taken from each of 5 standards (ranging from 0.3 ng/mL 
to 30 ng/mL), 2 controls, and all whole blood samples and added to a 1.5 mL conical 
tubes along with 300 µL reconstituted digestion reagent.  Each tube was mixed, then 
incubated for 15 minutes at 75°C.  To separate digested cellular contents, c trifugation 
was conducted at 1800 g for 10 minutes, after which 100 µL of supernatant were added to 
duplicate wells of a goat anti-mouse IgG coated 96-well plate.  Fifty microliters of anti-
tacrolimus monoclonal antibody were added, followed by plate incubation and shaking at 
room temperature and 700 rpm form 30 minutes.   After incubation, 50 µL of tacrolimus-
horseradish peroxidase conjugate were added and the plate was shaken ag in for 60 
minutes at 700 rpm.  Liquid contents of the wells were then removed by washing, and 
200 µL chromogen were added, and shaken again for 15 minutes at 700 rpm.  The 
reaction was stopped by 100 µL of acidic stop solution and the plate was immediately 
read at dual wavelengths of 450 and 630 nm on a Bio-Tek® Instruments UV/Vis µQuant 
plate reader (Winooski, VT).  The standard curve was plotted using Sigma Plot Systat 
Software Inc. (San Jose, CA) and fit with a 4-parameter logistic curve.   
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3.2.4.3 Analysis of tacrolimus levels in lung tissue 
TAC was extracted from rodent lung tissue by a liquid extraction procedure and 
quantitated using liquid chromatography / mass spectrometry (LC/MS).  Before tissue 
homogenization, 1.25 µg of internal standard (sirolimus) dissolved in 1 mL acetonitrile 
was added to the tissue.  Two milliliters of normal saline were added to the lung tissue 
before homogenization.  Lung tissue was homogenized in a scintillation vial for 
approximately 5 minutes at cooled temperatures.  To extract TAC from bound tissue 
proteins, 0.1 mL of 0.3N barium hydroxide, 0.1 mL of 0.4N zinc sulfate hepahydrous, 
and 7 mL acetonitrile were added to the homogenate.  The homogenate was vortexed for 
30 seconds and placed in 15 mL polypropylene centrifugation tubes (Fisher Scientific, 
Fair Lawn, NJ).  Centrifugation was conducted for 15 minutes at 3000g.  Supernatant was 
then removed and filtered through a Whatman 0.45 µm nylon syringe filter (Fisher 
Scientific, Fair Lawn, NJ).  Water and acetonitrile were removed from the supernatant by 
12 hr lyophilization ramping from -40°C to 25°C after freezing the sample.  The resulting 
solids were reconstituted in 2 mL acetonitrile and centrifuged again at 3000 g for 15 
minutes.  One milliliter of the supernatant was taken for injection and analysis by 
LC/MS.  A Thermo Fisher Surveyor Plus HPLC system with PDA (Waltham, MA) was 
used in combination with a Thermo Fisher LTQ FT Ultra Hybrid Mass Spectrometer 
(Waltham, MA) for sample analysis.  The system was outfitted with a C18 3µ Thermal 
Hypersil Gold 50 X 2.1 column, injected 10 µL of each sample, and run at a flow rate of 
10 µL/min.  Gradient flow was of acetonitrile and water were used where acetonitrile and 
water concentrations were 5% and 95% initially, changed to 80% and 20% at 17 min, and 
gradually ramped to back to 5% and 95% at 20 minutes, respectively.  TAC was 
quantitated by integration of peaks occurring between 825.5 and 827.5 m/z. 
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3.2.4.4 Complete blood count and serum chemistry 
After cardiac puncture, approximately 1 mL of blood was used for complete 
blood count (CBC) and serum chemistry.  Samples were drawn and the needle was 
removed to prevent excessive red blood cell lysing.  Lavender-topped BD Microtainer® 
tubes with K2EDTA (VWR Scientific, West Chester, PA) were filled betwen 250 µL 
and 500 µL.  Each tube was then inverted 10 times to ensure thorough anti-coagulant 
mixing.  For serum chemistry analysis, whole blood samples between 400 µL and 600 µL 
were added to yellow-topped BD Microtainer® SST tubes (VWR Scientific, West 
Chester, PA), inverted 5 times, and allowed to remain at room temperature to coagulate 
for 30 min.  Coagulated blood is then centrifuged at 6000 g for 90 seconds.  After
centrifugation, blood serum was pipetted into a 1.5 mL conical vial.  Both CBC and 
serum chemistry samples were kept at 4°C until analysis.  Analysis was run within 24 
hours of blood draw by IDEXX preclinical research services (Westbrook, ME). 
   
3.2.4.5 Tissue histology 
At completion of the dosing regimen, lung, kidney, liver, and spleen tissue of both 
control and experimental groups were reviewed by two different blided examiners.  
Eight rats having received 28 days of once daily TAC colloidal dispersion were 
evaluated; four were sacrificed 24 hours after the final dose, the other f ur sacrificed 168 
hours after the final dose.  Eight control rats followed the same dosing regimen and 
received aerosolized normal saline instead of TAC.  Lung tissue was instilled with 5 mL 
of 10% formalin through cannulation of the trachea, submerged in 40 mL 10% formalin, 
and embedded in paraffin wax.  Lung sections were stained with haematoxylin and eosin 
(H&E), cluster of differentiation 68 (CD 68), and periodic acid Schiff (PAS) and 
evaluated.  Kidney, liver, and spleen were also submerged in 40 mL formalin and fixed in 
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paraffin wax.  Non-lung tissue sections were stained only with H&E.  Histopathologic 
inflammation scores were assigned according to the criteria outlined by Cimolai et al 
(25).           
 
3.2.4.6 Statistical analysis 
Statistical analysis of CBC and serum chemistry results was run using Minitab® 
Release 14 statistical software (Minitab Inc., State College, PA).  One way ANOVA 
followed by a post hoc Tukey test was used at p=0.05 and p=0.01 to determine significant 
differences between control and experimental groups. 
  
3.3 RESULTS AND DISCUSSION 
3.3.1 In vitro characterization 
An amorphous nanoparticulate drug formulation offers advantages over 
crystalline drug products in that bioavailability may be enhanced by increased solubility, 
reduced drug particle size, and improved wetting.  The marketed oral formulation of 
TAC, Prograf®, uses this rationale by providing improved solubility through a solid 
dispersion of TAC and hydroxypropyl methylcellulose (HPMC) (26).  For purposes of 
pulmonary delivery, lactose is a more attractive choice for stabiliz tion of TAC due to its 
recognition by the FDA as a safe excipient for pulmonary products.  Additionally, lactose 
is water soluble and has been used as a lyoprotectant (27), making it likely to provide 
stability to amorphous TAC upon storage.  When added to aqueous media, the 
solubilization of lactose and thermodynamic instability inherent in amorphous TAC 
results in a supersaturated solution during the initial stages of dissolution.  After 
approximately 30 minutes, supersaturated TAC comes out of solution to f rm the more 
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kinetically favored precipitated state.  In order to determine the stability of our 
amorphous drug product for reconstitution over 3 months at the conditions previously 
described, PXRD and supersaturation dissolution testing were conducted.  I  was 
determined that the drug formulation maintained its amorphous nature throughout the 3 
month period.  Figures 3.1 and 3.2 show that amorphous TAC is still present throughout 
the 3 month period and that the capacity to supersaturate SLF is still present.  It is clear 
that a ratio of 1:1, lactose to TAC, was adequate to maintain the low density porous 
nature of the formulation and prevent recrystallization.  The ability to supersaturate SLF 
containing 0.02% DPPC and the presence of amorphous drug has been shown to increase 
both the Cmax and Tmax in the blood and lungs when compared to crystalline drug 
formulations dosed to ICR mice (20), and may be instrumental in improving 
bioavailability in humans.  
To determine the effect of varying methods of degradation, a battery of 
accelerated degradation tests were performed.  At absorbance measurements taken 
between 215 nm and 300 nm, all major degradation peaks showed the highest absorbance 
at 215 nm, allowing for detection of degradants and TAC at the same wav length.   
Chromatographic results of acidic, alkaline, oxidative, and thermal degra ation can be 
seen in Figure 3.3 and Table 1.  TAC was susceptible to both alkaline and acidic 
hydrolysis, while thermal and oxidative degradation procedures had less eff ct.  Based on 
chromatographic results of samples stored for up to 3 months, the manufactured drug 
product showed less than 0.2% degradants at each time point.  Assuming that the 
potential human dose of TAC in this drug product is 6 mg once daily, this drug product is 
below the thresholds for identification (0.5% degradants) and qualification (1.0% 
degradants) according International Conference of Harmonisation (ICH) guidelines, and 
only requires that degradants be reported (28).  Measurements of drug purity and potency 
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within the drug product were measured by HPLC analysis and are isplayed in Table 2.  
Percent potency was calculated assuming that the theoretical potency of TAC was 50% of 
the formulation weight. 
Organic solvent remaining after lyophilization is regulated by the FDA in drug 
products based on a toxicity classification system to ensure patient safety.  Residual 
solvent may also accelerate or contribute to product physical instability due to its 
solubilizing effect on the active ingredient.  Testing for residual solvent was conducted 
for quantification of ACN that may remain in the drug product after th  URF production 
process.  Based on trends in peak height and a chromatograph noise height of 500 counts, 
the detection limit (based on 3:1 signal to noise ratio) of this system was approximately 
0.1 µL/mL for detection of ACN in DMSO.  The limit of quantitation (LOQ) for this 
method based on a 10:1 signal to noise ratio is approximately 0.25 µL/mL for detection 
of ACN in DMSO.  According to ICH guidelines, 410 ppm of ACN is the allowable 
concentration in a 10 g drug product (29).  While our drug product is approximately 5 g 
after reconstitution with 5 mL saline, we assumed 410 ppm to be the maximum allowable 
concentration of ACN residual in TAC powder for reconstitution.  As shown in Figure 
3.4, no detectable amount of ACN was measured when a dose of 50 mg TAC powder for 
reconstitution was dissolved in 1 mL DMSO. It can therefore be determined that this drug 
product is below the maximum allowable ACN concentration, even at levels well beyond 
the anticipated human dose.  
         
3.3.2 In vivo tolerability 
To determine the amount of TAC present in the lungs and corresponding systemic 
concentrations, blood and lung tissue levels were analyzed by ELISA and LC/MS.  After 
28 consecutive daily nebulized doses, analysis of lung tissue and whole blo d revealed 
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peak concentrations of 1758.7 ± 80.0 ng/g  and 10.1 ± 1.4 ng/mL, respectively.  Figure
3.5 shows the relationship between lung and blood concentrations at 1, 24, and 168 hrs
after the final dose was administered.  In a separate single dose study, rats exposed to the 
same nebulized dose (6.4 mg TAC colloidal dispersion) showed 1 hr tissue and blood 
levels of 294.8 ng/g and 4.9 ng/mL, respectively (study not yet published).  These results 
demonstrate that there is substantial drug accumulation in the lungs after multiple 
pulmonary doses, reaching nearly 6 times single dose levels after 28 consecutive doses.  
It is most likely that accumulation of TAC is a result of the lipophilic nature of the 
molecule.  TAC, with a Log P of 3.8, shows a strong preference for lipid solubilization, 
while CSA has a  Log P of 4.3 (30).  With a similar lipophilic nature and molecular 
weight, it might be expected TAC and CSA would behave similarly in vivo, binding to 
proteins and lipid membranes.  Multiple studies have been conducted to evaluat  the 
efficacy and pharmacokinetics of aerosolized CSA, as mentioned above.  Similar to our 
findings, investigators have determined that cyclosporine exhibits substantial lung 
retention, having a mean terminal half life of 40.7 hr after aerosolization compared to 6.5 
hr with intravenous administration (31).   Rationale for lung retention has been attributed 
in part to two major mechanisms.  First, drug interaction with phospholipids (32) and 
proteins (33) in pulmonary fluid as well as drug association with the pulmonary epithelial 
have been demonstrated and are believed to be a significant cause in pulmonary drug 
retention.  Additionally, hydrophobic molecules such as CSA (34) and itraconazole (35) 
in the lung have been shown to experience macrophage uptake, where prolonged release 
and/or transport to bronchial-associated lymphoid tissue (BALT) may occur.  Monitoring 
of TAC association with a common alveolar protein, surfactant protein A, has been 
accomplished in vitro by Canadas and coworkers.  By derivatizing TAC with a 
fluorescing moiety, the equilibrium association constant and Gibbs binding free energy of 
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TAC to an alveolar lipoprotein were determined.  Results showed that, like CSA, TAC 
preferentially binds to proteins in the alveolar fluid (33). 
 By providing high local concentrations and maintaining systemic levels 
well below those known to cause adverse side effects, inhaled TAC colloidal dispersion 
represents an improvement on current therapies for lung transplant recipients.  Another 
potential application of inhaled TAC could be for supplementary dosing to assist with 
patients showing poor or highly variable gastrointestinal absorption.   Administration of 
large immunosuppressive doses to the lungs may be able to contribute to main enance of 
therapeutic blood levels by acting as a biological depot, resulting in slow release from 
lung tissue, reducing oral dosing requirements, and limiting the impact of poor intestinal 
absorption.  This could be particularly useful in patients showing poor oral 
bioavailability, such as in cystic fibrosis populations, where the permeability of the 
intestinal wall is reduced (36).  Investigation into the ability of the lungs to serve as a 
potential drug reservoir for sustained release will be investigated in futurestudi s.         
Comparison of CBC and serum chemistry results of rodents dosed for 28 
consecutive days with TAC colloidal dispersion to those administered aerosolized normal 
saline showed no clinically significant difference for both 1 day and 1 week after the final 
dose (Table 3).  While mean eosinophil count of the group sacrificed one week after the 
final dose did show significant difference (0.5% vs. 1.7%; p < 0.01) from the saline dosed 
group, this is still within the normal range (37).  More importantly, the value was not 
significantly different after 28 days of treatment with inhaled tacrolimus and histological 
evaluation of the lungs revealed no increase in eosinophils for either treatment group.  In 
fact, no individual animal in this study showed eosinophil levels higher that 196 cells/µL.  
Decreased platelet count may be due to partial clotting of samples and/or analysis of 
samples at room temperature rather than 37°C, which has been reported to cause 
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clumping in EDTA-anticoagulated blood (38).  While TAC has shown to cause cases of 
diabetes mellitus and hyperglycemia, in our study hyperglycemia was also noted in 
control rats at statistically similar levels.  The increased level of blood glucose can be 
attributed to the use of high levels of isoflurane which both decreases glucose clearance 
and increases glucose production (39).  
Normal liver and kidney function were determined by serum chemistry analysis.  
The hepatic panel, seen in Table 4, while having no difference between groups, showed 
elevated aspirate amino transferase and alanine amino transferase l vels for several 
potential reasons.  Hypoxia after animal euthanasia, red blood cell hemolysis (40), and 
liver damage (41) caused by excessive isoflurane inhalation during sacrifice all could 
have contributed to these increased transferase levels.  Significant differences were 
observed in creatinine and albumin levels; however, both showed improved kidney 
function relative to control.  Change in serum creatinine was assumed clinically 
insignificant, since normal maintenance therapy with TAC is often associated with 
increased serum creatinine due to nephrotoxicity (42).  Interestingly, creased albumin 
levels have been reported in the treatment of lupus nephritis with low doses of oral TAC 
(43).  In one study, TAC trough levels of 4-6 ng/mL reversed hypoalbuminae ia in 5 of 
6 patients over two years of therapy (44). 
  Evaluation of lung, liver, spleen, and kidney tissues in both experimental 
and control groups prepared by H&E stain showed no evidence of inflammation, cell 
lysis, or histologic lesions.  Nephrotoxicity, one of the most common occurring side 
effects of TAC, is defined as interstitial lesions, vasoconstriction, and fibrosis of renal 
tissue (45).  Over expression of transforming growth factor (TGF)-β α –smooth muscle 
actin leads to an overproduction of fibrous tissue, normally associated with wound 
healing and vasoconstriction (46).  Calcineurin inhibitor-induced nephrotoxicity is 
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defined structurally as any occurrence of lesions within the fixed specimen.  
Nephrotoxicity can be diagnosed pathologically when tissue biopsy shows evidence of 
progressive arteriolar hyalinosis, striped cortical fibrosis, or severe tubular 
microcalcification (47).  In our study, histological examinations of the kidneys showed no 
evidence of nephrotoxicity, and were in distinguishable from controls. 
   In addition to H&E staining, the lungs were stained with CD68 and PAS 
for determination of alveolar macrophage and monocyte presence and airway mucus 
production, respectively.  Figure 3.6 displays lung sections representativ  of those 
evaluated in for each stain.   Results in both cases showed no difference to control slides 
analyzed, meaning inhaled TAC did not cause increased macrophage, monocyte, or 
mucus production, which may commonly be associated with pulmonary irritation.  These 
results demonstrate that inhaled TAC not only is safe in rodents, but may also cause 
minimal-to-no irritation.  Considering the only excipient included in the formulation is 
lactose, an excipient generally recognized as safe for inhalation, one would not expect 
considerable toxicity in the lung unless it was drug related.  As mentioned previously, 
inhaled CSA, aerosolized by solubilizing CSA in propylene glycol, has been succes ful in 
clinical testing in humans (7); however, it has produced upper airway irritation in a 
portion of patients, most likely due to the hygroscopicity of propylene glycol.     
 
3.4 CONCLUSION  
It has been successfully demonstrated that TAC colloidal dispersion dosed once 
daily for 28 days at clinically relevant levels does not induce signs of blood or tissue 
toxicity.  Multiple doses showed some lung accumulation; however, systemic l vels 
remained lower than those seen in normal oral dosing.  No significant ch ges were seen 
in hepatic and renal function panels and lung tissue showed no signs of damage or 
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inflammation.    Furthermore, TAC powder for reconstitution proved to maintain its 
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Chapter 4: Evaluation of Tacrolimus Dispersion for Nebulization in an 
Ovalbumin-induced Asthma Model 
 
4.1 INTRODUCTION  
Asthma is a reversible respiratory disease characterized by epithelial 
inflammation, increased mucus production, and constriction of the airways.  Effecting 
over 300 million people worldwide (1), asthma is a common disease that represents a 
significant burden to international heath care.  Anti-inflammatory and bronchodilator 
therapy, provided by inhaled corticosterioids (IC) and β2- agonists, is commonly used to 
treat the symptoms of asthma, and is effective in most patients.  As a first line therapy for 
treatment of asthma, use of IC is increasing among all age groups.  As a consequence of 
frequent use, many patients develop partial or full resistance to orticosteroids, resulting 
in a need for increased dosage or alternative therapy.  These patients constitute 
approximately 5 to 10 % of all asthmatics account for nearly 50% asthma related  health 
care costs (2).  Increased IC dosage is often associated with unwanted complications, 
particularly in children (3),  and can lead to adverse side effects such as adrenal 
insufficiency, glucose intolerance, skin thinning, decreased bone density, and potential 
growth suppression (4).  As a result of these complications and developed tolerance to 
corticosteroid-based asthma therapy, alternative anti-inflammatory pharmaceuticals have 
been investigated.        
Immunomodulaing therapies using both small molecule pharmaceuticals and 
biopharmaceutical have been investigated for treatment of corticosteroid r sistance (CR) 
in asthma; however none of been generally accepted the standard therapy.   
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Biopharmaceuticals have been developed for treatment of severe or CR asthma and 
specifically designed to bind with and block immune-signaling cytokines and antibodies.  
Specifically, tumor necrosis factor alpha (TNF-α) has been targeted due to its role in the 
Th-1 immune response, which is unresponsive to corticosteroids and is thought to be a 
driver of severe asthma.  Infliximab and etanercept have been develop d and investigated 
for their capability of decreasing unbound TNF-α in blood and lung tissue, although 
overall efficacy is still uncertain (5).  Immunoglobulin E (IgE) blocking antibody 
(omalizumab) has also been investigated as a biopharmaceutical therapeutic for severe 
asthma.  Trials have shown clinical improvement in approximately two-thirds of patients 
who received this treatment for 12 to 16 weeks along with IC and β2- agonists, 
suggesting that omalizumab may be effective for some patients as an add-on therapy (6).  
Some of the more frequently investigated non-biologic alternatives to β2-agonists and IC 
include methotrexate, gold, and cyclosporine; all of which have been giv orally.  The 
efficacy of these therapies has been determined in reduction of inflammation and 
corticosteroid dependence in multiple clinical trials (7).        
 
4.1.1 Calcineurin inhibitors in asthma trials 
Calcineurin inhibitors are immunosuppressive drugs that disrupt early activation 
and signaling on the immune response and are frequently used in oral maintenance 
therapy for transplant recipients.  Cyclosporine, a well characterized calcineurin inhibitor, 
has been investigated for treatment of asthma due to its ability inh bit a broad range of 
interleukins and other signaling factors that lead to T-cell activation.  In clinical trials, 
cyclosporine has been shown to reduce corticosteroid dependency while improving lung 
function in cases of severe asthma (8, 9).  Limitation of the adverse side effects 
associated with corticosteroid therapy may be achieved with calcenurin inhibitors; 
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although, the untoward side effects of these immunosuppressants have also b en well 
documented (10, 11).  To minimize potential systemic effects, inhaled cyclosporine has 
been investigated in lung transplant patients (12) as well as in nimal asthma models 
(13).  Tacrolimus, a calcineurin inhibitor up to 100 times more potent that cyclosporine 
(14), has more recently been accepted as a more effective therapy fo  transplant patients, 
suggesting it may also show improved outcomes for treatment of asthma.                  
 
4.1.2 Efficacy in asthma models 
 Initial investigation into the application of tacrolimus to asthma therapy 
has mostly limited to animal models.  In early pre-clinical testing, tacrolimus was 
investigated as an immunosuppressive agent to be given orally for the suppression of 
lung eosinophilia, a common indication of airway inflammation.  Three diff rent dosing 
regimens were used in ovalbumin-sensitized Dunkin-Hartley guinea-pigs to determine if 
oral tacrolimus could effectively prevent eosinophil migration into the airway.  Results 
showed that once-daily oral dosing for three days after sensitization and three days after 
challenge significantly reduced eosinophils count in bronchoalveolar lavage (BAL) fluid 
compared to controls (15).  Surprisingly, when the immunosuppressive regimen was 
dosed for three days directly before antigen challenge, no reduction in eosinophiliar 
migration was seen in any of the drugs tested (tacrolimus, cyclosporine, 
cyclophosphamide).  Findings in this study suggest that tacrolimus may play more of a 
role in disrupting T-cell response to initial antigen sensitization as well as late stage 
inflammation characterized by eosinophils recruitment.  This may suggest that tacrolimus 
is better suited to treat severe refractory asthma rather than acute asthma.  Additional 
research into the reduction of airway inflammation through administration of 
subcutaneous tacrolimus was performed by Lapa and coworkers.  By administration of 
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0.5 mg/kg of tacrolimus 1 hour before and 5 hours after ovalbumin challenge, eosinophil 
migration into the airway/bronchial tissue as well as bronchial yperactivity to 
acetylcholine challenge was prevented (16).          
More recently, studies of tacrolimus intended for localized administrat on to the 
lungs has been developed and tested in antigen-sensitized animal models.  Morishita and 
associates have investigated whether local delivery of tacrolimus to an asthma-induced 
airway will significantly inhibit inflammation.  In albumin sensitized Hartley guinea pigs, 
it was shown that pMDI delivery of 150µg of tacrolimus given before antigen challenge 
was comparable to 1 mg/kg oral tacrolimus in the reduction of airway inflammation (17).  
Interestingly, peak lung and blood drug concentrations were 8 and 7 times lower for the 
inhaled tacrolimus than in oral dosing, showing potential to localize the drug effect 
without systemic effects.  In this model, tacrolimus significantly reduced IL-5 levels in 
lung tissue and, correspondingly, airway eosinophilia.  While anit-IL-5 antibody therapy 
has been proven somewhat clinically ineffective (18), tacrolimus shows promise to block 
multiple pathways of asthmatic inflammation through inhibition of multiple cytokines 
(IL-2, IFN-γ, IL-4). 
In excised human lung tissue, tacrolimus was investigated and compared to 
dexamethasone to determine the extent of cytokine inhibition, mRNA expression, and 
chemical mediator suppression of each drug (19).  Both drugs showed evid nce of IL-5 
and TNF-α inhibition, which were most likely to be produced by mast cells since the ex 
vivo study limited the amount of eosinophils and lymphocytes available from blood for 
cytokine production.  These findings were expected and are well documented in literature 
for both steroid and immunosuppressive agents.  More significant findings were shown in 
investigation of the chemical mediators of allergy, histamine a d leukotriene E4.  As 
shown in Figure 2, tacrolimus significantly inhibited release of histamine and leukotriene 
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E4, while dexamethasone did not.  The exact mechanism of mediator inhibitio  s not 
known; however, this inhibition has been reported in literature previously (20).  It is 
hypothesized that tacrolimus interferes with the stem cell factor regulation of mature mast 
cells, effectively preventing histamine release.  This same study also found that while 
tacrolimus inhibits histamine excretion, it actually promotes mat cell differentiation in 
vivo.  In addition to affecting T-lymphocytes and mast cells, tacrolimus has also been 
found to inhibit eosinophils degranulation (21).  
 
4.1.3 Study rationale 
In this study we aim to investigate the efficacy of a novel inhaled tacrolimus 
formulation in a widely accepted asthma-induced mouse model.  We hypothesize that 
prophylactic dosing of tacrolimus dispersion for nebulization to asthma induced-mice 
will show significant reduction of lung inflammation compared to those given no 
treatment.  Inflammation and chemical signaling were measurd by white blood cell 
infiltration into the airways/tissue and cytokine concentration in lung fluid.  Additionally, 
prophylactic treatment with an inhaled corticosteroid, dexamethasone, was performed for 
validation of our model for the evaluation of prophylactic therapeutics.               
 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
 Tacrolimus was purchased from Haorui Pharma-Chem, Inc (Edison, NJ).  
Other chemicals used for sensitization and dosing included lactose m nohydrate, egg 
albumin (ovalbumin) spray dried powder, and dexamethasone sodium phosphate, all 
purchased from Fisher Scientific (Fair Lawn, NJ).  Aluminum hydroxide gel adjuvant 
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(Alhydrogel 1.3%) was obtained from Accurate Chemical (Westbury, NY).  Normal 
saline (0.9% sodium chloride inj, USP) was purchased from Hospira, Inc (Lake Forest, 
IL).  Hepairn Sodium (10,000 IU/mL) was purchased form Baxter Healthcare (Deerfield, 
IL).  Formalin solution (10%) was purchased from Sigma-Aldrich (St. Louis, MO).  High 
Performatnce Liquid Chromatography (HPLC) grade acetonitrile, zinc sulfate 
heptahydrate, and barium hydroxide (0.3N) were also purchased form Fisher Scientific 
(Fair Lawn, NJ).   
 
4.2.2 Asthma model and dosing regimen 
 An ovalbumin-induced asthma model was developed using female 
BALB/c mice, based on previously proven models (22, 23).  A 28 day model was 
developed, where sensitization took place over 25 days, and challenge (induction of 
inflammatory response) occurred over the final 3 days.  Animals were euthanized on day 
29 for analysis.  A total of 37 mice were used and broken down into 4 groups: Negative 
control (5 mice), Positive control (14 mice), Tacrolimus dose (12 mice), and 
Dexamethasone dose (6 mice).   
Sensitization occurred on day 0 and day 14 where 0.1 mL intraperitoneal (IP) 
injections of 0.025 % w/v OVA were administered to each animal.  Negative control 
group received 0.1 mL IP normal saline (NS).  IP injections were prepared by combining 
2.5 mg OVA with 10 mL alhydrogel in a 15 mL sterile centrifuge tube and mixing (300 
rpm) at room temperature for 1 hour.  On days 26, 27, and 28, mice were challenged with 
aerosolized ovalbumin (OVA) solution after prophylactic aerosol dosing.  For challenge, 
a 10 mg/mL OVA solution was prepared by adding 300 mg OVA to 30 mL NS.  All 
except the negative control group were challenged with 20 minutes of nebulized OVA 
solution on three consecutive days (day 26, 27, and 28).  The negative control group 
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received 20 minutes of aerosolized NS on the same days.   Prophylactic dosing occurred 
1 hour prior to each challenge and involved aerosolization of either tacrolimus dispersion 
for nebulization (TAC), dexamethasone solution (DEX), or NS.  TAC was prepared by 
incorporation of 45.3 mg tacrolimus powder for dispersion, comprising tacrolimus and 
lactose (1:1) (24), into 3 mL NS by probe sonication with a Branson S ifier 450 
(Danbury CT) (output 6, 10% interval).  The 3 mL dispersion was added to the nebulizer 
reservoir within 30 minutes of preparation and nebulized to completion.  DEX was 
prepared by dissolving 5 mg dexamethasone sodium phosphate in 50 mL NS, mixing at 
300 rpm for 1 hour, and storing at 4°C until use.  For dosing, 5 mL DEX was added to the 
nebulizer reservoir and nebulized to completion.  Positive and negative control groups 
received 5 mL NS for nebulization instead of prophylactic treatment.  Twenty-four hours 
after completion of the third challenge, animals were euthanized by isoflurane inhalation 
followed by cardiac puncture.                   
 All aerosol dosing was conducted in a 6 port nose-only dosing chamber 
(24) in accordance with an Institutional Animal Care and Use Committee (IACUC) 
approved protocol.  Aerosols were produced by an Aeroneb® Pro (Aerogen, Galway, 
Ireland) vibrating mesh nebulizer and entered the dosing chamber at 1 L/min. 
 
4.2.3 Determination of tacrolimus lung levels 
Tacrolimus lung deposition was quantified by measuring the lung concentratio  
of 4 mice after dosing 45.3 mg of tacrolimus dispersion for nebulization in 3 mL NS.  
Excised lung tissue from mice euthanized 1 hour after completion of nebulization was 
subjected to an extraction procedure from quantification of drug levels.  The extraction 
procedure is detailed in Section 3.2.4.3.  Briefly, lung tissue was injected with an internal 
standard and homogenized in NS.  To facilitate protein separation from d ug, 0.3N 
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barium hydroxide, 0.4N zinc sulfate, and acetonitrile (ACN) were added to the 
homogenate.  The homogenate was centrifuged to collect the supernatant solution and 
remove precipitated protein.  Samples were dried and reconstituted in acetonitril.  L quid 
chromatography / mass spectrometry (LC/MS) was used to quantify tacrolimus in 
prepared samples.  A Thermo Fisher Surveyor Plus HPLC system with PDA (Waltham, 
MA) was used in conjunction with a Thermo Fisher LTQ FT Ultra Hybrid Mass 
Spectrometer (Waltham, MA) for determination of tacrolimus extracted.     
 
4.2.4 Complete blood count 
 After euthanasia, blood drawn from cardiac puncture was added to BD 
Microtainer® tubes with K2EDTA to prevent coagulation.  Samples from each animal 
were submitted for analysis by IDEXX preclinical research services (Westbrook, ME) 
and run within 24 hours.   
 
4.2.5 Differential WBC count of BALF 
 Bronchoalveolar lavage (BAL) was performed after euthanasia for 
analysis of cells and proteins present in pulmonary fluid and on the epithelial layer.  
Gavage tubes attached to 1 mL syringes were inserted into the trachea through a small 
incision and tied tightly with suture to create a water-tight seal.  Phosphate-buffered 
saline (PBS) (0.8 mL) was instilled into the lungs and withdrawn slowly.  
Bronchoalveolar lavage fluid (BALF) was then added to a conical vial and centrifuged at 
420 x g for 2 minutes.  A 100 µL sample of supernatant was removed for cytokine 
analysis and replaced with an equal volume of PBS. Samples were shipped at 
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approximately 4°C to IDEXX preclinical research services (Westbrook, ME) for slide 
preparation and pathologist reviewed differential white blood cell (WBC) counts.   
 
4.2.6 Cytokine analysis in BAL 
 Quantification of cytokines, specifically interleukins 3 (IL-3), 4 (IL-4), 5 
(IL-5), 13 (IL-13), were determined using a custom mouse quantibody arra  (Raybiotech, 
Inc, Norcross, GA).  Procedures were followed as directed in supplier protocol.  A 16 
well quantibody slide was used, 6 wells devoted to standards and 10 devoted to samples.  
Blocking of the slide was conducted by adding 100 µL of sample diluent into each well 
incubating for 30 minutes on an orbital shaker (200 rpm).  After blocking, diluent was 
removed and replaced with standards and samples for 1 hour of incubation.  The slide 
was then washed with supplied wash buffer after which the detection antibody cocktail 
was reconstituted and added to each well (80 µL).  Removal of antibody cocktail was 
followed by washing.  Cy3 equivalent dye-conjugated streptavidin was then added (80 
µL) to provide a fluorescing signal.  The slide was again washed and read using a 
GenePix® 4000B scanner and GenePix® Pro software (MDS Analytical Technologies 
Inc., Sunnyvale, CA).       
 
4.2.7 Pathological tissue evaluation 
 After BAL, while the gavage tube was still inserted in the trachea, 
approximately 1 mL of 10 % formalin was instilled, fully inflating the lungs.  The trachea 
was then tied off, and the heart-lung block was excised from the thoracic cavity and 
submerged in formalin.  Tissues were shipped to IDEXX preclinical research services 
(Westbrook, ME) where they were trimmed, processed, blocked, section d, and stained 
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with H&E.  An animal pathologist reviewed all slides for inflammatory cell infiltrate and 
pulmonary lesions.  Inflammation scores were assigned to each sample investigated based 
on mixed cell infiltration and were assigned a score of 0-4, where 0 shows no signs of 
inflammation and 4 is severe inflammation.  
 
4.2.8 Statistical analysis 
 Pathological scoring, CBC, and BAL analysis were subject to statistical 
analysis to determine significant differences in data collected.  One way ANOVA 
followed by a post hoc Tukey test (if necessary) performed using M itab® Release 14 
statistical software (Minitab Inc., State College, PA).  Confidence intervals ranging from 
p < 0.1 to p < 0.0001 were used to determine significant differences. 
 
4.3 RESULTS AND DISCUSSION  
4.3.1 Model validation 
 Validation of the ovalbumin-induced asthma model used in this study was 
determined through pathological review of sectioned and stained lung tissue, BAL 
analysis, and CBC analysis of whole blood.  Typically, lung inflamm tion in BALB/c 
mice is quantified by mixed inflammatory cell infiltration, specifically, eosinophilia in 
BALF (25).   Inflammation scores of positive and negative control mice are shown in 
Table 4.1.  A marked difference is seen between these two groups since no inflammation 
was induced by ovalbumin, resulting in no detection of inflammation the egative control 
model after blinded pathological review.  Infiltrate was characteized by mononuclear 
cells (mainly lymphoplasmacytic cells) and granulocytes (primarily neutrophils).  
Interestingly, perivascular infiltration of inflammatory cells was marked in the lungs of 
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asthma induced positive control mice.  This finding is supported by previous studies that 
have reported an increase in vascular permeability in ovalbumin challenged rodents for 
up to 24 hours after delivery of ovalbumin aerosol (26).   
Inflammation on the epithelial surface of challenged mice was also determined 
through assessment of BALF.  Figure 1 shows changes in inflammatory cells present, 
specifically lymphocytes and eosinophils (p < 0.005), after OVA induced inflammation.  
Eosinophilia, a key feature of atopic asthma, is often used as a prim ry ndicator the 
disease.   
 Circulating white blood cell (WBC) levels are also typically indicative of 
an immunological response.  Table 4.4 shows an elevated mean WBC count for a imals 
receiving ovalbumin sensitization and challenge, confirming that mild systemic immune 
response has occurred.  A sensitization period of 21 to 28 days is used in most ovalbumin 
induced animal models (22, 23), and is likely sufficient to elicit an immune response 
upon antigen presentation.  It is critical that the sensitization period is long enough to 
allow for “IgE switch”.  This phenomenon describes a change initiated by chemical 
signals that promotes B cell production of the IgE isotype of immunoglobulin. Both IL-4 
and IL-13 have been demonstrated to be significant factors in promoting IgE switch in B 
cells, where production of IgM, a non-allergenic immunoglobulin, transitio  to 
production IgE (27).  Having a high binding affinity for mast cells and basophils, IgE 
bound with its receptor, FcεRI, is know play a prominent role in the initial cascade of 
inflammatory cytokines and chemokines.  This is evident in the effectiveness seen in anti-
IgE therapy in severe asthmatics.  IgE has also been demonstrated to contribute local 
regulation of refractory or severe asthma (28), suggesting that local inhibition of IgE may 
be of considerable importance.  For these reasons, IL-4 and IL-13 are considered 
instrumental cytokines in proliferation of traditional asthma.  Since the role of IgE is 
 89 
critical to asthmatic inflammation, a full “IgE switch” is necessary to produce the 
maximum response in an animal model.    
                  
4.3.2 Tacrolimus prophylaxis 
 Determination of tacrolimus deposition in the lungs showed that a mean of 
0.566 µg tacrolimus was present after single dose administration (Table 4.4).  As 
previously mentioned, tacrolimus dosed both orally and pulmonarily, has been show  to 
inhibit expression of both Th1 and Th2 cytokines in animal models; however, only 
cytokines involved with the Th2 response are evaluated in this study.  Figure 4.2b shows 
a significant reduction (p < 0.05) in IL-13 expression in animals receiving tacrolimus 
prophylaxis in comparison to those with no prophylactic therapy.  The biological effects 
of IL-13 are similar to that of IL-4, since they share a common alpha-chain receptor for 
signal transduction.  IL-13 has been shown to be primarily involved in the recruitment of 
eosinophils and synthesis of IgE, two of the main physiological signs of a Th2 response 
(29).  While no statistical difference is seen in IL-4 and IL-5 expr ssion in tacrolimus 
dosed and positive control animals due to the variability of the bioassay, data trends 
toward reduction in these to cytokines after tacrolimus administration.  This trend is 
supported by prior studies showing reduction in BAL levels of IL-4 and IL-5 in 
tacrolimus dosed animals (17). 
 Observations of data pertaining to cytokine expression in BALF are 
supported by the corresponding mixed inflammatory cell counts observed.  Although 
variability is high, a significant difference (p < 0.1) is seen between eosinophil presence 
in BALF form tacrolimus and positive control groups.  As eosinophil recruitment is 
thought to be signaled by IL-5 expression, the reduction of both of these factors (as seen 
in Figures 1 and 2b) is evidence of reduction of Th2 medicated asthma with tacrolimus.   
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Additionally, lymphocytes present in BALF are also statistically reduced (p < 0.05) in 
tacrolimus dosed animals.  Lymphocytes are most likely inhibited on the epithelial 
surface due to tacrolimus inhibition of a variety of cytokines including IL-4, IL-5, IL-8, 
and IL-13. As in the reduction of eosinophilia in pulmonary fluid, reduction of 
immunoregulating lymphocytes also indicates the effect of tacrolimus on diminishment 
of the immune response to a foreign antigen.          
 Surprisingly, inflammation scores assigned by an animal pathologist did 
not correspond to the reduction of inflammation seen in BALF.  Both positive control and 
tacrolimus dosed animals showed lymhoplasmacytic and neutrophilic inflammation, 
particularly around the lung vasculature.  Cyclosporine, being mechanistic lly similar to 
tacrolimus, has shown similar results in recent findings. It has been previously noted that 
cyclosporine reduces expression of inflammatory cytokines such as IL-2, IL-4, IL-5, and 
IFN-γ as well as eosinophil infiltration, although airway hyperresponsive ess and 
neutrophil accumulation are unaffected (30).  It may be that while calceneruin inhibitors 
have a pronounced effect on the inflammatory cascade induced locally, they do not 
reduce the vascular permeability of bronchial blood vessels, allowing in tial neutorphilic 
infiltration into challenged tissue.  This may explain why pathological evaluation of lung 
tissue sections did not demonstrate a reduction in perivascular infiltration of 
inflammatory cells, while inflammatory cells on the lung epithelum, as seen in BAL, are 
reduced.  It is uncertain whether calcineurin inhibitors prevent vascular leakage, although 
these results would suggest that it does not.       
It is worth noting that a significant difference was seen betwe n the two groups 
receiving tacrolimus (denoted by F and G in Table 4.2).  This difference suggests that 
there was some variability of scoring between groups and that additional pathological 
review may be needed.      
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4.3.3 Dexamethasone prophylaxis 
 Confirmation of inflammation reduction (as determined through BAL 
differential) with prophylactic dosing of dexamethasone validated th  use of this model 
for the evaluation of prophylactic therapies.  Reduction of lymphocyte (p < 0.1) and 
eosinophil (p < 0.1) presence in BALF compared to positive controls was found to be 
statistically significant, as would be expected in inhaled corticosteroid therapy.  While the 
mean eosinophil levels of tacrolimus are lower than that of dexam thasone, due to high 
variability in BALF samples, no difference can be stated.  In a previous study evaluating 
the effect of dexamethasone and cyclosporine on eosinophil proliferation in the presence 
of IL-5, researchers found eosinophil survival was more greatly inhibited by 
dexamethasone, while degranulation was more inhibited by cyclosporine (31). These 
findings indicated that cyclosporine (and likely tacrolimus) may effectively block the 
degranulating effects of IL-5 on eosinophils; although the exact mechanism by which this 
occurs is unknown.  In reference to our results, this may suggest that tacrolimus in the 
lungs may reduce eosinophil levels due to the reduction degranulation, signaling, and 
subsequent eosinophil recruitment.  This may prove to have a greater inhibitory effect on 
inflammatory signal proliferation and late stage asthma.  Alternatively, dexamethasone 
reduces eosinophils in the airway due to disruption IL-5 signaling that normally promotes 
cell survival, resulting in apoptosis.  This suggests that dexamethasone could be more 
relevant to the inhibition of acute or early stage asthma.      
Evaluation of cytokine expression after prophylactic dosing with dexam thasone 
showed no signification difference from levels in the positive control g up. It is 
uncertain why dexamethasone was associated with an increase in IL-5 expression, as it 
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has been well established that this glucocorticoid diminishes the expr ssion of IL-5 (32).  
Variability in bioanalytical testing is most likely the reason for this inconsistency.   
Prior art and BALF cell counts would suggest that dexamethasone does reduce 
signs of inflammation, although inflammation scoring of dexamethasone dosed animals 
proved to show no statistical difference from animals receiving no treatment.  The mean 
score is lower in dexamethasone dosed rats than in tacrolimus dosed rat , suggesting 
more effective reduction of deep tissue inflammation.  Permeability of pulmonary 
vasculature has been shown by researchers to be reduced by administratio  of β2- agonist 
as well as corticosteroids (33), which may explain the reduction in perivascular 
inflammation.  More samples are needed to determine if a statistical difference is present.   
Systemic circulation of WBC after challenge shows interesting changes in 
animals dosed with dexamethasone.  Total WBC is reduced in comparison to tacrolimus 
treatment; although, not with statistical significance.  A signif cant difference was seen in 
an increase in circulating neutrophils in comparison of dexamethasone treat d animals to 
negative control animals.  Clinically, corticosteroid administration often results in a 
temporary increase in circulating neutrophils due to demargination.  Corticosteroids act 
on non-circulating neutrophils in the margination pool as well as promote the egress of 
neutrophils from bone marrow (34).  
  
4.3.4 Calcineurin inhibitor and corticosteroid synergy 
 Recently, the mechanisms of CR that develop over repeated dosing have 
been investigated.  Findings have shown that expression of FK506 binding protein 51 
(FKBP-51), an intracellular chaperone protein, is induced by the presence of 
corticosteroids (35).  Interestingly, FKBP-51 has been shown to disrupt gl cocoritcoid 
receptor (GR) complex interaction with corticosteroids, inhibiting its translocation to the 
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nucleus and serving as a negative feedback loop.  This finding is supported by preclinical 
studies in non-human primates that have shown that excessive expression of FKBP-51 to 
reduce efficacy of corticosteroids (36).    
FKBP is named for the molecule for which it was first discovered to bind, FK 
506, which is more commonly known as tacrolimus. Tacrolimus has been shown to have 
an affinity for FKBP-51; although, it is thought to be lower than its affinity for FKBP-12 
(37).  Nevertheless, it is plausible that tacrolimus co-administration with a corticosteroid 
could enhance the activity of that corticosteroid through interference with the FKBP-51 
negative feedback loop.  This would allow more effective steroid-induced nuclear 
translocation of the GR, resulting in transcription modulation for immunosuppression.  In 
addition to the synergistic mechanisms associated with FKBP-51, it seems that 
physiological effects of these drugs may be therapeutically complementarily.   
Another potential synergy may exist between calcineurin inhibitors ( acrolimus) 
and corticosteroids through reduction on neutrophilic inflammation.  Immediate reduction 
of eosinophil levels in the airways often results from corticoser id therapy; however, its 
effect on neutrophilic infiltration, which is more characteristic of severe asthma and 
airway remodeling, is uncertain (38).  Clinical studies have found that increased 
neutrophil presence in the sputum reduces the effect of corticosteroid  therapy on 
eosinophilic airway inflammation (39).  Cyclosporine has been shown to limit neutrophil 
chemotaxis (40) due to inhibition of its major signaling cytokine, IL-8.  Tacrolimus has 
also been show to inhibit IL-8 (41), and can therefore be assumed to prevent neutrophil 
chemotaxis as well.  By preventing recruitment of neutrophils into the lung airways, 
neutrophilic inflammation can be prevented and inflammatory cell resistance to 
corticosteroids may be reduced.  Aside from tacrolimus, other macrolides (antibiotic such 
as clarithromycin) have been found reduced IL-8 and neutrophilic inflammation in 
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patients (42); however, these antibiotic macrolides do not offer the breadth of cytokine 
inhibition and inflammation reduction seen in calcineurin inhibitors.   
 
4.4 CONCLUSION  
 In an ovalbumin-induced asthma model, inhaled tacrolimus has shown to 
reduce the Th2 response when given 1 hour prior to challenge.  This conclusi  is 
supported by noted reduction in inflammatory cytokines and cells present in the airway of 
BALB/c mice.  Likewise, dexamethasone showed a decrease in airway inflammation as 
evident through reduction of epithelial inflammatory cells, validating this model for 
prophylactic evaluation.  Future studies will be conducted to evaluate the potential 
synergistic therapy of tacrolimus and dexamethasone based on potential complementary 
modes of inflammation reduction and molecular binding.  Additionally, testing of inhaled 
tacrolimus in neutrophilic asthma model is necessary to determin  its effect on Th1 
mediated asthma in vivo. 
 This study has confirmed that pulmonary administration of tacrolimus can 
effectively inhibit the Th2 immune response.  As an immunosuppressive agent with 
capability to inhibit a broad range of cytokines, tacrolimus shows promise as a 
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Chapter 5: Respirable Low-Density Microparticles Formed In Situ from 
Aerosolized Brittle Matrices   
 
5.1 INTRODUCTION  
Dry powder inhalation has been established as a method for pulmonary delivery 
and as a viable and efficacious method for lung disease management.  Important 
advancements including multidose capabilities, improved device design, and drug/carrier 
particle engineering have led to improvements in drug aerosolizati n efficiency and 
patient compliance.  While setbacks in use of dry powder inhalers (DPI), for systemic 
drugs have been noted, as in inhaled insulin (1), many academic and industrial 
researchers continue to investigate the potential of the pulmonary route as a fast, 
noninvasive means of systemic therapy that bypasses first pass metabolism.  
 Nearly all currently marketed DPI products rely on carrier-based formulations 
where micronized drug particles adhere to a coarse carrier, typically lactose. The carrier 
is used to improve powder flow through ordered mixing and reduce electrostatic and van 
der Waals interactions between micronized drug particles.  Inertial and aerodynamic 
forces provided by a combination of patient inspiration and device design subsequently 
deaggregate drug from carrier, allowing inhaled micronized drugparticles to ultimately 
reach the deep lung.  This formulation strategy is inexpensive and easily scalable;  
however, it can result in high dose variability and low efficiency, making it less than 
ideal for delivery of expensive biopharmaceuticals or potent drugs with a narrow 
therapeutic window.  Typically, carrier-based DPIs can be expected to deliver only 10 to 
35% of the emitted dose to the lower airways (2), while the majority f the dose fails to 
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deaggregate from the carrier particles and deposits in the mouth or on the oropharynx.  
Interest in delivery of more potent and expensive pharmaceuticals is leading to the 
investigation of more efficient and precise therapeutic formulations.            
 Recently, new formulation strategies have been designed for more 
effective aerosolization and flow-rate independent delivery.  Large porous particles for 
inhalation were introduced by Edwards et al as a method to enable the delivery of 
geometrically large particles (20 µm) to the deep lung where sustained release of PLGA 
encapsulated drugs could occur (3).  The fundamental concept behind this elivery 
strategy relies on the similar aerodynamic behavior of particles n the respirable range (1-
5 µm) and large particles (>10 µm) with a low skeletal density (<0.4 g/mL).  The 
relationship between aerodynamic (dae) and geometric (dg) diameter is given in equation 
1. 
 
                                                    dae= dg ( ρs / X ) 
0.5                                            (1) 
 
where ρs is the particle or skeletal density and X is the dynamic shape correction 
factor.  The dynamic shape factor is necessary to calculate the equivalent aerodynamic 
diameter of particles with increased drag due to their nonspherical shape.  Typically, 
dynamic shape factors range from 1 to 2, where 1 represents a perfectly spherical particle 
with a smooth surface and 2 represents a plate-like particle with a rough or irregular 
surface.  Another aspect of aerodynamic behavior, particle slip, has also been show to 
effect the aerosolization of respirable particles, however, this factor need only be 
considered for particles less that 10 µm in diameter (2).   
Several advantages have been proposed and demonstrated in the use of porous 
particles for lung delivery.  In comparison to traditional DPIs which require the 
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generation of high flow rates for deaggregation, porous formulations are easily dispersed 
with less dependence on the air velocity.  Increased deaggregation is thought to stem 
from limited surface contact and reduction of particle cohesion due to van der Waals 
forces.  Additionally, elevated drag produced by high surface area and irregular surface 
morphology also contributes to improved powder dispersion.  Once deposited in lower 
airway, particles with a geometric diameter between 1 and 5 µm are rapidly phagocytized 
by alveolar macrophages, 10% being cleared from the epithelial flu d within with first 
hour, and over 80% after 24 hours (4).  Particle diameters less than 100 m or more than 
10 µm have shown evidence of greatly reduced macrophage clearance, enabling the 
possibility of sustained release drug therapy from the pulmonary epithelium.  Porous 
particles in the deep lung, while too large for phagocytosis, also might be expected to be 
only partially submerged in the 7-70 nm thick layer of epithelial fluid lining the alveolar 
space (5), leaving only a portion of the particle available for dissolution.  In contrast,  
nanoparticles are completely submerged and wetted in lung fluids after deposition and are 
available for partitioning into tissues and systemic circulation (6, 7).  Furthermore, the 
high surface area and thin boundary layer facilitates rapid dissolution. (8-10)  
Because nanoparticles are aerodynamically too small for deep lung delivery, they 
must be delivered in a microparticle carrier.  Nanoparticles have been delivered by 
nebulization to the deep lungs as a dispersion in aqueous media (6, 11-15).  Trojan 
particles have also enabled the delivery of nanosized drug through preformed hollow 
spherical nanoparticle aggregates produced by spray drying (16).  Recently, open friable 
flocs of high aspect ratio drug particles, formed by thin film freezing, havebeen delivered 
to the deep lung with pressurized metered dose inhalers (7).  The space filling high aspect 
ratio particles are templated by the hydrofluoroalkane droplets upon actuation to form 
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low-density particles with the proper aerodynamic diameter for deep lung delivery and 
high dosages.   
Formulation technologies such as milling, spray drying, spray-freeze drying, 
supercritical fluid processing, and controlled aggregation have all been used in 
production of low-density, dry particles for inhalation (17-19).  In this study, a new 
approach to low-density particle delivery is investigated using a cryogenic particle 
production method.  In thin film freezing (TFF), a frozen solid solution is formed rapidly 
by dropping a solution directly onto a cryogenically cooled solid substrate.  The rapid 
freezing prevents segregation and heterogeneity of the solutes (20).  Solvent removal by 
lyophilization limits the mobility of the dissolved solute and results in a low-density 
matrix.  This freezing technique has also been used to produce stable protein particles for 
inhalation (7) and was found to produce less denaturation than other cryogenic techniques 
due to the reduction of air exposure (21). 
We hypothesize that highly respirable low-density microparticles an be produced 
by in situ shearing of aerosolized brittle matrices in a passive inhalation device.  Powder 
geometries created by TFF are designed to have a lower skeletal density (< 0.05 g/cm3) 
than those measured in previous studies (0.05 to 0.1 g/cm3).  The powders created by TFF 
are composed of large interwoven matrices rather than discrete particles (3).  
Additionally, the concept of in situ shearing of brittle matrices to produce respirable 
particles ~ 50 µm in diameter is novel relative to previous studies in which the particles 
for delivery are preformed.  Given that the alveolar diameter has been shown to be 400 
µm in human adults, these particles are sufficiently small for deep lung deposition (22).  
The high surface area of the brittle matrices, composed of sub-500 nm primary structures, 
produced by TFF enhances the dissolution rate, which favors high absorption and 
bioavailability (10, 20)  Furthermore, clearance by alveolar macrophages before 
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dissolution may be reduced due to the large geometric size of deposited particles (3).  
Formulation, moisture sorption, and in vitro characterization techniques were also studied 
to optimize aerosolization and produce data not biased by particle bounce.       
 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
 Αlpha-lactose monohydrate, mannitol, and raffinose pentahydrate were 
purchased from Fisher Scientific (Fair Lawn, NJ).  High Performance Liquid 
Chromatography (HPLC) grade acetonitrile and phosphoric acid (85%) were also 
purchased from Fisher Scientific.  Tacrolimus anhydrous was purchased from Haroui 
Pharma-Chem (Edison, NJ). 
 
5.2.2 Formulation preparation 
TFF technology was employed for the production of dry powders.  Briefly, a 
cosolvent mixture of acetonitrile (ACN) and water was used to dissolve tacrolimus and 
sugar excipient.  Tacrolimus and lactose (TACLAC), tacrolimus and mannitol 
(TACMAN), tacrolimus and raffinose (TACRAF), and tacrolimus without a sugar 
excipient (TAC) were dissolved in the cosolvent solution.  The ratio of tacrolimus to 
excipient was 1 to 1 and each solution prepared for TFF had a total solids concentration 
of 0.75% w/v.  The solutions were rapidly frozen on a cryogenically cooled (< -50°C) 
stainless steel surface and then maintained in the frozen state in liquid nitrogen.  A 
detailed description of the TFF process is given by Overhoff et al (23) and Engstrom et al 
(21).   Solvents were sublimated by lyophilization using a VirTis Advantage Tray 
Lyophilizer (VirTis Company Inc., Gardiner, NY), leaving a drug and sugar solid 
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dispersion in dry low-density particles.  Lyophilization was performed over 40 hours at 
pressures less than 200 mTorr while the shelf temperature was gradually ramped form -
60°C to 25°C.  Product was removed form the lyophilizer after dry N2 was bled into the 
chamber to equilibrate to atmospheric pressure.  Product was quickly covered in order to 
prevent ambient humidity from affecting the formulation.  Powders were stored in a 
transparent vacuum desiccator at room temperature.           
 
5.2.3 Powder density and compressibility  
Bulk and tapped density of TFF produced powders were measured according t  a 
method adapted from USP <616> method I using a Varian Tapped Density Te er 
(Varian, Palo Alto, CA).  An adaptation was made due to the limited supply of powder 
for testing where a 100 mL graduated cylinder was replaced by a5 mL graduated 
cylinder.  Hausner ratio and Carr’s (Compressibility) index were calculated for each 
formulation based on USP guidelines.  Additionally, skeletal densities of dispersed 
powders were calculated based on measured aerodynamic and geometric diameter for 
comparison to measured density values.  Calculations were performed according to 
equation 1, where the dynamic shape factor (X) was assumed to be 1.5 for all dispersed 
powders. Mass median aerodynamic diameter (MMAD) was determined based on all 
particles emitted from the device for these calculations.      
 
5.2.4 Powder morphology and homogeneity 
For qualitative determination of particle structure and morphology, scanning 
electron microscopy (SEM) was performed.  A Hitachi S-5500 SEM (Hitachi High 
Technologies America, Inc., Pleasanton, CA) equipped with energy-dispers ve X-ray 
 105 
(EDX) was used at 10 kV accelerating voltage after sputter coating the specimen with 
silver for 30 seconds at vacuum.  Determination of homogenous distribution of 
tacrolimus in lactose was determined by EDX through qualitative measurement of 
elemental nitrogen presence, which only occurs in drug molecule.     
 
5.2.5 Geometric particle size analysis 
Geometric diameter of TFF produced aerosolized and non-aerosolized powder 
was determined by low angle light scattering using a Malvern Spraytec® (Malvern, UK) 
outfitted with an inhalation cell and an induction port.  A Handihaler® (Boeringher 
Ingelheim GmbH, Ingelheim am Rhein, Germany) containing a size 3 hypromellose 
(HPMC) capsule (Capsugel, Peapack, NJ) was secured to the mouth of the induction port 
by a molded silicone adapter.  Aerosolization of powder was achieved at a flow rate 51 
L/min, providing a 4 kPa pressure drop across the device.  Data acquisition took place 
over 4 seconds and only when laser transmission dropped below 95%.    Non-aerosolized 
powder diameter was measured by adding powders to the opening of the inhalation cell 
without the induction port and without air flow.  
 
5.2.6 Aerodynamic particle size analysis 
A Next Generation Pharmaceutical Impactor (NGI) (MSP Corp., Shoreview, MN) 
was used to determine aerodynamic properties of low-density microparticles.  A 
Handihaler® containing size 3 capsules and approximately 3 mg of formulation was 
attached to the induction port by a molded silicone adapter.  All tests, with the exception 
of those investigating the influence of gelatin capsules on aerodynamic diameter, were 
conducted with size 3 HPMC capsules.  Aerosols were produced over 4 second  at a flow 
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rate of 51 L/min.  Stage cut size diameters were calculated as instructed by Marple et al 
to be 8.8, 4.9, 3.1, 1.8, 1.0, 0.6, 0.4, and 0.2 µm for stages 1 through 7 and micro-orifice 
collector (MOC), respectively (24).  In most impaction tests run, collection surfaces were 
coated with 1% Tween 80 in ethanol, which is one of many coating materials 
recommended by the European Pharmaceutical Aerosol Group (EPAG) (25).  Tween 
solution was applied to each collection surface (approx 1 mL) and allowed to dry for 1 
hour.   After aerosolization, collection of deposited powders was accomplished by rinsing 
with 2, 5, 10, and 2.5 mL mobile phase for the device, induction port, pre-separator (if 
used), and stages 1 – MOC, respectively.  The pre-separator is designed to collect coarse 
particles ( > 15 µm) before the enter the body of the NGI and was included only when 
coarse lactose is used.  High performance liquid chromatography (HPLC) and a method 
for tacrolimus detection were used to quantify the collected drug from each rinsing (26).  
Samples were analyzed using a Waters 515 liquid chromatograph with a Waters 996 
Photo Diode Array (Waters Corp., Milford, MA) at 215 nm.  A Lichosphere RP C18 
column 4 mm X 250 mm, 5 µm (Varian Corp. Lake Forest, CA) was used at 50 °C and a 
flow rate of 1.5 mL/min.  Mobile phase was composed of ACN, water, and phosphoric 
acid at a ratio of 600 to 400 to 1.   
Total emitted dose (TED) of each test was calculated as the perc ntage of dose 
emitted over total dose assayed.  Fine particle fraction (FPF) and MMAD were calculated 
using Sigmaplot 2000 (Systat Software Inc, San Jose, CA) to fit a 3 parameter logistic 
curve to plotted data.  MMAD and geometric standard deviation (GSD) were calculated 
based on drug deposition on stage 1 through MOC, while FPF was calculated based on 
TED and represent the percentage of particles with an aerodynamic diameter less than 5 
µm.          
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5.2.7 Water sorption  
Water sorption profiles were determined for brittle matrix powders manufactured 
by TFF using Dynamic Vapor Sorption (DVS-1) (Surface Measurement Systems Ltd, 
London, UK).  For each formulation, glass sample cells were filled to capacity (0.5 mL) 
resulting in weights ranging from 5 to 30 mg, depending of particle density.  Samples 
were dried with nitrogen gas until a baseline was established with less than 0.002 % 
change in dm/dt.  Each formulation was run for a complete sorption/desorption cycle 
between 0 and 90% relative humidity (RH).  Humidity was increased/decreased by 5% 
after equilibrium was reached, as determined by a dm/dt less than 0.002%.  Sorption 
isotherms were calculated and plotted according to percent change in mass minus the 
initial dry formulation weight.  DVS was also used to create a controlled humidity 
environment for powder dispersion to be tested using laser scatter.  Humidities of 90, 50, 
20, and 0% were exposed to powder formulations for 30 minutes in succession.  
Equilibrium was assumed after 30 minutes, and an aliquot of powder was emoved for 
testing.  All testing began with 90% humidity so that skeletal density changes due to 
hygroscopicity would be applied to subsequent samples taken at 50, 20, and 0% RH.   
 
5.3 RESULTS AND DISCUSSION 
5.3.1 Influence of testing conditions 
Prior to characterization of TFF produced brittle matrices, methods of analysis, 
specifically NGI testing, were evaluated.  For determinatio  of aerodynamic diameter, 
many researchers have noted that NGI testing conditions and paramete s can greatly 
influence results, the extent of which is often dependant on formulation properties (27).  
For example, liquid aerosols have been shown to experience droplet evaporation during 
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testing, causing a skewing of data toward aerosols with smaller MMADs and larger FPFs.  
The dry environment of impaction equipment is most likely not predictive of aerosol 
performance in vivo since physiological relative humidites in the airways are near 100%.  
Adjustments for humidity have been made by cooling NGI equipment priorto use, 
resulting in a device internal RH of approximately 100% (28).  Testing of dry aerosols 
produced by pMDI and DPI devices may also show bias in some cases due to particle 
bounce and re-entrainment.  This behavior has been addressed by several authors, the 
majority of which recommend correction by coating of collection surfaces (27, 29).  
While no guidelines have been adopted by the USP for collection plate co ing, the 
EPAG has recommended coatings of Brij, silicone, Tween, among others, o create a thin 
film to cause impacted particles to adhere after deposition (25).   
The influence of particle bounce on NGI characterization of low-density powders 
has not been fully investigated, and was therefore considered before evaluation of low-
density microparticles.  As seen in Table 1, a substantial increase in MMAD was seen 
when a film coating was applied to stages 1 – 7 and MOC.  During investigation of 
beclomethasone dipropionate aerosols of unit density, Kamiya et al showed an increase in 
MMAD of 1.06 µm after NGI collection plates were surface coated (30).  A more 
exaggerated difference was seen in the low-density particles ested in this study showing 
an MMAD increase of 3.1 µm after coating.   Fine particle fraction was also affected by 
surface coating, decreasing almost two fold when tested on coated surfaces.  It could be 
assumed that highly porous particles with low density are not only subject to particle 
bounce, but that particle fracture and re-entrainment may also occur after plate impaction.  
Similar fracturing effects may also explain reduction in MMAD when a pre-separator 
was included (Table 1).  Although addition of a pre-separator would be expect d to affect 
MMAD based on reduced deposition on stage 1, the skewing of deposition toward plates 
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4 through 6 suggests that particle fracture in the pre-separator occurred (Figure 1).  Given 
the potential for MMAD biasing and the fact that no coarse carrier particles are included 
in this DPI formulation, pre-separators should be excluded when characterizing brittle 
matrices for aerosolization.        
 
5.3.2 Investigation of formulation strategy 
 TFF technology produces low-density pharmaceutical matrices, often 
containing amorphous drug, stabilized with high Tg excipients (20).  In previous reports, 
TFF has been used as a particle engineering technology to enhance t e aqueous solubility 
of poorly water soluble drugs for oral and pulmonary applications (7, 31). Through 
stabilization of amorphous drug morphologies with glassy excipients, inclus on of 
hydrophilic materials, and increased surface area, TFF manufactured powders have been 
shown to offer improvements in wetting, dissolution rates, and solubility, leading 
ultimately to increased bioavailability (12, 32-34).  Given the desirable attributes of these 
powders and the efficiency of low-density powders for deep lung delivery, we 
hypothesized that these particles would result in superior aerosol perf rmance relative to 
previously researched porous particles made by traditional manufacturing techniques.  
The primary and bulk structure of aerosolized brittle matrices of tacrolimus and lactose 
are shown in SEM images of Figure 2.  In this formulation, drug and excipient are present 
in a one-to-one ratio in a solid dispersion.  SEM samples analyzed by EDX reveal a 
homogeneous dispersion of tacrolimus and lactose, indicated by the presence of nitrogen 
(Figure 3b).  Other studies have produced amorphous powders with TFF and have shown 
through x-ray diffraction (XRD) patterns and differential scanning calorimetry (DSC) 
that these dispersions often form solid solutions (34).       
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For effective delivery of respirable low-density microparticles, a passive 
inhalation device with the ability to produce high shear velocities is required.  
Fortunately, most device designs already require turbulent, high shear airflow to provide 
adequate force for the separation of micronized drug from carrier lactose.  The 
Handihaler®, a single dose capsule-based DPI, was chosen for aerosolization of brittle 
matrices in this study.  Through a patient induced pressure drop, contents of a size 3 
capsule within the device are released by flow within and around the capsule.  Prior to 
discussion of further formulation considerations, aerosol performance dep n ence on 
capsule composition is first investigated.  HPMC and gelatin capsules were studied for 
their influence on the aerodynamic performance of powders emitted.  Significantly 
different behavior was observed.  Interestingly, Table 2 shows HPMC capsules produced 
a significant improvement (P < 0.05) in FPF over that of gelatin capsules while MMAD 
was unchanged.  We hypothesize that shape and area of the puncture hole created could 
influence the velocity/turbidity of air entering and leaving thecapsule.  In previous 
reports of puncture shape of gelatin and HPMC capsules, it was concluded that more 
irregularly shaped holes were formed in the less brittle HPMC capsules, relative to 
gelatin (35).  For delivery of this formulation, a smaller, non-spherical puncture may 
provide a greater shear force than a large spherical opening, imparting for fracture of 
friable matrices.  Other non-aerodynamic advantages of powders rel ased from HPMC 
capsules include low moisture content and increased stability at elevated humidity (36). 
Determination of friability of brittle matrix formulations was performed by 
comparing geometric particle distribution of low-density particles emitted from the DPI 
device with that of “bulk” or non-aerosolized matrices.  The effect of shearing induced by 
the Handihaler® was substantial as indicated by the difference between the volume 
moment mean (d4,3) of bulk (502.4 µm) and DPI emitted (62.0µm) particles (Figure 4).  
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The volume moment mean is a numerical representation of the “center of gravity” of a 
volumetric distribution, also known as the De Brouckere mean diameter (37). Because 
particle fracture is vital to the aerodynamic performance of these particles, excipient 
selection focusing on material properties such as strength, brittleness, and hygroscopicity 
is critical.  The ability to fracture the bulk particles with air flow is consistent with the 
fracture of large open friable flocs of similar particles produced by TFF, in which shear 
was produced by a hydrofluoralkane in a pMDI (7).   In each case, the shear produces 
particles with proper aerodynamic and geometric diameters to achieve high fine particle 
fractions.  A major difference for the pMDI approach is that the particles collapse as the 
HFA droplets evaporate.  An additional caveat to formulation of dry powder for 
inhalation is that these excipients be nontoxic and non-irritating for delivery to the lungs 
or otherwise generally recognized as safe (GRAS) by the FDA.       
 
5.3.3 Pharmaceutical sugars in aerosolized brittle matrices 
The influence of pharmaceutical sugars on aerosol performance was determined 
by measurement of both geometric and aerodynamic properties.  In this pulmonary 
delivery platform, the fundamental principle for producing highly respirable 
microparticles relies on the brittle fracture of ultra low-density matrices to create small 
diameter particles of the same structure and density.  Accordingly, pharmaceutical 
materials shown to experience brittle fracture under applied strss were chosen, such as 
those used in direct compression (DC) tabletting.  Sacchirides used for DC are more 
likely to experience brittle fracture than ductile cellulose excipients, and are more 
appropriate for our application.  In addition, some sacchirides are established as being 
non-irritating in the lungs.  Two sacchirides, α-lactose and raffinose, were selected based 
on their brittle properties; however, the ability to induce brittle fracture with a passive 
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DPI device had not been determined.  Mannitol, a less hygroscopic sugar alcohol, was 
also selected for evaluation as an excipient in brittle matrix powders.  After production, 
initial visual observations of unpackaged product showed that the skeletal structure of 
TACMAN and TAC were less susceptible to ambient humidity than other formulations. 
Aerodynamic evaluation of emitted low-density microparticles on a stage coated 
NGI showed elevated TED and FPF when compared to traditional dry powder inhalation 
formulations (2).  Initial testing of newly prepared formulation revealed TACLAC and 
TACRAF as the most efficiently performing aerosols, with FPF of 70.3 and 63.5%, 
respectively (Table 3).  Distribution of deposition on within the NGI, shown in Figure 5a 
reveals a lower stage deposition of TACLAC and TACRAF in comparison with the other 
formulations.  Assuming that all formulations have similar density, it could be concluded 
that increased particle fracture of particles containing anhydrous α-lactose and anhydrous 
raffinose resulted in improved aerodynamic properties.  Although some drawbacks to 
anhydrous material exists (as will be discussed), complete water removal from 
sacchirides often results in an significant increase in friability and brittleness (38, 39).  
Specifically, anhydrous raffinose is noted for its friability and has been determined to be 
the “most fragile” pharmaceutical sugar (38).  It is interesting to note that the more 
brittle, anhydrous form of raffinose is also amorphous, contrasting with the general 
conception that amorphous sugars are more ductile.  Differing from raffinose, anhydrous 
α-lactose is similar to others excipients in that the amorphous form is commonly less 
brittle than the crystalline.  High TED for all formulated powders is indicative of the 
reduced surface cohesion of low-density powders, normally caused by van der Waals, 
capillary, and electrostatic forces in traditional formulations; although, further analysis 
shows that these forces do still play a role in particle dispersion.                          
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Effect of RH on the aerosols comprising low-density microparticles was studied 
to determine sensitivity to water sorption.  Figure 5 and Table 3 showa comparison of 
NGI tested formulation stored at 50%RH and results from initial tests.  Humidity had an 
inhibitory effect on the performance of TACLAC, most likely due to increased plasticity 
of the brittle matrix.  TACMAN proved to benefit from additional moisture, as shown by 
an increase in FPF, perhaps due to reduction in electrostatic charging.  Figure 6b shows 
the bimodal distribution indicative of electrostatic adhesion of TACMN at low RH.  It 
can also be seen that TED decreased slightly in every 50% RH formulation, which could 
be expected due added formulation adhesion to the capsule wall in the presence of 
moisture. Water sorption to powder surfaces can both improve and hinder aerosol 
dispensability.  Previous reports have shown that dry powder formulations stored at 
approximately 60% RH maximize the drug FPF (40).  In general, humidities > 60% result 
in capillary forces predominating, while electrostatic charge remains low.  Relative 
humidities < 60% will cause elevated electrostatic adhesion of powders du  to the lack of 
moisture-induced charge dissipation.  For brittle matrices, presuming they are 
amorphous, the plasticizing effect of water must also be considered.  Amorphous 
materials are particularly susceptible to water plasticization, as is the case for anhydrous 
lactose and raffinose, which will result in reduced brittle fracture and could lead to 
increased particle density due collapse of the matrix structure (39).   
 
5.3.4 Influence of moisture sorption 
Based on differences in aerosol characteristics between initially tested and powder 
tested after storage at ambient conditions, moisture sorption may play a key role in the 
respiration of low-density microparticles.  Determination of moisture sorption of each 
formulation at RH between 0 and 90 percent was determined gravimetrically by DVS.  
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Sorption and desorption isotherms were determined after one cycle and shown in Figure 
7.  As might be expected, hydrophilic materials lactose and raffinose showed high 
moisture sorption, particularly at RH above 70 %.  Previous investigators have 
determined that raffinose samples with more than 17.9% weight gain due to moisture are 
capable of forming the pentahydrous form, although no reduction in mass loss due to 
crystallization is apparent in sorption analysis.  Unlike the rapid crystallization seen in 
lactose, it has been reported that full crystallization of raffinose takes up to 30 hours to 
occur at elevated humidity (41), so crystallization would not be apparent t each step.  
Slow moisture uptake by raffinose was evident during sorption testing of TACRAF using 
the method described in this study, since slow water absorption (and corresponding slow 
baseline stabilization) meant long cycle times. The time requird for raffinose to 
complete sorption/desorption cycle was 75 hours, while lactose only required 35 hours.  
This leads to the conclusion that both materials are very hydroscopic; although, 
anhydrous lactose adsorbs water much more readily.   
Multiple cycle DVS of TACLAC also provided incite into morphological hanges 
of the particles (Figure 8).  While a mass of moisture sorbed typically increases with 
increasing humidity, beginning at approximately 55% RH and 5% w/w water sorption 
TACLAC began to undergo stints of moisture loss, which is indicative of crystallization 
(42).  Crystallization during these three cycles is also made evident by the decreased 
water sorption capacity in cycles 2 and 3.  It is apparent for DVS analysis that TACLAC, 
created as an amorphous powder, is unstable at ambient humidity (50%) and requires 
packaging with dry gas.  TACRAF, while able to absorb greater amounts of water, did 
not experience morphological changes due to moisture adsorption.          
To determine the influence of moisture adsorption on aerosol production, volume 
distribution of each formulation at humidities from 0 to 90% were determin d.  Each 
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sample was exposed to 90% relative humidity before the appropriate humidity was 
applied so that moisture-induced density changes (matrix collapse) would not cause 
skewing of volumetric size distributions.  All formulations experienced electrostatic 
charging at 0% RH, resulting in bimodal particle size distribution of each formulation 
(Figure 6).   Similar moisture induced bimodal distribution was seen in TACLAC when 
stored at 90%RH; although, in this case cohesion could be assumed to be ue to capillary 
forces of adsorbed water.  Raffinose, being more hygroscopic than lactose, might be 
expected to show similar cohesion at high humidities; however, raffinose is known to 
incorporate water in crystal hydrates so much of the water is not present on the particle 
surface to induce cohesion (41).  Increased brittleness resulting in smaller particle 
diameters of TACRAF is noted in Figure 6c due to formation of anhydrous/amorphous 
material at 0% RH.  In dry conditions, previous studies have observed that hydrogen 
bonding between raffinose and water is replaced by bonding between neighboring 
raffinose molecules, leading to disorder in packing (or amorphous state) (41).  Humidity 
influence on TACMAN (Figure 6b) and TAC (Figure 6d) proved to be quite s milar, 
which is a reflection on their similar structural and morphological st bility during 
moisture changes.  While it seems only electrostatic adhesion had a significant impact on 
the particle distribution of TAC and TACMAN, TAC at 0% RH appears to undergo 
increased brittle fracture.       
 Although direct testing of material brittleness and friability was not conducted (as 
in brittle fracture index testing (43) an interesting correlation can be drawn between the 
d4,3  DPI emitted microparticles and “bulk” powders from  each formulation (Table 4).  In 
agreement with previous findings, particle brittleness (as determin d by ratio of d4,3 
sheared to unsheared) of lactose and raffinose formulations proved to be greater than 
those of mannitol and tacrolimus.                         
 116 
Further investigation into anti-cohesive and hydrophobic materials (i.e. leucine, 
DPPC) may help limit water adsorption, decreasing cohesion at high humidity (44).  
Added aerodynamic improvements may also be imparted by promoting crystallization of 
anhydrous lactose without adsorbing moisture, enabling increased brittle fracture and 
smaller particle diameter.  Inclusion of a crystal forming agent, such as mannitol, in the 
TFF formulation of TACLAC may impart more brittleness to the particles through 
formation of anhydrous crystals (45).  
   
5.3.5 Formulation density 
Although each formulation was produced with 0.75% w/v solids per cubic 
centimeter, it cannot be assumed that all powders have identical density.  Lyophilized 
powders, particularly ones containing hygroscopic and low Tg materials, have been 
shown to be susceptible to collapse, shrinkage, and meltback (46).  While moisture 
sorption is normally monitored in lyophilized products to ensure protein or chemical 
stability, in this study the effect of moisture sorption on powder cohesiveness and particle 
density are of primary interest.   
Bulk and tap density testing, as defined by the USP, were used to characterize 
density of each powder formulation (Table 5a).  While all densities m asured were 
extremely low, the bulk density of TACLAC was approximately twice that of the other 
formulations, most likely due to matrix water absorption and subsequent particle 
contraction.  Tap density was also measured and used to calculate Carr’s index.  Carr’s 
index, or compressibility index, is used to describe a ductile material hat undergoes 
plastic deformation or a brittle material that fractures under an applied force (47).  
Assuming that all changes in powder density were due to brittle fracture, this data 
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provided another indication that TACRAF is the most brittle of the powders investigated, 
showing a Carr’s index of 50.       
For comparison with USP density testing, correlation between size distribution 
data produced by cascade impaction (NGI) and laser diffraction (Spraytec®) analysis 
were also used to determine microparticle density.  Knowing both the MMAD and the 
volumetric median diameter (D[50]), equation 1 was used to calculate the skeletal density 
of the sheared microparticles exiting the DPI.  Approximation of the shape factor was 
necessary due to its effect on aerodynamic diameter, and was assumed to be 1.5.  SEM 
images (Figure 2) portrayed a jagged and irregular morphology of the aerosolized 
particles, similar that of a sand particle, which has a dynamic shape factor of 1.57 (2).  
Calculation of particle density proved to be slightly lower thatmeasured by bulk density 
testing; however, comparing formulations to one another showed a similar relationship 
(Table 5b).  It is possible that a lower prediction based on emitted aerosols was due to 
non-emitted particles remaining in the device that were excluded from characterization.  
Relative to each other, TACMAN and TAC produced the lowest density particles, most 
likely due to their non-hygroscopic nature, while TACRAF, and particularly TACLAC, 
showed higher density.  Changes in skeletal densities of lactose, and perhaps raffinose, 
upon exposure to ambient moisture are due to their tendency to adsorb wate  and could 
be explained by two mechanisms.  It is likely that adsorbed water effectively plasticizes 
the fragile matrix causing lowering of the glass transition emperature (Tg) and relaxation 
of supporting structures, subsequent collapsing the particle.  Increased mobility of 
amorphous material will also lead to formation of a more thermodynamically stable, 
crystalline form.  Powder collapse due to low material Tg has been observed previously in 
sucrose formulations, where inclusion of Dextran-40 significantly increased the Tg and 
resulted in improved structural integrity and longer stability (48).  By increasing Tg of the 
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matrix material, molecular mobility would be limited resulting i  reduction of particle 
shrinkage and crystal formation.  Another possibility exists for particle collapse at high 
humidity (< 65%) where the material becomes deliquescent, partially dissolving in 
adsorbed moisture and effecting the integrity of the particle (49).  It is doubtful, however, 
that deliquescent dissolving of lactose is a viable cause for particle collapse since the 
critical relative humidity needed for this to occur is 99% RH.  Mannitol and tacrolimus, 
being non-hygroscopic and hydrophobic, respectively, do not experience noticeable 
changes in skeletal density over time due to less water adsorption and a higher Tg.  
It is clear that hygroscopicity plays a large role in the final skeletal density of 
these low-density powders.  Even if packaging and storage conditions are maintained at 
0% RH, it is conceivable that highly hygroscopic particles may show substantial changes 
in density and geometric diameter when exposed to the humidity of the airways; 
although, reduction of density and geometric diameter might not have any impact of 
aerodynamic diameter.  Due to moisture sensitivity, the density of TFF produced matrices 
are difficult to predict and cannot be assumed to be equivalent to the dissolved solids 
concentration of the TFF processed solution.  Non-hygroscopic materials, such as 
mannitol, may allow for greater control of skeletal density through dissolved solids 
concentration and may allow for the creation of brittle matrices with tailored densities. 
While aerosolization of brittle sacchirides, lactose and raffinose, showed superior 
performance, selection of appropriate formulation will depend on intended storage 
conditions and dosing requirements.  As hygroscopic materials, both lactose and raffinose 
are susceptible to ambient moisture and should be packaged in completely dry conditions.  
Formulation with mannitol proved to be influenced less by humidity than others, 
however; the 100% potent TAC formulation proved to behave similarly.  The only 
benefit to mannitol in this regard may be in stabilizing the amorphous form of the drug 
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for increased solubility (34).  Long term stability studies are still necessary to determine 
any additional performance variability of these formulations.   
 
5.4 CONCLUSION  
Inhalation of low-density microparticles formed from brittle matrices with a 
marketed DPI device is a viable platform for highly efficient deep lung delivery of drugs.  
Unlike delivery strategies that utilize preformed particles, the brittle matrix TFF powders 
are sheared into extremely low-density (0.05 – 0.01 g/cm3) microparticles in situ by 
patient inspiration.  After incorporation of biocompatible materials such as 
pharmaceutical sugars into the formulations, aerosolization of the resulting brittle 
matrices produced fine particle fractions (FPF) as high as 70.3% and total emitted doses 
(TED) consistently higher than 95%.   
Additional benefits of this platform for inhalation therapeutics include solubility 
enhancement for amorphous particles, rapid dissolution for high surface aea sub-500 nm 
primary structures, and the ability to formulate process-sensitive actives with TFF.  
Future studies focusing on dose consistency, in vivo characterization, and process scale 
up will be investigated to determine the viability of this platform as an alternative to large 
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Table 1.1:  Calcineurin inhibitor delivery methods for transplant immunosuppression   
Route Drug Delivery technology Improvements Brand name R eferences *
Oral Cyclosporine drug solubilized in emmulsion n/a Sandimmune® [15]
In situ  microemulsion improved bioavail., less variability Neoral® [16]
Charged nanoparitlces improved bioavail. [21]
polycaprolactone nanoparticles target lyphoctes, improved bioavail. [19]
polymeric micelles Caco-2 permeability, enhanced solubility [22]
pH sensitive nanopatricles targeted area of GI tract, improved bioavail. [23]
polymeric microspheres controlled release, enhanced solubility [25]
stabilized amorphous particles enhanced solubility [27], [28]
Tacrolimus stabilized amorphous particles n/a Prograf® [35]
hydrophilic cyclodextrin enhanced solubility [44]
biodegradable nanoparticles targeted area of GI tract [45]
pH sensitive nanoparticles targeted area of GI tract [46]
Parenteral Cyclosorine drug solubilized in Cremphor® EL n/a Sandimmune®
liposomal
tissue targeting, longer half life, reduced 
toxicity [54]
polymeric micelles
reduced toxicity, prolonged release, 
enhanced solubility [56], [57]
biodegradable microspheres sustained release, reduced toxicity [60]
Tacrolimus drug solubilized in emmulsion n/a Prograf®
biodegradable microspheres prolonged release [61]
liposomal tissue targeting, longer half life [55]
Implant Cyclosorine polymeric reservoir sustained release [63]
Pulmonary Cyclosporine disolved in ehtanol high lung levels,  low systemic levels [66], [67], [68]
disolved in propylene glycol less irritating to lung Pulminiq™ [74], [75], [69]
liposomal enhanced solubility, lung retention [77]
Tacrolimus metered dose inhaler high lung levels,  low systemic levels [80], [81]
ethanol solution suitable for nebulization [83]
dispersed amorphous nanoparticles less irritating, enhanced solubility [87]
Sublingual Tacrolimus Prograf® capsule content reduced metabolism, high systemic levels [99], [100]
* references can be found in Section 1.8
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Table 2.1: Geometric droplet size distribution of a) pure deionized water and b) 
tacrolimus colloidal dispersion in deionized water 
 
a) 
     
 Average 
Standard 
Deviation Minimum Maximum 
Trans (%) 50.9 5.578 36 64.1 
Dv(10) (µm) 2.707 0.1368 1.964 2.906 
Dv(50) (µm) 6.243 0.1673 5.875 6.677 
Dv(90) (µm) 12.65 0.5501 11.54 14.86 
D[3][2] (µm) 3.399 0.4364 2.291 4.588 
D[4][3] (µm) 7.059 0.2233 6.625 7.805 
Cv (PPM) 9.765 1.533 6.437 14.63 
SSA (m²/cc) 1.765 0.24425 1.308 2.619 
Obs (%) 49.1 5.578 35.9 64 




     
 Average 
Standard 
Deviation Minimum Maximum 
Trans (%) 49.1 5.595 30.9 61 
Dv(10) (µm) 2.825 0.2274 1.741 3.063 
Dv(50) (µm) 6.55 0.1347 5.995 6.792 
Dv(90) (µm) 13.33 0.4966 11.82 14.89 
D[3][2] (µm) 3.576 0.5369 2.042 4.728 
D[4][3] (µm) 7.059 0.1763 6.653 7.787 
Cv (PPM) 10.79 1.519 7.609 15.76 
SSA (m²/cc) 1.678 0.3135 1.269 2.938 
Obs (%) 50.9 5.595 39 69.1 




Table 3.1:  Degradation and peak retention of TAC subjected to acid, alkaline, oxidative, 
and thermal forced degradation 
    
Condition Time (hr) Tacrolimus (%) 
Retention times of 
degradation  
products (min) 
Acid 1 76.4 4.3, 5.9, 6.8, 10.2 
Base 1 3.3 
6.1, 9.3, 12, 14.2, 
19.5, 22.7 
H2O2 1 99.4 5.4 
Heat  6 97.9 3.6, 5.6, 6.6, 9.5 
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Table 3.2: TAC powder for redispersion a) purity and b) potency after 3 months storage 
a) 
  Purity (%) Degradants (%) Stdev 
initial 99.9208 0.0792 0.0082 
1 month 99.8455 0.1545 0.0003 
2 month 99.8517 0.1483 0.0314 
3 month 99.8268 0.1732 0.0253 
    













   
  Potency (%) Stdev. 
initial 48.92 1.51 
1 month 48.16 0.24 
2 month 46.86 0.34 
3 month 47.99 0.45 
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Table 3.3: CBC and serum chemistry of SD rats receiving TAC colloidal dispersion for 
28 days and sacrificed 24 hours (4 weeks) or 168 hours (4 weeks +1) after 






Control 4 weeks 4 weeks + 1
Cholesterol (mg/dL) 86.6 ± 9.5 73.6 ± 31.6 102.5 ± 21
Glucose (mg/dL) 488.9 ± 70.4 435.5 ± 191.2 488 ± 201.3
Calcium (mg/dL) 11.1 ± 0.4 11.9 ± 1.1 11.3 ± 0.7
Phosphorous (mg/dL) 11.5 ± 3.4 10.9 ± 3.3 11.9 ± 3.2
Chloride (mg/dL) 99.8 ± 1.8 n/a 97.7 ± 3.7
Potassium (mg/dL) 9.2 ± 3.5 n/a 9.5 ± 3.2
Sodium (mg/dL) 145.8 ± 1.4 n/a 146.7 ± 2.3
A/G Ratio 1.1 ± 0.1 † 1.2 ± 0.1 ** †† 1 ± 0.1 *
B/C Ratio 30.1 ± 4.1 63.5 ± 20.7 ** 
††
26.7 ± 5.7
* significant difference from control; p < 0.05 † significant difference from 4 weeks + 1; p < 0.05
** significant difference from control; p < 0.01 †† significant difference from 4 weeks + 1; p < 0.01
Hematologic Parameters
Control 4 weeks 4 weeks + 1
WBC (103/µL) 5.1 ± 0.8 4.6 ± 1.1 6.1 ± 2
RBC (106/µL) 8.1 ± 0.5 8.5 ± 0.8 8.3 ± 0.4
HGB (g/dL) 15.1 ± 0.7 15.2 ± 1.4 15.5 ± 0.6
HCT (%) 50.6 ± 3.3 51 ± 4.8 51 ± 3.1
MCV (fL) 62.6 ± 1.4 60.4 ± 1.5 * 61.7 ± 2.3
MCH (pg) 18.7 ± 0.6 18 ± 0.6 18 ± 0.6
MCHC (g/dL) 29.9 ± 1 29.7 ± 0.5 30.4 ± 0.7
Platelet (103/µL) 743.3 ± 123.5 699.5 ± 186.3 725.5 ± 281.2
Neutrophils (cells/µL) 564.5 ± 232.3 590.1 ± 380.9 705.2 ± 301.8
Neutrophils (%) 11.4 ± 4.5 14.5 ± 13.1 12 ± 5.4
Lymphocytes (cells/µL) 4351.9 ± 730.4 3851.9 ± 1227.3 5153 ± 1820
Lymphocytes (%) 86.1 ± 3.6 81.8 ± 12.4 83.5 ± 6
Monocytes (cells/µL) 78.8 ± 69.4 99.8 ± 58.2 158.3 ± 101.8
Monocytes (%) 1.6 ± 1.5 2.1 ± 1 2.7 ± 1.5
Eosinophils (cells/µL) 27.8 ± 40.2 50.4 ± 37 105.5 ± 55.1**
Eosinophils (%) 0.5 ± 0.8 1 ± 0.5 1.7 ± 0.5**
Basophils (cells/µL) 20.9 ± 29.4 32.9 ± 39 11.3 ± 27.8
Basophils (%) 0.4 ± 0.5 0.6 ± 0.7 0.2 ± 0.4
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Table 3.4: Serum chemistry of SD rats receiving TAC colloidal dispersion for 28 days 





Control 4 weeks 4 weeks + 1
ALP (U/L) 171.8 ± 35.1 190 ± 46.4 167.2 ± 17.4
ALT (U/L) 176.9 ± 303.2 125.8 ± 137.7 111.2 ± 71.4
AST (U/L) 239.4 ± 319.1 173.4 ± 161.4 171.5 ± 151.4
Bilirubin (mg/dL) 0.075 ± 0 0.0625 ± 0.1 0.05 ± 0.1
Renal Function
Control 4 weeks 4 weeks + 1
Albumin (g/dL) 3.2 ± 0.2 3.7 ± 0.4 ** † 3.2 ± 0.2
Protein (g/dL) 6.2 ± 0.4 14.7 ± 22.3 6.6 ± 0.5
Globulin (g/dL) 3 ± 0.2 3.2 ± 0.3 3.4 ± 0.3
BUN (mg/dL) 19.8 ± 2.3 20.6 ± 2.1 18.2 ± 2
Creatinine (mg/dL) 0.7 ± 0.1 0.4 ± 0.1 ** 
††
0.7 ± 0.1
* significant difference from control; p < 0.05
** significant difference from control; p < 0.01
† significant difference from 4 weeks + 1; p < 0.05
†† significant difference from 4 weeks + 1; p < 0.01
 132 
Table 4.1:  Comparison of lung inflammation induced by OVA sensitization and 
challenge with that of NS sensitization and challenge 
 
     
Group Animal ID Treatment Prophylactic dose 
Inflammation 
score 
POS cntrl BALB/c 1F1 OVA,NS,OVA 5 mL NS 3 
 BALB/c 1F2 OVA,NS,OVA 5 mL NS 3 
 BALB/c 1F3 OVA,NS,OVA 5 mL NS 2.5 
 BALB/c 1F4 OVA,NS,OVA 5 mL NS 2.5 
 BALB/c 1F5 OVA,NS,OVA 5 mL NS 2.5 
 BALB/c 1F6 OVA,NS,OVA 5 mL NS 2.5 
 BALB/c 1F7 OVA,NS,OVA 5 mL NS 2.5 
 BALB/c 1F8 OVA,NS,OVA 5 mL NS 3 
 BALB/c 1G1 OVA,NS,OVA 5 mL NS 2.5 
 BALB/c 1G2 OVA,NS,OVA 5 mL NS 2.5 
 BALB/c 1G3 OVA,NS,OVA 5 mL NS 2.5 
 BALB/c 1G4 OVA,NS,OVA 5 mL NS 3.5 
 BALB/c 1G5 OVA,NS,OVA 5 mL NS 2 
 BALB/c 1G6 OVA,NS,OVA 5 mL NS 3.5 
   mean score    2.7 * 
      standard deviation 0.3 
NEG cntrl BALB/c 1F18 NS,NS,NS 5 mL NS 0 
 BALB/c 1F19 NS,NS,NS 5 mL NS 0 
 BALB/c 1F20 NS,NS,NS 5 mL NS 0 
 BALB/c 1F21 NS,NS,NS 5 mL NS 0 
 BALB/c 1F22 NS,NS,NS 5 mL NS 0 
   mean score 0 
      standard deviation 0 
OVA,NS,OVA = OVA IP inj, NS prophylaxis, OVA challenge  
NS,NS,NS = NS IP inj, NS prophylaxis, NS challenge  
*  significant difference from NS,NS,NS (p<0.0001)   
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Table 4.2:  Comparison the effect of prophylactic treatment on lung inflammation 
induced by OVA sensitization and challenge 
 
      
Group  Animal ID Treatment Prophylactic dose 
Inflammation 
score 
DEX BALB/c 1G13 OVA,DEX,OVA 0.5 mg DEX / 5 mL NS 2 
 BALB/c 1G14 OVA,DEX,OVA 0.5 mg DEX / 5 mL NS 3 
 BALB/c 1G15 OVA,DEX,OVA 0.5 mg DEX / 5 mL NS 2 
 BALB/c 1G16 OVA,DEX,OVA 0.5 mg DEX / 5 mL NS 2 
 BALB/c 1G17 OVA,DEX,OVA 0.5 mg DEX / 5 mL NS 2.5 
 BALB/c 1G18 OVA,DEX,OVA 0.5 mg DEX / 5 mL NS 3.5 
   mean score 2.5 
      standard deviation 0.6 
TAC BALB/c 1F9 OVA,TAC,OVA 45.3 mg TACLAC / 3 mL NS 3 
 BALB/c 1F10 OVA,TAC,OVA 45.3 mg TACLAC / 3 mL NS 3 
 BALB/c 1F11 OVA,TAC,OVA 45.3 mg TACLAC / 3 mL NS 2.5 
 BALB/c 1F12 OVA,TAC,OVA 45.3 mg TACLAC / 3 mL NS 3 
 BALB/c 1F13 OVA,TAC,OVA 45.3 mg TACLAC / 3 mL NS 3 
 BALB/c 1F14 OVA,TAC,OVA 45.3 mg TACLAC / 3 mL NS 3 
 BALB/c 1F15 OVA,TAC,OVA 45.3 mg TACLAC / 3 mL NS 3.5 
 BALB/c 1F16 OVA,TAC,OVA 45.3 mg TACLAC / 3 mL NS 3 
 BALB/c 1F17 OVA,TAC,OVA 45.3 mg TACLAC / 3 mL NS 3 
 BALB/c 1G19 OVA,TAC,OVA 45.3 mg TACLAC / 3 mL NS 2 
 BALB/c 1G20 OVA,TAC,OVA 45.3 mg TACLAC / 3 mL NS 2 
 BALB/c 1G21 OVA,TAC,OVA 45.3 mg TACLAC / 3 mL NS 2.5 
   mean score   2.8 * 
      standard deviation 0.3 
OVA,DEX,OVA = OVA IP inj, DEX prophylaxis, OVA challenge  
OVA,TAC,OVA = OVA IP inj, TAC prophylaxis, OVA challenge  
* note - scores from G significantly different from F (p < 0.005)  
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Table 4.3: Tacrolimus levels present in mice receiving a single dose (45.3 mg) of
tacrolimus dispersion for nebulization. 
 
 
    
  
Lung weight 
(g)  TAC (µg) 
Lung conc. 
(µg/g) 
BALB/c 1 0.188 0.499 2.656 
BALB/c 2 0.173 0.452 2.618 
BALB/c 3 0.165 0.595 3.601 
BALB/c 4 0.178 0.716 4.036 
  mean 3.228 ± 0.71 
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Neg cntrl 9.5 ± 0.7 4.1 ± 2.4 16.4 ± 7.4 81.6 ± 7.1 1.2 ± 0.4 0.8 ± 0 .8
Pos cntrl 9.2 ± 0.8 7.4 ± 7.5 23.6 ± 11.4 72.9 ± 12.1 2.7 ± 2.7 0.9 ± 0.8
DEX 9.9 ± 0.6 3.7 ± 0.8 30.5 ± 7.2 * 67.0 ± 7.4 2.5 ± 1.2 0.0 ± 0.0
TAC 9.6 ± 0.9 6.3 ± 4.7 23.3 ± 11.6 73.4 ± 12.8 3.0 ± 1.5 0.3 ± 0.7
* significant difference (p < 0.01) from Neg cntrl
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Table 5.1: Investigation of NGI testing parameters of low density particles produced by 
URF. 
 
        
Formulation Test conditions    Aerodynamic properties   
 Coating Pre-sep  TED (%) FPF (%) MMAD (µm) GSD  (µm) 
TACLAC no no  98.63 81.5 2.19 2.22 
TACLAC no yes  98.29 51.3 1.85 1.92 
TACLAC yes no  98.14 45.6 5.25 2.41 
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Table 5.2: Effect of capsule type on the aerodynamic performance of brittle-matrix 
particles emitted.   
         
   TED (%)      FPF (%) MMAD (µm) GSD 
Gelatin 95.49 ± 0.77 47.93 ± 2.31 1.84 1.97 
HPMC 93.92 ± 1.37 59.03 ± 2.66 1.83 1.84 
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Table 5.3: Aerodynamic properties of brittle-matrix particles containing tacrolimus and a 
pharmaceutical sugar tested after production and exposure to 50% RH. 
      
Formulation Condition TED (%) FPF (%) MMAD (µm) GSD  (µm) 
TAC initial 97.4 54.6 4.24 2.06 
 50% RH 96.5 55.9 4.14 2.11 
TACRAF initial 96.6 63.5 3.31 2.83 
 50% RH 93.7 61.5 3.33 2.57 
TACMAN initial 97.3 48.4 4.55 2.10 
 50% RH 94.6 56.4 4.24 2.06 
TACLAC initial 94.8 70.3 2.81 2.40 
  50% RH 93.8 60.5 3.62 2.29 
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Table 5.4: Comparison of formulation shearing in DPI device as determined by the 
volume moment mean ratio of unsheared to sheared powders. 
    
Formulation  d4,3 (unsheared) d4,3 (sheared) Shearing ratio 
TAC 542.8 89.44 6.07 
TACRAF 502.4 67.53 7.44 
TACMAN 529.7 90.61 5.85 
TACLAC 460.7 58.27 7.91 
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Table 5.5:  Density of formulated powders based on a) USP <616> guidelines for density
testing and b) measured aerodynamic and geometric diameters 
a) 





(g/mL) Hausner ratio Carr's  index  
TAC 0.0186 0.0294 1.67 40.0 
TACRAF 0.0212 0.0423 2.00 50.0 
TACMAN 0.0147 0.0227 1.54 35.0 
TACLAC 0.0350 0.0553 1.58 36.7 
     
b) 
          









(µm)  X ρ (g/mL) 
TAC 51.45 4.58 1.5 0.0119  59.61 4.47 1.5 0.0084 
TACRAF 40.71 3.5 1.5 0.0111  45.31 3.8 1.5 0.0106 
TACMAN 64.78 5.15 1.5 0.0095  60.3 4.39 1.5 0.0080 
TACLAC 49.1 n/a 1.5 n/a   30.22 3.12 1.5 0.0160 







Table A1: Patents relevant to the development of tacrolimus for inhalation  
Patents
Patent No. File Date Issue Date Assignee / Inventor Title Claims Justification
6,361,760 4/22/1998 3/26/2002 Fujisawa Pharmaceutical Co. Aerosol compositions 1. An aerosol composition comprising a tricyclic 
compound (I) of the following formula:
8. A process for a preparation of the aerosol 
composition as claimed in claim 1, comprising; (1) 
kneading said tricyclic compound (I) or a 
pharmaceutically acceptable salt thereof with a medium-
chain fatty acid triglyceride of the formula 
CH3(CH2)nCOOH, where n is 4-10, (2) distributing the 
resulting kneaded mass into dispensers, and (3) filling 
each dispenser with said liquefied hydrofluoroalkane 
under cooling or elevated pressure.
No medium-chain fatty acids are 
used in the preparation of our 
formulation.  No HFA is needed 
since our formulation is not 
designed for a pMDI.
6,884,433 4/14/2003 4/26/2005 Fujisawa Pharmaceutical Co. Sustained release formulation containing 
tacrolimus
1. A sustained-release formulation comprising a solid 
dispersion composition, wherein the solid dispersion 
composition comprises tacrolimus or its hydrate, in a 
mixture comprising a water-soluble polymer and a 
water-insoluble polymer, and an excipient.
Our formulation is not intended 
for sustained release and does 
not incoporate polymeric 
excipients.
6,780,324 3/18/2002 8/24/2004 Labopharm, Inc. Preparation of sterile stabilized nanodispersions 1. A process for the production of a loaded micelle 
containing a biologically active agent comprising: 
forming a solution including at least one dispersing 
agent, at least one biologically active agent, and at 
least one solvent; lyophilizing said solution wherein a 
solid product is formed; and rehydrating said solid 
product; whereby said loaded micelle is produced.
Lyophilization is required to 
produce our formulation; 
however, no micelles are used to 
inhance solubility.
15. A process in accordance with any one of claim 1 or 
3 or 5 or 7 wherein said biologically active agent is at 
least one hydrophobic pharmaceutical composition 
selected from the group consisting of paclitaxel, 
doxorubicin, melphalan, docetaxel, teniposide, 
etoposide, daunomycin, vinblastine, indomethacin, 
ibuprofen, cyclosporine, tacrolimus, biphenyl dimethyl 
dicarboxylate, ketoconazole, amphotericin B, 
fenobibrate, and combinations thereof.
see claim 1
7,306,787 3/12/2002 12/11/2007 Nektar Therapeutics Engineered particles and methods of use 1. A method of delivering a therapeutic dose of a 
bioactive agent to the pulmonary air passages in a 
single breath, the method comprising: providing a 
receptacle containing a mass of particles, the particles 
comprising a bioactive agent and having perforated 
microstructures with a bulk density of less than 0.5 
g/cm3; and administering the particles as an aerosol 
from the receptacle to a subject's respiratory tract; 
wherein the particles are sized and shaped so that at 
least 50% of the mass of the particles are delivered to 
the subject's respiratory tract and wherein the fine 
particle fraction of particles of the aerosol is greater 
than 60% w/w.
Particles in our pulmonary 
formulaiton are not intended to 
be delivered via DPI.
3. A method according to claim 2 wherein the particles 
comprise a geometric diameter of 1–30 microns.
Once disperse our particles are 
in the nanoparticle range.
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Table A.1: Patents relevant to the development of tacrolimus for inhalation (continued) 
Patents
Patent No. File Date Issue Date Assignee / Inventor Title Claims Justification
5,817,333 5/22/1995 10/6/1998 Fujisawa Pharmaceutical Co. Liposome perparation containing a tricyclic 
compound
1. A preparation comprising FK506 stably entrapped in 
a liposome, said liposome consists essentially of 
phosphatidyl choline and cholesterol. 
No liposomal encapsulation is 
used in this formulation.
5,635,161 6/7/1995 6/3/1997 Abbott Laboratories Aerosol drug formulations containing vegetable 
oil
1. A pharmaceutical composition for aerosol delivery 
comprising a medicament suitable for pulmonary 
delivery, a halogenated alkane propellant and a 
biocompatible C16+ unsaturated vegetable oil having 
an HLB value of less than 14, wherein the medicament 
is present in a concentration of from about 0.05% to 
about 5% by weight, the vegetable oil is present in a 
concentration of from 0.001% to about 10% by weight, 
the halogenated alkane propellant is selected from the 
group consisting of HCFC 123, HCFC 124, HCFC 
141b, HCFC 225, HCFC 125, 
perfluorodimethylcylobutane, DYMEL 152a, HFC 134a 
and HFC 227ea and the biocompatible C16+ 
unsaturated vegetable oil is selected from olive oil, 
safflower oil and soybean oil.
Vegetable oil is not used to 
solubilize the active in our 
formulation.  Tacrolimus is 
stabilized in the solid amorphous 
form.
5,260,301 12/1/1992 11/9/1993 Fujisawa Pharmaceutical Co. Pharmaceutical solution containing FK-506 1. A pharmaceutical solution which comprises FK 506, 
a pharmaceutically acceptable surface active agent 
comprising polyoxyethylene hydrogenated castor oil, 
and a pharmaceutically acceptable nonaqueous 
solvent selected from the group consisting of ethanol, 
pyropylene glycol, glycerin and polyethylene glycol.
No castor oil or non aqueous 
solvent used in our formulation.  
Tacrolimus is stabilized in the 
solid amorphous form.
7,250,420 11/24/2003 7/31/2007 Pfizer Inc Method of treatment of transplant rejection 23. A method according to claim 19, wherein the one or 
more additional agents is selected from the group 
consisting of cyclosporin A, rapamycin, tacrolimus, 
leflunomide, deoxyspergualin, mycophenolate mofetil, 
azathioprine, daclizumab, muromonab-CD3, 
antithymocyte globulin, aspirin, acetaminophen, 
ibuprofen, naproxen, piroxicam, prednisolone and 
dexamethasone.
Tacrolimus is the primary agent 
in our formulation.
6,440,458 3/25/1999 10/7/1999 Fujisawa Pharmaceutical Co. Sustained released preparations 1. A sustained-release formulation comprising 
tacrolimus or its hydrate wherein the time (T63.2%) 
required for 63.2% of the maximum amount of 
tacrolimus or its hydrate to be dissolved is 0.7 to 15 
hours, as measured according to the Japanese 
Pharmacopoeia, the 13-th edition, Dissolution Test, No. 
2 (Puddle method, 50 rpm) using a test solution which 
is an aqueous 0.005% hydroxypropyl cellulose solution 
adjusted to pH 4.5, which comprises a solid dispersion 
composition, wherein tacrolimus or its hydrate is 
present as an amorphous state in water-insoluble 
polymer.
Peak tacrolimus concentrations 
are reached at approximately 30 
min in our formulation; it is not 
sustained release The 
formulation is composed of 
amorphous tacrolimus in a water 
solube disaccharide.
4. The sustained-release formulation in claim 1, 
wherein the solid dispersion composition is 
characterized by (1) lactose or calcium hydrogen 
phosphate is contained as an excipient and/or 
lubricant, and (2) the particle size of the said solid 
dispersion composition is equal to or smaller than 350 
µm. 
Our formulation is a solid solution 
of tacrolimus and lactose.
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Table A.1: Patents relevant to the development of tacrolimus for inhalation (continued) 
Patents
Patent No. File Date Issue Date Assignee / Inventor Title Claims Justification
5. The sustained-release formulation in claim 4, 
wherein the solid dispersion composition is 
characterized by (1) tacrolimus or its hydrate is present 
as an amorphous state in ethylcellulose, (2) lactose is 
contained as an excipient, and (3) the particle size of 
the said solid dispersion composition is equal to or 
smaller than 250 µm. 
Lactose is used in our 
formulation to stabilize 
amorphous tacrolimus.
6,576,259 10/17/2001 6/10/2003 Fujisawa Pharmaceutical Co. Sustained release formulation containing 
tacrolimus
1. A sustained-release formulation comprising 
tacrolimus or its hydrate, wherein the time (T63.2%) 
required for 63.2% of the maximum amount of 
tacrolimus or its hydrate to be dissolved is 0.7 to 15 
hours, as measured according to the Japanese 
Pharmacopoeia, the 13-th edition, Dissolution Test, No. 
2 (Puddle method, 50 rpm) using a test solution which 
is an aqueous 0.005% hydroxypropyl cellulose solution 
adjusted to pH 4.5. 
Peak tacrolimus concentrations 
are reached at approximately 30 
min in our formulation; it is not 
sustained release 
2. The sustained-release formulation in claim 1, which 
comprises a solid dispersion composition, wherein the 
tacrolimus or its hydrate is present as an amorphous 
state in a solid base.
Our formulation is a solid solution 
of tacrolimus and lactose.
4. The sustained-release formulation in claim 2, in 
which the solid base is selected from a group 
consisting if water-soluble polymer and wax.













Table A.2: Patent applications relevant to the development of tacrolimus for inhalation 
Patent 
Applications
Patent App. No. File Date Pub. Date Assignee / Inventor Title Claims Justification
2006/0159766 15-Dec-05 20-Jul-06 Elan Nanoparticulate tacrolimus formulations 1. A nanoparticulate tacrolimus formulation comprising: 
(a) particles of tacrolimus having an effective average 
particle size of less than about 2000 nm; and (b) at 
least one surface stabilizer.
No surface stabilizer (as defined 
in claim 13) is used in our 
formulation. 
13. The composition of claim 1, wherein the surface 
stabilizer is selected from the group consisting of an 
anionic surface stabilizer, a cationic surface stabilizer, 
a zwitterionic surface stabilizer, a non-ionic surface 
stabilizer, and an ionic surface stabilizer
Lactose is not considered a 
surface stabilizer as described in 
this claim.
30. A method of making a tacrolimus composition 
comprising contacting particles of tacrolimus with at 
least one surface stabilizer for a time and under 
conditions sufficient to provide a tacrolimus 
composition having an effective average particle size of 
less than about 2000 nm.
see claim 31
31. The method of claim 30, wherein the contacting 
comprises grinding, wet grinding, homogenizing, or 
precipitation.
Rapid freezing technology is 
used to make our formulation; 
none of the processes listed in 
claim 31 are used.
2006/0210638 16-Mar-06 9/21/2006 Elan Injectable compositions of nanoparticulate 
immunosuppressive compounds
1. An injectable nanoparticulate formulation 
comprising: (a) particles of tacrolimus having an 
effective average particle size of less than about 2000 
nm; and (b) at least one surface stabilizer.
No surface stabilizer is used in 
our formulation.  Our formulation 
is not intended for injection.
2006/0154953 1/5/2006 7/13/2006 Keri et al. Amorphous tacrolimus and preparations thereof 1. Amorphous tacrolimus in a free drug particulate 
form.
Amorphous tacrolimus is 
manufactured with lactose, and 
is not a free drug particle in our 
formulation. 
7. A process for preparing amorphous tacrolimus, 
comprising dissolving tacrolimus in an organic polar 
solvent, and removing the organic polar solvent to 
obtain amorphous tacrolimus. 
Organic polar solvent is used, 
however; stabilizing lyoprotectant 
is used to produce a stable, 
amorphous product 
12. The process of claim 7, wherein the solvent is 
removed by evaporation.
Evaporation is not used for 
solvent removal; sublimation is 
used.
2006/0177500 7/9/2004 8/10/2006 Shin et al. Solid dispersion of tacrolimus 1. A solid dispersion comprising tacrolimus and solid 
surfactant having a property of hydrophile lipophile 
balance (HLB) value higher than or equal to about 7.
No surfactant used in our 
formulation. Latose is not a 
surfactant.
2006/0287352 8/30/2004 12/21/2006 Holm et al. Modified release compositions comprising 
tacrolimus
1. Solid composition comprising an active ingredient 
selected among tacrolimus and analogues thereof, 
wherein less than 20% w/w of the active ingredient is 
released within 0.5 hours, when subjected to an in vitro 
dissolution test using USP Paddle method and using 
0.1 N HCl as dissolution medium.
Our formluation is not intended 




Table A.2: Patent applications relevant to the development of tacrolimus for inhalation (continued) 
Patent 
Applications
Patent App. No. File Date Pub. Date Assignee / Inventor Title Claims Justification
2006/0035918 11/4/2003 2/16/2006 Fujisawa Pharmaceutical Co. Use of tacrolimus (fk506) derivatives combined 
with beta2-agonist for the treatment of asthma
2. A method for treating or preventing acute or chronic 
asthma, by administering an effective amount of an 
FK506 derivative and an effective amount of a β2-
agonist to a human being or an animal.
In our formulation tacrolimus is 
the primary agent; there is no 
coadministration of additional 
drugs. 
2002/0102294 11/12/1998 8/1/2002 Bosch et al. Aerosols comprising nanoparticle drugs 1. An aerosol composition of an aqueous dispersion of 
nanoparticulate drug particles, wherein: (a) essentially 
each droplet of the aerosol comprises at least one 
nanoparticulate drug particle; (b) the droplets are of a 
respirable size; and (c) the nanoparticulate drug 
particles comprise a poorly soluble crystalline drug, 
have an effective average particle size of less than 
about 1000 nm, and have a surface modifier adsorbed 
on the surface thereof. 
The aerosol intended in our 
formulatoin contains a dispersion 
of amorphous drug.  No surface 
modifier is used.
2. The aerosol composition of claim 1, wherein the 
drug is selected from the group consisting of proteins, 
peptide, bronchodilators, corticosteroids, elastase 
inhibitors, analgesics, anti-fungals, cystic-fibrosis 
therapies, asthma therapies, emphysema therapies, 
respiratory distress syndrome therapies, chronic 
bronchitis therapies, chronic obstructive pulmonary 
disease therapies, organ-transplant rejection therapies, 
therapies for tuberculosis and other infections of the 
lung, fungal infection therapies, respiratory illness 
therapies associated with acquired immune deficiency 
syndrome, an oncology drug, an anti-emetic, an 
analgesic, and a cardiovascular agent.
see claim 1
2003/0185838 5/8/2003 10/2/2003 Podolsky Methods and compositions for treating lesions of 
the respiratory epithelium
16. The method of claim 12, wherein said second 
therapeutic agent is an anti-inflammatory agent, 
antimicrobial agent, antihistamine, neurokinin receptor 
antagonist, leukotriene receptor antagonist, 
decongestant, cholinergic receptor antagonist, 
phosphodiesterase inhibitor, or beta-adrenergic 
bronchodilator.
Tacrolimus is the primary and 
only therapeutic agent in our 
formulation.
2006/0124903 6/8/2004 6/15/2006 Astellas Pharma Inc. Aerosol preparation comprising sealed container 
and enclosed therein aerosol composition 
containing marcolide compound 
1. An aerosol preparation, comprising: an aerosol 
composition containing a macrolide compound; and an 
enclosure enclosing the aerosol composition, the 
enclosure including a valve part having a gasket 
comprising at least one resinous material selected from 
the group consisting of butyl rubber, ethylene-propylene 
rubber, chloroprene rubber, polyethylene, polybutylene 
terephthalate, polyacetal, polyamide, 
polytetrafluoroethylene, polypropylene and 
thermoplastic elastomer. 
Our formulation is not a pMDI, 
valved, or inclosed formulation.
2005/0244339 4/14/2005 11/3/2005 Pari GmbH Pharmaceutical aerosol composition 1. Sterile composition for administration as an aerosol, 
comprising a poorly water-soluble active agent, a non-
ionic surfactant component and a phospholipid 
component, wherein the active agent is not a 
surfactant.
No non-ionic surfactants or 




Table A.2: Patent applications relevant to the development of tacrolimus for inhalation (continued) 
Patent 
Applications
Patent App. No. File Date Pub. Date Assignee / Inventor Title Claims Justification
2006/0128739 6/24/2005 6/15/2006 Maryanoff et al. Solvent free amorphous rapamycin 1. A method of preparing amorphous rapamycin 
comprising: dissolving rapamycin in 2-propanol to form 
a solution; forming an amorphous rapamycin 
precipitate by adding water to the solution; and drying 
the amorphous rapamycin precipitate for a 
predetermined period of time.
Our amorphous formulation is 
not formed by precipitation 
methods; it is formed by a rapid 
freezing method. 
12. An amorphous therapeutic agent administerable 
orally, parentarally, intravascularly, intranasally, 
intrabronchially, transdermally, rectally or via a stent 
coated therewith, the amorphous therapeutic agent 
formed by the process comprising: dissolving an 
amount of crystalline therapeutic agent in a solvent to 
form a solution; adding an agent to the solution to 
precipitate the therapeutic agent from the solution; 
filtering the precipitate; washing the precipitate to 
remove impurities; and drying the precipitate.
Our amorphous formulation is 
not formed by precipitation 
methods; it is formed by a rapid 
freezing method. 
19. The method of claim 12, wherein the crystalline 
therapeutic agent is a variant of rapamycin.
see claim 20
20. The method of claim 19, wherein the variant of 
rapamycin includes at least all analogs, derivatives and 
conjugates that bind to FKBP12, and other 
immunophilins.
According to this definition, 
tacrolimus is a variant of 
rapamycin.
2006/0094744 9/28/2005 5/4/2006 Maryanoff et al. Pharmaceutical dosage forms of stable 
amorphous rapamycin like compounds
1. A pharmaceutical dosage form comprising 
substantially amorphous rapamycin like compounds 
and a pharmaceutically acceptable excipient.
see claim 18
18. A process for making a pharmaceutical dosage 
form comprising admixing a substantially amorphous 
rapamycin like compound with at least one 
pharmaceutically acceptable excipient.
The excipient in our formulation 
is processed and rendered 
amorphous along with tacrolimus 
, it is not admixed. 
2008/0132533 12/30/2005 6/5/2008 GL PharmTech Corp. Solid dispersion comprising tacrolimus and 
enteric coated macromolecule
1. A rapidly soluble tacrolimus solid dispersion 
formulation comprising tacrolimus and enteric polymer, 
wherein the weight ratio of tacrolimus and the enteric 
polymer is in the range of 1:0.8˜1.2, and the latter is 
selected from the group consisting of 
hydroxypropylmethylcellulose phthalate, enteric 
acrylate copolymer, hydroxypropylmethylcellulose 
acetate succinate or carboxymethylethylcellulose.
Our formulation is rapidly soluble; 
however does not incorperate an 
enteric polymer.
2003/0235614 4/14/2003 12/25/2003 Fujisawa Pharmaceutical Co. Sustained-release formulation 1. A sustained-release formulation of a macrolide 
compound, wherein the time (T63.2%) required for 
63.2% of the maximum amount of macrolide 
compound to be dissolved is 0.7 to 15 hours, as 
measured according to the Japanese Pharmacopoeia, 
the 13-th edition, Dissolution Test, No. 2 (Puddle 
method, 50 rpm) using a test solution which is an 
aqueous 0.005% hydroxypropyl cellulose solution 
adjusted to pH 4.5.
Peak tacrolimus concentrations 
are reached at approximately 30 





Table A.2: Patent applications relevant to the development of tacrolimus for inhalation (continued) 
Patent 
Applications
Patent App. No. File Date Pub. Date Assignee / Inventor Title Claims Justification
3. The sustained-release formulation in claim 1, which 
comprises a solid dispersion composition, wherein the 
macrolide compound is present as an amorphous state 
in a solid base.
see claim 4
4. A solid dispersion composition usable in the 
sustained-release formulation in claim 3, wherein the 
macrolide compound is present as an amorphous state 
in a solid base.
see claim 7
7. The composition in claim 4, wherein the water-
soluble base is a water-soluble polymer
The formulation is composed of 
amorphous tacrolimus in a water 














Table A.3: Journal publications relevant to the development of tacrolimus for inhalation 
Journals
Journal Edition Compostion Author Title Teachings






Ingu et al. Effects of inhaled FK 506 on the suppression of 
acute rejection after lung transplantation: use of 
a rat orthotropic lung transplantation model
Tacrolimus inhalation enhaced lung allograft surviva in 
rats. Graft survival at 10 puffs/day was comparable with 
0.1 mg/kg/day IM injection.  Lower systemic levels 
were seen with inhalation therapy. 
Our formulaiton does not use a 
chemical solubility enhancer 
such as meduim chain 









Ide et al. Efficacy and saftey of inhaled tacrolimus in rat 
lung transplantation
Minimal tacrolimus concentration to prevent lung 
allograft rejection after inhalation is 270.4 ng/g.  
Associated whole blood levels were low (4.87 ng/ml).  
Higher blood and lung levels were achieved with IM 
injection.  
Our formulaiton does not use a 
chemical solubility enhancer 
such as meduim chain 
triglycerides and is not designed 
for pMDI delivery.




Canadas et al. Characterization of liposomal tacrolimus in lung 
surfactant-like phospholipids and evaluation of 
its immunosuppressive activity
Tacrolimus can be incorperated to into DPPC and 
POPG mono and billayers up to 0.4 mol %.  IL-2 
production was reduced 80% by liposomal tacrolimus 
in culture.  This is a suggested for intratracheal 
administation. 
No lipids are used in our 
formulation.  Solubility is 
enhanced throught the 
stabilization of amorphous drug 
particles.
Int. Arch Allergy 
Immunol




Morishita et al. FK506 aerosol locally inhibits anitgen-induced 
airway inflammation in guinea pigs
Inflamation inhibition was similar with 3 puffs tacrolimus 
pMDI and 1 mg/kg oral dose in sensitized guinea pigs.  
Inhalatin induced systemic levels were 1/21 that of oral 
systemic levels. 
Our formulaiton does not use a 
chemical solubility enhancer 
such as meduim chain 









Schrepfer et al. Effect of inhaled tacrolimus on cellular and 
humoral rejection to prevent posttransplant 
obliterative airway disease
4 mg/kg was given orally and via aerosol in tracheal 
transplanted rats.  Inhaled tacrolimus showed blood 
levels 5.5 fold lower than oral formulation.
No organic solvents are used to 
dose our formulaiton.  Solublity is 
enhanced through the dosing of 










Woolley et al. Endotracheal calcineurin inhibition ameliorates 
injury in an experimental model of lung ischemia-
reperfusion
Decreased alveolar neutrophil and cytokine expression 
was seen in endotracheal tacrolimus.  It also reduced 
lung lung vascular permeability
It unclear whether Fujisawa's oral 
or pMDI tacrolimus was provided 
for this study.  Regardless, there 
are no similarites to our 
formulation.




Canadas et al. Equilibrium studies of a fluorescent tacrolimus 
binding to surfactant protein A
Flourescently labled tacrolimus was found to bind to 
surfactant protien A, which is found in alveolar fluid.  
The equilibrium constant was found to be 107 M-1.
The drug used in this in vitro 




Table B.1: Comparison of TAC:LAC dispersion aerosol characteristics by air-jet nd 
vibrating mesh nebulization. 
Nebulizer Dispersion Conc. TED (µg) TED (%) FPF (%) MMAD (µm) GSD (µm)
Air Jet 5 mg/ 3 mL 98.73 5.39 58.68 2.41 2.33
10 mg/ 3 mL 331.29 12.99 62.51 1.91 2.33
15 mg/ 3 mL 570.89 19.20 54.94 1.91 2.45
Vibrating Mesh 5 mg/ 3 mL 785.53 50.51 44.18 4.06 2.73
10 mg/ 3 mL 563.00 17.42 46.32 3.79 2.85
15 mg/ 3 mL 1640.01 22.64 47.03 3.95 2.63
TED = Total emitted dose
FPF = Fine particle fraction (4.7 µm or smaller) 
MMAD = Mass median aerodynamic diameter
GSD = Geometirc standard deviation  
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Table C.1: Nebulization of aqueous media and tacrolimus dispersion for nebulization 
using a) deionized water and b) normal saline as dispersion media. 
A)
Trans (%) 50.90 ± 5.58 49.10 ± 5.60
Dv(10) (µm) 2.71 ± 0.14 2.83 ± 0.23
Dv(50) (µm) 6.24 ± 0.17 6.55 ± 0.13
Dv(90) (µm) 12.65 ± 0.55 13.33 ± 0.50
D[3][2] (µm) 3.40 ± 0.44 3.58 ± 0.54
D[4][3] (µm) 7.06 ± 0.22 7.06 ± 0.18
Cv (PPM) 9.77 ± 1.53 10.79 ± 1.52
SSA (m²/cc) 1.77 ± 0.24 1.68 ± 0.31
Obs (%) 49.10 ± 5.58 50.90 ± 5.60
B)
Trans (%) 35.30 ± 4.90 59.50 ± 5.05
Dv(10) (µm) 1.32 ± 0.59 2.24 ± 0.20
Dv(50) (µm) 6.07 ± 0.19 5.54 ± 0.15
Dv(90) (µm) 12.81 ± 0.43 11.46 ± 0.50
D[3][2] (µm) 2.04 ± 0.32 3.00 ± 0.48
D[4][3] (µm) 6.80 ± 0.25 6.30 ± 0.20
Cv (PPM) 13.10 ± 1.22 6.31 ± 0.90
SSA (m²/cc) 2.94 ± 0.05 2.00 ± 0.31
Obs (%) 64.70 ± 4.90 40.50 ± 5.05
Trans = laser transmission
D[3][2] = surface area moment mean
D[4][3] = volume moment mean
Cv = measurement concentration
SSA = specific surface area
Obs = laser obscuration
   aqueous only    dispersion 
   aqueous only     dispersion
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Table D.1: FK binding protein (FKBP) and ATP-binding cassette (ABC) protein 
interactions with tacrolimus 
binding 
protiens synonyms binding effect binding affinity
Immunophilins FKBP-12 FKBP1A immunosuppression Along with FKBP12.6, are the only 
immunophilins to bind with TAC and 
inhibit calcinuerin [1]
FKBP-12.6 FKBP1B immunosuppression Along with FKBP12, are the only 
immunophilins to bind with TAC and 
inhibit calcinuerin [1]
FKBP-13 FKBP2 insufficent binding The affininty of TAC for FKBP-13 is 
about 50 fold less than FKBP-12 [2]; 
perdominates in mast cells [2]
FKBP-25 FKBP3 insufficent binding The affininty of TAC for FKBP-25 is 
about 200 fold less than FKBP-12 [2]; 
shows 8 fold more affinity for SIR [2]
FKBP-36 FKBP6 insufficent binding No affintiy for TAC demonstrated [2]
FKBP-38 FKBP8 insufficent binding  Unknown
FKBP-51 FKBP5 inhibits FKBP-51 association with the 
GR heterocomplex [3], [4]; 
overexpression dose not effect TAC 
immunosup [5]; 
The affninty of TAC for FKBP-51 is less 
than FKBP-12 [5]
FKBP-52 FKBP4, FKBP59, 
HSP56, P59
 inhibits FKBP-52 association with the 
androgen receptor heterocomplex [6]; 
TAC presence does not affect GR 
receptor biniding [7]
The affininty of TAC for FKBP-52 is 
about 100 fold less than FKBP-12 [2]; 
Prolyl isomerase (PPI) activity is the 




ABCG2 breast cancer 
resistance protein 
(BCRP)
inhibits - not substrate [8]  Unknown
ABCB1 P-glycoprotein, 
MDR1
inhibits - competitive inhibition [9]  Unknown
[1] Wiederrecht et al; Perspect Drug Disc Design, 1994, v2, 57-84
[2] Tai et al; Science, 1992, v256, 1315-1318
[3] Reynolds et al; J Clin Endocrin Metab, 1999, v84(2): 663-669
[4] Denny et al, Endocrin, 2005, v146(7), 3194-3201l
[5] Li et al, J Cell Biochem, 2002, v84, 460-471
[6] Periyasamy et al; Endocrinology, 2007, v148(10): 4716-4726
[7] Hutchison et al, Biochem, 1993, v32, 3953-3957
[8] Gupta et al; Cancer Chemother Pharmacol, 2006, v58: 374-83
[9] Aroeci et al; Blood, 1992, v80: 1528-36  
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Treatment NS NS NS NS NS NS NS NS
Dose frequency (per day) 1 1 1 1 1 1 1 1
Duration (days) 28 28 28 28 28 28 28 28
Gender male female male female male female male female
WBC (*10^3 cell/µL) 6.6 4.5 5 5 5.1 5.6 3.9 4.7
RBC  (*10^6 cell/µL) 8.79 7.45 8.42 7.93 8.06 7.69 8.73 7.68 10 7
HGB (g/dL) 16.1 14.4 15.7 15.3 15.4 14.2 15.2 14.5
HCT (%) 53.3 46.6 54.7 50.5 50.4 47.7 54.5 47.2 48 36
MCV (fL) 61 63 65 64 63 62 62 61
MCH (pg) 18.3 19.3 18.7 19.3 19.1 18.4 17.5 18.9
MCHC (g/dL) 30.2 30.9 28.8 30.3 30.5 29.7 28 30.8
Neutrophils (%) 10 7 11(1) 11 21 8 14 8 34 9
Lymphocytes (%) 87 91 86 86 79 89 84 87 85 68
Monocytes (%) 1 1 2 1 0 1 2 5 5 0
Eosinophils (%) 1 0 0 2 0 1 0 0 6 0
Basophils (%) 1 1 0 0 0 1 0 0 2 0
Platelet (*10^3 cell/µL) 792 745 822 975 644 743 628 597
Neutrophils (cell/µL) 660 315 550(50) 550 1071 448 546 376
Lymphocytes (cell/µL) 5742 4095 4300 4300 4029 4984 3276 4089
Monocytes  (cell/µL) 66 45 100 50 0 56 78 235
Eosinophils (cell/µL) 66 0 0 100 0 56 0 0
Basophils (cell/µL) 66 45 0 0 0 56 0 0
  Polychromasia slight n/a slight n/a slight n/a slight n/a
  Anisocytosis n/a n/a slight n/a slight n/a slight n/a
  Remarks clumped n/a clumped n/a n/a n/a n/a n/a  
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Treatment NS NS NS NS NS NS NS NS
Dose frequency (per day) 1 1 1 1 1 1 1 1
Duration (days) 28 28 28 28 28 28 28 28
Gender male female male female male female male female
Alkaline Phosphatase (U/L) 150 139 181 150 232 167 215 140
Alanine Amino Transferase (U/L) 59 47 917 191 66 36 50 49 40 30
Aspartate Amino Transferase (U/L) 67 84 719 791 81 39 65 69 75 45
Albumin (g/dL) 3 3.2 3.2 3.7 3 3 3 3.1 4.8 3.8
Total Protein (g/dL) 6 6.3 6.2 7 6.1 6.1 5.8 6 7.6 5.6
Globulin (g/dL) 3 3.1 3 3.3 3.1 3.1 2.8 2.9 3 1.8
Total Bilirubin (mg/dL) 0.1 0 0 0.1 0.1 0.1 0.1 0.1 0.5 0.2
Direct Bilirubin (mg/dL) 0.1 0 0 0.1 0.1 0.1 0.1 0.1
Blood Urea Nitrogen (mg/dL) 18 20 16 24 20 20 19 21 21 15
Creatinine (mg/dL) 0.7 0.7 0.7 0.8 0.6 0.6 0.6 0.6 0.8 0.2
Cholesterol (mg/dL) 88 103 81 91 75 93 75 87 130 40
Glucose (mg/dL) 556 408 481 535 477 366 553 535 135 50
Ca 2+ (mg/dL) 11.3 10.7 11.6 10.9 11.5 10.6 10.9 11.2 13 5
Phosphorus (mg/dL) 10.7 8.5 17.5 14.5 11.2 7.3 13.1 9.2 8.3 5.3
Cl - (meq/L) 101 101 99 97 101 102 99 98
K + (meq/L) 8.8 6.4 14.4 14.7 7.9 5.2 9 7.1 5.8 3.7
Na + (meq/L) 146 147 145 143 147 147 146 145 140 127
A/G Ratio 1 1 1.1 1.1 1 1 1.1 1.1
B/C Ratio 25.7 28.6 22.9 30 33.3 33.3 31.7 35
Indirect Bilirubin (mg/dL) 0 0 0 0 0 0 0 0
NA/K Ratio 17 23 10 10 19 28 16 20
Hemolysis Index none none + + none none none +
Lipemia Index none none none none none none none none
 "+" =  slight hemolysis  
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Table F.1:  Raw inflammation scores of asthma model lung tissue when treated with 
normal saline and tacrolimus dispersion for nebulization. 
    
Animal ID Treatment Dose Inflammation score  
BALB/c 162 NS 5 mL 2.5 
BALB/c 163 NS 5 mL 2.5 
BALB/c 164 NS 5 mL 2.5 
BALB/c 165 NS 5 mL 2.5 
BALB/c 166 NS 5 mL 2 
BALB/c 167 NS 5 mL 2 
BALB/c 168 NS 5 mL 2 
BALB/c 169 NS 5 mL 2 
  mean score 2.25 
   standard deviation 0.25 
BALB/c 178 TAC 45.3 mg / 3 mL 1 
BALB/c 179 TAC 45.3 mg / 3 mL 2 
BALB/c 180 TAC 45.3 mg / 3 mL 2 
BALB/c 181 TAC 45.3 mg / 3 mL 2 
BALB/c 182 TAC 45.3 mg / 3 mL 2 
BALB/c 183 TAC 45.3 mg / 3 mL 1.5 
BALB/c 184 TAC 45.3 mg / 3 mL 2 
BALB/c 185 TAC 45.3 mg / 3 mL 2 
  mean score 1.81* 
    standard deviation 0.34 
NS = normal saline   
TAC = tacrolimus   
*  significant difference from saline (p<0.05)  
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Table H.1: Pathological evaluation of inflammation in asthma induced mice dosed with 
prophylactic combination of tacrolimus and dexamethasone. 
     
Group Animal ID Treatment Prophylactic dose 
Inflammation 
score 
TAC/DEX BALB/c 1G7 OVA,TAC/DEX, OVA TAC + DEX  2.5 
 BALB/c 1G8 OVA,TAC/DEX, OVA TAC + DEX  2.5 
 BALB/c 1G9 OVA,TAC/DEX, OVA TAC + DEX  2 
 BALB/c 1G10 OVA,TAC/DEX, OVA TAC + DEX  2.5 
 BALB/c 1G11 OVA,TAC/DEX, OVA TAC + DEX  2 
 BALB/c 1G12 OVA,TAC/DEX, OVA TAC + DEX  2.5 
   mean score     2.3 † * 
      standard deviation 0.3 
OVA,TAC/DEX,OVA = OVA IP inj, TAC prophylaxis, OVA challenge  
† significant difference from OVA,NS,OVA (p<0.05)   






Figure 1.1: Cycle of CD4 T cell activation with sites of immunosuppressive action. (Reprinted with permission from Mueller 
et al, 2004). 
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Figure 1.2: Maintenance immunosuppressive drug use in adult lung recipients: CyA, 
cyclosporine; TAC, tacrolimus; MMF, mycophenolate mofetil; AZA, 
azathioprine (Reprinted with permission from Trulock et al, 2007) 
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Figure 1.3: Induction therapy by year in adult lung recipients: ALG, anti-lymphocyte 
globulin; ATG, anti-thymocye globulin; IL-2R, interleukin-2 receptor 
(Reprinted with permission from Trulock et al, 2007). 
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Figure 1.4: Survival of lung transplant recipients receiving aerosolized cyclosporine in 
addition to normal immunosuppressive maintenance therapy (Reprinted with 
permission from Iacono et al, 2006). 
 
 161 
Figure 1.5: Supersaturated dissolution profile for (●) amorphous URF composition 
TAC:lactose (1:1); (■) crystalline URF composition TAC alone and (---) 
equilibrium solubility of TAC in the dissolution media fluids (SLF) 
containing 0.02% DPPC at 100 rpm and 37°C (Reprinted with permission 
from Sinswat et al, 2008). 
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Figure 2.1: Pathologically reviewed slides of transplanted lung tissue representing a) no 
rejection and b) acute graft rejection at 3 days post-op and and c) no 





Figure 2.2: Analysis of resulting particle size of particulate drug formulation within an 
aqueous media () 5, (■) 15, and (●) 30 minutes after dispersion via probe 























Figure 2.3: Scanning electron microscopy images at a) 6K and b) 40K magnification of 







Figure 2.4:  Aerodynamic droplet size of nebulized tacrolimus colloidal dispersion 
determined by Next Generation Pharmaceutical Impaction. 
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Figure 2.5:  Total lung and whole blood drug concentration in transplant and non-
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Figure 2.6:  Drug concentration in the trachea of transplanted and non-transplanted 
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Figure 2.7:  Drug concentrations in a) left and b) right lungs of transplanted d non-
transplanted (control) Lewis rats after a single dose of tacrolimus colloidal 
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Figure 3.1: Supersaturation dissolution profile for TAC colloidal dispersion initially () 
and after 1 month (), 2 months (□), and 3 months (■) in simulated lung 
fluid (SLF) containing 0.02% DPPC at 37°C and a paddle speed of 100 rpm.  








































Figure 3.3.  Chromatographic results from a) acidic, b) alkaline, c) oxidative, nd d) 




































































































































































































Figure 3.5:  Tacrolimus concentration remaining in a) lung tissue and b) whole blood 
after 28 daily nebulized doses of 6.4 mg tacrolimus dispersion for 
nebulization. 


























































Figure 3.6: Histological staining of lungs with a) H&E, b) CD 68, and c) PAS for 
evaluation of cellular inflammation, monocyte/marcrophage presence, and 
mucus production, respectively.  
a)                                                                          b) 
            
           c) 
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Figure 4.2: Cytokine evaluation from groups of asthma induced mice treated with a) 



























































Figure 5.1:  Deposition of brittle-matrix powder in a NGI tested with (light) and without 
(dark) a pre-separator.  Percent deposition is based only on stages 2 through 
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Figure 5.2: SEM images of TACLAC a) respirable brittle-matrix particles, b), c) 








Figure 5.3:  Images of TACLAC taken by SEM/EDX to display the prevalance of atomic 












Figure 5.5:  Aerodynamic diameter distribution of TACLAC, TACRAF, TAC, and 
TACMAN a) directly after production and b) after exposure to 50% RH 






Figure 5.6:  Influence of (◊) 0%, (□) 20%, (○) 50%, and (−) 90% RH on the volume 








Figure 5.7 – Isotherms of sorption ( − )  and desorption (---) of  () TACRAF, (■) 
TACLAC , (X) TAC and, (♦) TACMAN produced after one cycle between 




Figure 5.8: Effect of increased humidity on TACLAC vapor sorption and morphology as 
measured by dynamic vapor sorption. 
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Figure G.1 Aerodynamic particle size distribution of formulations including a) coarse 
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Figure G.2: SEM images of TACLAC with shearing coarse lactose taken from samples 
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APPENDIX A:  PRIOR ART AND PATENT SUMMARY OF TACROLIMUS FOR 
INHALATION  
A.1 Purpose 
The purpose of this inquiry was to determine the patent and journal history of 
tacrolimus and its use as an inhaled therapy.  It was necessary to confirm that none of the 
intellectual property developed by the authors of WO2008127746 (A1) had been 
previously disclosed to the public in a patent, patent application, or journal publication.    
 
A.2 Methods 
Patents published by the United States Patent and Trademark Office (USPTO) 
were searched.  Journal searches were carried out through databases available to UT. 
 
A.3 Results 
Tables A1 through A3 summarize the patent and journal history of tacrlimus for 
inhalation.  No evidence was seen of previous disclosure of the intelectural property 
encompassed in WO2008127746 (A1). 
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APPENDIX B: NEBULIZATION OF TACROLIMUS DISPERSION WITH AIR –JET AND 
VIBRATING MESH DEVICES 
B.1 Purpose 
The purpose of this study was to compare emitted dose and aerodynamic 
properties of tacrolimus respirable droplets produced by air-jet and vibrating mesh 




Tacrolimus powder for redispersion was prepared as described in Secton 2.2.2., 
where Ultra-rapid Freezing (URF) was used to produce as solid solution of tacrolimus 
and lactose (1:1).  Quantities of 5, 10, and 15 mg of formulation were dispersed in 3 mL 
of deionized water by probe sonication.  A Next Generation Pharmaceutical Impactor 
(NGI) was used to evaluate the aerodynamic performance of the droplets produced by 
either air-jet or vibration mesh nebulization.  An Aeroneb® Pro (Aerog n, Galway, 
Ireland) or a Micromist® (Hudson RCI, Durham, NC) were used to produce an aerosol 
by vibrating mesh and air-jet technology, respectively. .To power nebulization in the 
Micromist®, dry nitrogen gas was supplied a 8 L/min into the venturi port on the bottom 
of the nebulizer.  A flow rate of 30 L./min pulled the aerosolized droplets through the 
NGI at ambient temperature and humidity.  Each stage, induction port, and nebulizer 
resivior were rinsed and quantified by HPLC analysis as detailed in Section 2.2.3.2.  Plate 
impaction results were analyzed by fitting data to a 3 parameter logistic curve in 
SigmaPlot. (Systat Sofware Inc., San Jose, CA).  Mass median aerodynamic diameter 
(MMAD) was calculated based on drug collected on states 1 through 7 and micro-orifice 
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collector (MOC) in accordance with USP 31 <601> guidelines.  Fine particle fraction 
(FPF) was calculated as the percentage of the total emitted dose with an aerodyn mic size 
less than 4.7 µm.  
 
B.3 Results 
Both nebulizers tested showed relatively inefficient nebulization in comparison to 
dispersion nebulization.  Saline and glycerol solutions have been shown previously to 
emit between 70 and 80% of the volume loaded in the nebulizer reservoir, although 
deionized water only emits 58% of the volume provided (1).  As shown in Table B1, the 
highest emitted dose measured was 50.5% at a 5 mg/ 3 mL with the Aeroneb®.  It is 
likely that at concentration increases total emitted dose (TED) decreases in the vibrating 
mesh nebulizer due to particle aggregation and Ostwald ripening (described in Section 
2.4.1).  The opposite trend is seen in the air-jet nebulizer, where concentration and TED 
are directly proportional.  Although, overall, the vibrating mesh nebulizer emits more 
drug, leaving less in the reservoir.  Another interesting difference was the disparity 
between the mass median aerodynamic diameters produced by the two nebulizers.  
Nebulized droplets produced by the air-jet showed a lower MMAD in comparison to the 
vibrating mesh.  It may be that the baffles located internally in the air-jet nebulizer only 
allowed very fine (below 5 µm) droplets to be emitted (2).  Overall, low dose dispersions 
(5 mg/ 3 mL) are respirable and emitted the most efficiently form the vibrating mesh 
nebulizer.  However, at all concentrations, a more respirable plume is produced by the 
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APPENDIX C: THE INFLUENCE OF TACROLIMUS DISPERSION ON AEROSOL 
CHARACTERISTICS  
C.1 Purpose 
This appendix is intended to supplement the study conducted in Chapter 2.  The 
objective was to determine if tacrolimus powder for dispersion effects the volumetric 
median diameter (VMD) after it is dispersed in either deionized water (DIW) or normal 
saline (NS).  Typically, vibrating mesh nebulizers are used to aer solize drug in aqueous 
solution.  While no mesh clogging is typically observed with tacrolimus dispersion for 
nebulization, the effect of dispersed particulates on device operation, and ultimately 
VMD, has not previously been investigated.      
 
C.2 Methods 
Tacrolimus dispersion for nebulization was prepared in DIW according to 
methods described in Section 2.2.2.  Dispersions were also prepared in NS by the same 
method.  Briefly, 6.4 mg of tacrolimus/lactose (1:1)(TACLAC), were dispersed in 3 mL 
of aqueous media and nebulized with a Aeroneb® Pro (Aerogen, Galway, Irelnd) until 
completion.  Nebulized mists was measured volumetrically by a Malvern Spraytec 
(Malvern Instuments, Worcestershire, UK) by mounting the mouth of the nebulizer 
approximately 2.5 cm away from the emitted laser and 2.5 cm from the detector, as 
recommended by Ghazanfari et al (1).  It has been previously noted that positioning of 
the nebulizer during laser diffraction analysis can greatly effect the mean and distribution 
of the data collected (2), so it was of high importance that the nebulizer positioning 
remained the same.   Data was acquired during the entire nebulization period and was 




Differing results are shown in Table C.1 when comparing dispersion in DIW or 
NS to nebulization of only aqueous media.  After dispersion of TACLAC in DIW, the 
VMD became slightly larger (a difference of 0.31 µm) in comparison to nebulization of 
only DIW.  This suggests that potential interruption of the nebulization mechanism may 
be occurring.  It is worth noting, however, that the volume moment mean (D[4][3]) was 
the same for both DIW preparations, suggesting no difference the overall plume size 
distribution.  Interestingly, when NS is used as a dispersion media, VMD decreases when 
TACLAC is dispersed.  It may be that an increase in solubilized material slightly 
increased fluid viscosity, which in turn will decrease VMD (1).  It is uncertain why this 
same principle did not apply to dispersions in DIW.  Using the Aeroneb® Pro, a previous 
study has shown that VMD decreases and fine particle fraction increases when electrolyte 
concentration (NaCl) increases in the nebulization fluid (1).  This conclusion is supported 
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APPENDIX D: A REVIEW OF TACROLIMUS PROTEIN BINDING  
D.1 Purpose 
The objective of this research was to better understand the mechanism of action of 
tacrolimus through a thorough literature search.  The affinity of acrolimus toward certain 
binding proteins may also prove important in potential synergistic effects with other 
drugs.   
 
D.2 Methods 
Journal searches with a focus on medicinal chemistry and biochemistry journals 
were carried out through resources available to the UT library. 
 
D.3 Results 
A summary of prior art findings are given in Table D.1.  The literature states that 
FK binding proteins (FKBP) 12 and 12.6 are responsible for immunosuppressive action 
of tacrolimus and possess the highest affinity for the molecule.  FKBP 51 shows less 
affinity for tacrolimus; however, may have reduced affinity for the glucocorticosteroid 
receptor complex when bound with tacrolimus. 
 
D.4 References 
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APPENDIX E: RAW BLOOD DATA OF SALINE DOSED SPRAGUE DAWLEY RATS 
E.1 Purpose 
The purpose of this appendix is to establish in-house data on saline dosed Sprague 
Dawley (SD) rats.  Archiving of in-house data is necessary due to discrepancies seen 
between “normal” data ranges given by IDEXX and those seen in non-treatment groups.  
This appendix pertains to the study discussed in Chapter 3.   
 
E.2 Methods 
Methods of animal sacrifice and blood draw are described in detail in Seciton 




Abnormalities in raw data displayed in Tables E1 and E2 are discussed in Section 
3.3.2.  In summary, differences in IDEXX and in-house data are thought to stem from 
toxicity induced by method of euthanasia as well as the amount of time elapsed between 
animal death and blood draw. 
 198 
APPENDIX F: PRELIMINARY EVALUATION OF INHALED TACROLIMUS IN AN 
OVALBUMIN -INDUCED ASTHMA MODEL .  
F.1 Purpose 
The purpose of this study was to determine if tacrolimus dispersion for 
nebulization, given prophylactically, could prevent ovalbumin-induced inflammation in 
the lungs of BALB/c mice.  Results from this preliminary study would be used to develop 
protocols for a more in-depth study of asthma therapy with tacrolimus.   
 
F.2 Methods 
Twenty BALB/c mice were used in this study conducted at the UTHSC at San 
Antonio.  Eight mice were prepared as a positive control group where t y received an 
intraperitoneal (IP) injection of ovalbumin (OVA) on day 1 and 14 of the s udy.  On day 
28, the mice were dosed with 3 mL nebulized normal saline (NS) as described in Section 
2.3.4.  One hour after dosing, animals received 3 mL challenge of nbulized ovalbumin 
solution.  An additional group of 8 mice were injected and dosed identically; accept NS 
was replaced with 45.3 mg tacrolimus powder for dispersion in 3 mL deioniz d water.  A 
control group of 4 mice were injected with IP saline and not given an aerosol treatment.  
Twenty-four hours after challenge, mice were euthanized by 5% isoflurane inhalation.  
Lung tissue from each mouse was removed sectioned and stained with H&E stain and 
read by a pathologist for inflammation.    
 
F.3 Results 
Table F.3 shows the scores assigned to each lung sample after histological 
evaluation.  Mean scores of animals dosed with tacrolimus showed a significant 
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difference from those dosed with NS (p<0,05).  There results indicate that the 
immunosuppressive mechanisms of tacrolimus are able to reduce the ability of the 
pulmonary immune system to react to a foreign antigen.  Other sudie  are needed to 
determine if inhibition of inflammation is dose dependant and whether time of dose 
administration relative to challenge has an effect.  It is unclear whether reduction in 
inflammation is due to inhibition of the Th1 and/or Th2 pathway; therefore, studies 
investigating cytokine presence in bronchoalveolar lavage fluid (BALF) should be 
assayed.    
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APPENDIX G:  INVESTIGATION OF COARSE AND M ICRONIZED LACTOSE TO 
INCREASE SHEARING IN BRITTLE -MATRIX PARTICLES  
G.1 Purpose 
It was hypothesized that inclusion of lactose particles would enabl  increased 
shearing of the brittle-matrix particles described in Chapter 5, subsequently reducing the 
mass median aerodynamic diameter (MMAD) and increasing the fine particle fraction 
(FPF).  The purpose of this study was to determine if inclusion of coarse or micronized 
lactose produced more respirable drug particles.  
 
G.2 Methods 
Multiple grades of lactose were used as shearing particles, ncluding InhaLac® 70 
(Meggle Wasserburg, Germany), Lactohale® LH 230 (Friesland Foods Domo, Zwolle, 
Netherlands), Fast-Flo® (Foremost, Baraboo, WI), and Ludipress® LCE (BASF Fine 
Chemical, Ludwigshafen, Germany).  Methods described in Section 5.2.6 were employed 
for cascade impaction testing of each formulation variation.  TheHandihaler® was used 
for next generation pharmaceutical impaction (NGI) testing at an operational flow rate of 
51 L/min.  InhaLac® 70, Fast-Flo®, and Ludipress® LCE, all of which contain coarse, 
non-respirable lactose (>100 µm), were tested for aerodynamic diameter by NGI with the 
pre-separator in place.  A formulation of tacrolimus and lactose (1:1) TACLAC) was 
prepared by URF as described in Section 2..2.2 and combined with one of th three 
coarse lactose additives in an #3 HPMC capsule (Capsugel, Peapack, NJ).  Specifically 3 
mg of TACLAC was measured and added to the capsule along with 15 mg of coarse 
lactose.  No blending or mixing of the powders was conducted.   Formulations containing 
LH 230 were tested without a pre-separator since the d50 of this grade of lactose is 8.2 
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µm, and many of the particles are respirable.  Formulations were pr pared with TACLAC 
as above, where 2 mg of TACLAC was added to an HPMC capsule along with 24 mg of 
LH 230.  Two different preparation procedures were followed when LH 230 was used.  
In the first (TACLAC w/ LH230 F1), bulk LH 230 powder was filled into the capsule 
unaltered.  In the second procedure, a 100 mesh sieve was used to separate large 
aggregates of LH 230.  After sieving the lactose was mixed with the correct proportion of 
TACLAC in a scintillation vial by shaking.  Twenty-six milligrams of this mixture was 
samples, filled into a capsule, and dried under dry nitrogen gas for 1 hour.  The 
formulation was then tested according to Section 5.2.6.           
Scanning electron microscopy (SEM) was also used to qualitatively determine if 
TACLAC particles were adhering to course lactose after activation of the Handihaler®.  
Double sided carbon tape sued to adhere SEM samples was placed within the solvent dish 
of the per-seperator during testing.  After NGI testing was carried out, a sample of course 
lactose impacting the carbon tape was evaluated by SEM as described in Sectio 5.2.4. 
 
G.3 Results 
Aerodynamic distribution of drug particles produced by both formulation 
strategies are shown in Figure G.1.  Figure G.1a shows that coarse lactose dose not 
significantly improve the aerosol performance of brittle-matrix particles.  Upon 
evaluation of the mass median aerodynamic diameter (MMAD) of each coase lactose 
formulation, a slight decrease in MMAD was seen in Ludipress and Fast-Flo 
formulations (0.1 µm and 0.11 µm less respectively), although multiple iterations are 
needed to determine where this is within the range of analytical error.     Figure G.2 
shows the presence of TACLAC adhered onto coarse Ludipress, confirming that particle 
adhesion is at least one cause of drug retention in the pre-separator.  Even without 
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inclusion of coarse lactose, TACLAC was retained in the pre-separator, as observed in 
Section 5.3.1. 
Since the problem of adhesion to large particles as seen in investigation of coarse 
lactose for shearing of brittle-matrix particles, smaller n ar-respirable lactose particles 
were investigated.  Initial testing using unprocessed LH 230 (TACLAC w/ LH230 F1) 
resulted in only 77% of dose being emitted from the capsule, compared to 95% in a test 
conducted with TACLAC alone.  The aggregated and hygroscopic nature of lact se, 
especially in cases of increase surface area, may be the rason for drug retention in the 
capsule.  Changing formulation preparation techniques (TACLAC w/ LH230 F2) showed 
improvement in emitted dose (91%); although still less than formulations of TACLAC 
alone.  Additionally, no increase in shearing can be concluded from analysis of 
aerodynamic distribution data shown in Figure G.2b.  In fact, it can be observed that 
inclusion of micronized lactose caused increase in aerodynamic diameter of drug 
particles.  It is likely that aggregates of lactose and TACLAC, as seen in tests with coarse 
lactose), caused retention of drug in high impaction stages.   
In future studies it would be interesting to evaluate lactose powders with a d50 of 
approximately 2 µm for inclusion as shearing particles, so that all adhered TACLAC 
particles would still impact on lower stages of the NGI.  Great care would need to be 
taken in formulation preparation so the aggregation due to moisture and electrostatic 
adhesion was avoided.     
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APPENDIX H:   INVESTIGATION OF TACROLIMUS /DEXAMETHASONE SYNERGY FOR 
ASTHMA THERAPY  
H.1 Purpose 
The objective of this study was to determine if coadministration of tacrolimus and 
dexamethasone (TAC/DEX) had synergistic inhibition of inflammation.  The rationale 
for this hypothesis is explained in Section 4.3.4.   
 
H.2 Methods 
Six BALB/c mice were sensitized, dosed prophylactically, and challenged as 
described in Section 4.2.2.  Prophylactic dose was administered by aerosolization of 45.3 
mg of tacrolimus (TAC) dispersion for nebulization in 3 mL normal sline (NS).  
Immediately after completion of TAC dosing, 5 mL of 0.1% dexamethasone (DEX) in 
NS was nebulized to the same mice.  One hour after completion of DEX dosing, mice 
were challenged for 20 minutes with 10 mg/mL ovalbumin in NS.  Bronchoalve l r 
lavage (BAL) was conducted and assayed as described in Section 4.2.5.  Tissues were 
extracted and prepared for pathological evaluation as explained in Section 4.2.7.  
   
H.3 Results 
Tissue pathology shown in Table H.1 serves as evidence that TAC/DEX 
prophylactic administration significantly reduces inflammation in asthma induced mice.  
As described in Section 4.3.1, pathologist review showed perivascular inflammation of 
tissue that included lyphoplasmacytic cells, neutrophils, and eosinophils.  Comparison of 
data to that of DEX and TAC dosed animals (Table 4.2) suggests superisor r duction of 
tissue inflammation.  Interestingly, TAC dosed animals of the same evaluation group 
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(group G), showed even more inflammation reduction than the TAC/DEX group (2.17 vs. 
2.33); however, only an n = 3 was used. 
It is unclear why airway inflammation of animals dosed prophylactic lly with 
TAC/DEX showed eosinophil levels equivalent to those seen in untreated animals 
(Figure H.1).  Although lymphocyte are reduced, one would expect the perc ntage of 
eosinophils to be inhibited as well.  The only potential explanation is that all WBCs 
(including  macrophages) were inhibited causing a skewing of percentages.  However, 
total WBC count of TAC/DEX dosed mice did not show a significant difference in 
comparison to positive control, and may not be a true representation of WBC
concentration in the lungs due to subtle variations in BAL procedure and slide 
preparation.            
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APPENDIX I:  READILY SCALABLE MANUFACTURING OF BRITTLE -MATRIX 
PARTICLES THROUGH BLISTER PACK FREEZING  
I.1 Purpose 
The objective of this study was to demonstrate proof-of-concept of Ultra-rapid 
Freezing (URF) technology adapted for manufacture in a pharmaceutical blister pack.  
This adaptation may facilitate a readily scalable pharmaceutical manufacturing process to 
create multiple blister doses of brittle-matrix particles for inhalation.      
 
I.2 Methods 
For investigation of this adaptation of URF, an Advair Diskus® 250/50 
(GlaxoSmithKline, Research Triangle Park, NC) and the blister packs contained within 
were used.  The device was opened, the blister strip was removed and peeled open.  The 
contents (drug and lactose) of each blister pack were removed.  The aluminum strip was 
cleaned with deionized water, rinsed with ethanol, and allowed to dry and room 
temperature. 
Production of brittle-matrix particles was conducted as outlined in Section 5.2.2.  
Tacrolimus and lactose (TACLAC) and tacrolimus (TAC) solutions were prepared 
separately in 1 mL of ACN:water (3.2) each.  Both solutions contained 0.75% w/v solids.  
A Pyrex® Petri dish was filled with liquid nitrogen, and blister packs were added.  One at 
a time, blister packs were removed from the liquid nitrogen bath, and 25 µL of drug 
solution was added to the concave indentation.  The product was frozen immediately 
upon contact and placed in a - 80°C freezer.  All frozen blisters wee lyophilized 
according to the recipe described in Section 5.2.2.  After lyophilization, all blister packs 
were stored under vacuum in a sealed desiccator.  
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Aerosol testing was conducted using a Next Generation Pharmaceutical Impactor 
(NGI) with coated collection surfaces as described in Section 5.2.6.  Carefully, a single 
blister containing either TACLAC or TAC was added to the inhalation position of the 
Adviar Diskus®, and the device was resealed and mounted on the induction port of the 
NGI by a silicone molded fitting.  Flow rate necessary to achieve a 4 kPa pressure drop 
across the Diskus was determined to be 66 L/min; therefore, all experiments were 
conducted at this flow rate.  Both TACLAC and TAC blister formulations were actuated 
three times before collection of the impacted formulation from the stages.  Rinsing and 
high performance liquid chromatography (HPLC) method for quantification of drug was 
performed as outlined in Section 5.2.6.  Fine particle fraction is define as the percentage 
of drug mass emitted that is below 5 µm in diameter. 
                
I.3 Results 
Figure I.1 shows the aerodynamic distribution of both formulations analyzed.  
The FPF measured for TACLAC and TAC formulations were 35.1% and 19.8%, 
respectively.  Clearly, the shear imparted by the Diskus® device is not sufficient to 
obtain the quantity of highly respirable particles made by the Handih ler® (see Chapter 
5). Although FPFs measured in this initial study were low in comparison to those 
reported in Chapter 5, brittle-matrix particles tested here still outperformed the 
formulations marketed with the Diskus®.  The Flutide Diskus® was evaluated for 
efficiency in a study by Steckel in 1997, where only 25.4% of the emitted dose was in the 
aerodynamic range below 6.4 µm (1).  TACLAC, when prepared by blister freezing, 
resulted in an aerosol with 41.0% of the emitted dose below 6.4 µm.      
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The total emitted dose (TED) for TACLAC and TAC formulations were 78.6% 
and 97.3%, respectively.  It was apparent during formulation production that temperature 
of the blisters packs determined the shape and morphology of the frozen formulation 
because of the effect on the rate of freezing.  This may have contributed to some of the 
difference in TED between formulations, as TACLAC blisters were thought to be warmer 
upon addition of the drug solution.  It was also observed that even upon storage in  
vacuum desiccator, the hydroscopic effects of lactose caused “collapse” of TACLAC 
particles as described in Section 5.3.4.  Cohesion caused by moisture sorption could also 
have caused increased retention of TACLAC in the blister.   
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